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ABSTRACT 
Background: Older adults are more vulnerable to the adverse effects of alcohol-medication 
interactions (AMIs) than younger populations, and are more likely to use medications capable 
of causing an AMI when used with alcohol (alcohol-interactive (AI) medications).  Survey 
findings from the United States (US) and Europe indicate many older adults use alcohol and 
AI-medications concomitantly. However, the prevalence of this issue in New Zealand is 
currently unknown, and few observational studies have explored the impact of concomitant 
alcohol and AI-medication use (concomitant alcohol/AI-medication use) on health outcomes 
in community samples.  Research exploring motivating factors underlying alcohol use by AI-
medication users indicates having awareness of AMI risks often motivates reduced alcohol 
consumption.  There is also evidence that depression may increase the likelihood of 
concomitant alcohol/AI-medication use, particularly when alcohol is used to ‘self-medicate’ 
depressive symptoms. However, the moderating effects of depression on alcohol use by AI-
medication users have not been directly assessed in a large community sample.   
Design and Methods: Two studies were conducted, both involved secondary analysis of 
existing survey data and national pharmaceutical claims data. Samples were drawn from a 
representative sampling frame of older adults living in New Zealand. The first study (study 1) 
analysed data from a survey of adults aged 54-70 years, and the second study (study 2) analysed 
data from an augmented sample aged 49-83 years.  The prevalence of concomitant alcohol/AI-
medication use was explored in both study samples overall, and in subsamples of participants 
aged ≥65 years. Study 1 investigated the potential impact of concomitant alcohol/AI-
medication use on general physical health and healthcare utilization. Study 2 assessed the 
potential relationships between alcohol use, AI-medication use, and depression. An evidence-
based protocol was developed to inform methods of classifying AI-medications and measuring 
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AI-medication use among survey participants using pharmaceutical dispensing records. 
Relationships between variables of interest were assessed using a series of hierarchical 
regression models and Chi-squared tests.    
Results: Alcohol and AI-medications were used concomitantly by approximately one-in-four 
participants aged 54-70 years, one-in-three participants aged 49-83 years, and two-in-five 
participants aged 65-83 years. Concomitant alcohol/AI-medication use was not significantly 
associated with physical health or healthcare utilization, although these non-significant 
findings may reflect limitations of the outcome measures used in the present research. Alcohol 
use was negatively associated with AI-medication use, with stronger associations being 
observed for medications associated with more severe AMIs.  These findings are consistent 
with research and theory indicating AMI awareness may lead to reduced alcohol consumption 
by AI-medication users. Depression did not influence the relationship between AI-medication 
use and alcohol use.  
Conclusions: The present research findings indicate many New Zealand older adults are at risk 
of AMI.  Providing relevant health warnings may help reduce the potential for AMI-related 
harm, although additional intervention may be needed for many older adults.   Future research 
in this area should include longitudinal health outcome measures that are specific to the effects 
of AMI, and measures that assess drinking motives directly.  The two studies presented in the 
present thesis were the first to explore the prevalence of concomitant alcohol/AI-medication 
use by older adults in New Zealand, which is a major contribution of this project overall. 
Another important contribution was the development of an evidence-based framework for 
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CHAPTER 1: BRIEF INTRODUCTION & THESIS OUTLINE 
New Zealand’s population is gradually aging due to a decline in both birth rates and death rates 
per capita (Statistics New Zealand, 2020).  Moreover, a large cohort of people born between 
1950 and the early 1970s commonly described as the ‘baby boomer’ generation are reaching 
older adulthood. New Zealand is therefore experiencing sudden growth in the population aged 
≥65 years (Statistics New Zealand, 2020). Research from the United States (US) indicates 
potentially harmful alcohol consumption patterns are more prevalent among the baby boomers 
than previous generations (Savage, 2014), and that drinking patterns among this cohort often 
continue into older adulthood (McEvoy et al., 2013).  Nationally representative survey data 
indicates approximately 40-50% of older adults living in New Zealand engage in potentially 
harmful alcohol consumption patterns (Stevenson et al., 2015; Towers et al., 2011; Towers, 
Sheridan et al., 2018).  Such high rates of potentially harmful drinking in this rapidly growing 
population are concerning, given that vulnerability to alcohol related harm increases during 
older adulthood (Moore et al., 1999). Additionally, older adults are considerably more likely 
than younger cohorts to use medications that have the potential to interact with alcohol in a 
way that poses harm (Moore et al., 2007).  Research conducted in the US and Europe indicates 
many older adults use alcohol and alcohol-interactive medications concomitantly (Holton et 
al., 2017), however the prevalence of this issue in New Zealand’s older adult population is 
currently unknown.  
The present thesis explores the prevalence of concomitant alcohol and alcohol-interactive 
medication use among older adults living in New Zealand, and investigates a variety of 
potential associations between alcohol use, alcohol-interactive medication use, physical health, 
healthcare utilization, and depression.  Chapters 2-8 provide a broad review of the literature 
relevant to the thesis topic, highlighting gaps in existing knowledge, and reviewing research 
and theory that informed hypotheses for the present research.  Chapter 9 introduces the present 
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research, states the research questions and hypotheses investigated in this project, and 
summarizes the content of subsequent chapters. Methods of previous studies exploring the 
prevalence of concomitant alcohol and alcohol-interactive medication use are reviewed in 
chapter 10. Chapter 11 describes the development and implementation of a research protocol 
for measuring alcohol-interactive medication use among survey participants using national 
pharmaceutical claims data.  Two studies were conducted in the present thesis, which are 
described in chapters 12 (study 1) and 13 (study 2). Both studies explored the prevalence of 
concomitant alcohol and alcohol-interactive medication use in large community samples of 
older adults living in New Zealand.  Study 1 explored the potential of impact of concomitant 
alcohol and alcohol-interactive medication use on health and healthcare utilization. Study 2 
explored potential relationships between alcohol use, AI-medication use, and depression.  




16 | P a g e  
 
CHAPTER 2: ALCOHOL USE IN OLDER ADULTHOOD 
This chapter reviews relevant research relating to alcohol use by older adults.  The definition 
of older adulthood adopted in the present research is discussed in section 2.1. The next section 
(2.2) discusses methods of measuring and describing drinking patterns in survey research, and 
survey studies into the drinking patterns of New Zealand older adults are then reviewed in 
section 2.3. Common motivating factors underlying alcohol use by older adults are then 
discussed in section 2.4, and health outcomes associated with alcohol use during older 
adulthood are described in section 2.5.   
2.1: DEFINITION OF OLDER ADULTHOOD  
The research conducted in the present thesis uses chronological age as an indicator of older 
adulthood, with a chronological age threshold of ≥65 years being used to identify subsamples 
of participants who are considered older adults. The threshold of 65-years was selected because 
this is the age at which New Zealand citizens reach eligibility for superannuation (New Zealand 
Government, 2020), and also because this was found to be a useful threshold for comparing 
the present research findings with previous studies in this area.  Participants aged below this 
threshold are also included in the present research to capture persons who are approaching 
older adulthood (the study 1 sample was aged 54-70 years, and the study 2 sample was aged 
49-83 years).  It should be noted that chronological age is an imperfect approach to classifying 
older adulthood, as the biological and cognitive changes associated older adulthood do not 
occur at any single chronological age (MacDonald et al., 2011). It should also be noted that 
studies reviewed throughout the introduction chapters of the present thesis use varying 
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2.2: MEASURING AND DESCRIBING DRINKING PATTERNS  
In survey research, patterns of alcohol use are measured primarily based on participant self-
report (Dawson, 2003; Dufour, 1999).  As self-report methods do not measure alcohol use 
directly, this approach presents several methodological issues that must be considered when 
interpreting survey research into drinking patterns.  Moreover, several terms describing various 
patterns of alcohol consumption commonly feature in the literature, although the way in which 
these terms are operationalized tends to vary from one study to the next. As research into the 
prevalence and correlates of alcohol use is a key focus of the present thesis, some issues 
regarding the way drinking patterns are measured and described by researchers are discussed 
below.   
2.2.a: Drinkers and non-drinkers  
The most basic classification of alcohol use reported on in survey research is the distinction 
between people who use alcohol (drinkers) and those who do not (non-drinkers or abstainers). 
Drinkers are typically defined as those who report using alcohol within a specific timeframe.  
However, timeframes within which alcohol use is measured may vary, and in some studies may 
be unspecified. For example, the 2012/13 New Zealand Health Survey (NZHS) (Ministry of 
Health, 2015) identified drinkers based on alcohol use during the past year, whereas the 2009-
2011 Attitudes and Behaviour towards Alcohol Survey (ABAS) (Research New Zealand, 2013) 
defined drinkers as those who reported drinking during the past four weeks, or those who said 
they use alcohol but had not done so in the past four weeks.  Therefore, specified timeframes 
across which alcohol use is measured are a key detail to consider when interpreting research 
distinguishing drinkers and non-drinkers.   
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2.2.b: Drinking frequency and drinking quantity  
Alcohol use is also often described in the literature based in terms of a) drinking frequency, 
which describes how often an individual consumes alcohol and/or b) drinking quantity, which 
refers to the amount of alcohol one typically consumes (Hodges & Maskill, 2014).  Some 
standardized screening instruments developed for the identification of alcohol problems 
include measures of drinking quantity/frequency. For example, items from the Alcohol Use 
Disorders Identification Test (AUDIT) (Saunders et al., 1993) or its shorted version (AUDIT-
C) (Bush et al., 1998) are included in several New Zealand surveys (e.g., Ministry of Health, 
2015; Oakley-Browne et al., 2006; Towers et al., 2011).  Alternatively, drinking 
quantity/frequency may be assessed using ‘ad hoc’ questionnaire items that are tailored to 
specific research questions.  While ad hoc measures are often necessary, an advantage of 
standardized measures is that their utility has been empirically tested (Dawson, 2003).     
As with research distinguishing drinkers and non-drinkers, an important consideration when 
interpreting drinking quantity/frequency data is the timeframe within which alcohol use is 
measured (Dawson, 2003). For example, the 2012/13 NZHS study (Ministry of Health, 2015) 
assessed drinking frequency by asking participants about the typical frequency at which they 
consumed alcohol during the past 12-months (‘at least 3-4 times weekly’; ‘1 or 2 times weekly’ 
’less than 1 or 2 times weekly’).  As another example, drinking frequency was measured in the 
2009-2011 ABAS study (Research New Zealand, 2013) by asking participants to estimate the 
number of days they used alcohol during the past month (1 day, 2-4 days, 5-10 days, 11-29 
days, or 30+ days). While both of these examples provide useful information, findings of 
studies reporting on drinking frequency/quantity measured across different timeframes cannot 
be directly compared for two reasons. Firstly, individual drinking patterns may change over 
time, and secondly, participants’ ability to accurately recall drinking quantity/frequency is 
likely to decrease with increasing timeframes (Dawson, 2003).  
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Drinking quantity survey questions are often worded in terms of the ‘typical’ or ‘usual’ number 
of alcoholic drinks consumed per drinking day (Dawson, 2003). However, the amount of 
alcohol contained in an alcoholic beverage depends on its volume (i.e., serving size) and 
alcohol concentration (Dawson, 2003; Dufour, 1999). To deal with this issue, drinking quantity 
is sometimes assessed in terms of standard drinks (SDs), with each SD representing a fixed 
amount of pure alcohol (Dawson, 2003). The specific amount of alcohol contained in a SD 
varies across countries, and reflects the most commonly used alcohol serving size of the 
respective population (Kalinowski & Humphreys, 2016). The appeal of drinking quantity 
measures using SDs is that they attempt to increase measurement accuracy (Dawson, 2003; 
Dufour, 1999). However, this approach may actually present an additional source of 
measurement error because many respondents do not attempt to convert their responses into 
SDs, and some may be incapable of doing so (Dawson, 2003).    
2.2.c: Moderate drinking, heavy drinking, binge drinking, and hazardous drinking  
Some common descriptors used to report particular drinking patterns include moderate 
drinking, heavy drinking, binge drinking, and hazardous drinking.   Moderate drinking and 
heavy drinking are terms researchers often use to categorize various levels of drinking quantity 
and/or frequency within a sample or population. In this context, heavy drinking typically 
implies a higher drinking quantity and/or frequency pattern, and may also refer to a drinking 
pattern that exceeds the recommendation of recognised guidelines for safe alcohol use (Dufour, 
1999). Binge drinking is another aspect of alcohol consumption that researchers may be 
interested in, which generally refers to instances when an individual consumes a large quantity 
alcohol on one occasion.  Binge drinking measured by the AUDIT (Saunders et al., 1993) or 
the AUDIT-C (Bush et al., 1998) is defined as ≥6 drinks consumed in the same day.  However, 
definitions may vary with regards to the amount of consumed alcohol that constitutes a binge 
drinking episode (Gmel et al., 2003; Herring, Berridge, & 2008), and some studies apply 
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different thresholds for men and women (e.g., Courtney & Polich, 2009). Hazardous drinking 
(also referred to as ‘risky drinking’) refers to an alcohol consumption pattern that poses risk of 
short-term or long-term harm (Hodges & Maskill, 2014). Hazardous drinking is generally 
determined based on an individual’s average drinking frequency, typical drinking quantity, and 
episodic binge drinking frequency. The AUDIT (Saunders et al., 1993) and the AUDIT-C 
(Bush et al., 1998) are commonly used measures of hazardous drinking.    
2.3: PATTERNS OF ALCOHOL USE BY ADULTS AND OLDER ADULTS IN NEW 
ZEALAND  
This section reviews survey research into the drinking patterns of New Zealanders, with 
particular attention being paid to New Zealand’s older adult population.  As discussed in the 
previous section (2.2), methods of measuring and describing patterns of alcohol use tend to 
vary.  Relevant information about the alcohol use measures and/or descriptors used in each 
study reviewed in this section is therefore provided throughout this section, either in text or in 
footnotes. Overall, the studies reviewed below indicate that a) the vast majority of New Zealand 
adults and older adults drink alcohol at least occasionally; b) when compared with younger 
cohorts, New Zealand older adults drink more often but consume less alcohol per drinking 
occasion; c) approximately 40-50% of New Zealand older adults drink hazardously; d) in New 
Zealand, males tend to drink more often and consume larger amounts of alcohol per occasion 
than females; and e) older adults living in New Zealand consume alcohol at a higher rate than 
those living in most other countries.  
2.3.a: Drinking prevalence  
Results from the 2012/13 NZHS study (Ministry of Health, 2015) indicate past 12-month 
drinking prevalence among New Zealanders aged ≥15 years is approximately 79%.   Similarly, 
the 2009-2011 ABAS study (Research New Zealand, 2013) found that 78% of a sample of New 
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Zealanders aged ≥18 years self-identified as drinkers1.  This study also explored drinking 
prevalence across different age groups, and found that 76% of those aged 45-64 years and 73% 
of those aged ≥65 years self-identified as drinkers (Research New Zealand, 2013).  More 
recently, the 2016 New Zealand Health Work and Retirement (HWR) study, which is a large 
nationally representative survey of New Zealand older adults, found that 83% of participants 
aged ≥50 years were identified as current drinkers based on AUDIT-C responses (Towers, 
Sheridan, et al., 2018).   Overall, these findings indicate that the vast majority of New Zealand 
adults drink alcohol at least occasionally, and that rates of alcohol use remain high in older 
populations. 
2.3.b: Drinking frequency and drinking quantity 
The 2012/13 NZHS (Ministry of Health, 2015) reported that approximately 31% of drinkers 
aged ≥15 years consume alcohol with ‘high frequency’ (3 or more times weekly). Drinking 
frequency in this study was higher among older age groups, with >50% of male drinkers aged 
≥75 years and >40% of female drinkers aged 65-74 years being identified as high frequency 
drinkers.  Similar age differences in drinking frequency were also observed in the 2009-2011 
ABAS study (Research New Zealand, 2013), with rates of past month daily drinking being 1% 
among drinkers aged 18-24 compared with 15% among those aged ≥65 years.  Both of these 
studies also found age differences in drinking quantity. The 2012/13 NZHS study (Ministry of 
Health, 2015) found that approximately 80% of drinkers aged 20-24 years reported drinking to 
intoxication during the past year, compared to <10% of those aged ≥75 years.  Similarly, the 
2009-2011 ABAS study, 54% of drinkers aged 18-24 consuming at least 7 drinks on their most 
recent drinking occasion, compared to 12% of those aged ≥65 years (Research New Zealand, 
 
1 Drinkers were defined as those who reported past four-week alcohol use, or those who said they use alcohol but 
had not done so in the past four weeks (Research New Zealand, 2013) 
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2013).  These results therefore indicate older drinkers in New Zealand drink more often but 
consume less alcohol per drinking occasion when compared with younger cohorts.   
2.3.c: Hazardous drinking 
Three publications from the HWR survey (Stevenson et al., 2015; Towers el al., 2011; Towers, 
Sheridan et al.,2018) provide information about the prevalence of hazardous drinking measured 
using standardized AUDIT-C threshold scores2 (Bush et al., 1998; Dawson et al., 2005).  
Findings from the 2006 NZHWR survey indicate a hazardous drinking prevalence of 
approximately 45% to 50% among New Zealanders aged 55-70 years (Stevenson et al., 2015; 
Towers et al., 2011), and 2016 NZHRW survey findings indicate approximately 40% of New 
Zealanders aged 50-89 years drink hazardously (Towers, Sheridan et al., 2018).    These 
findings indicate a substantial portion of New Zealand’s older adult population use alcohol in 
a way that poses risk of serious harm.  
2.3.d: Gender differences 
New Zealand survey findings show gender differences in drinking patterns in adult and older 
adult populations. The 2009-2011 ABAS study (Research New Zealand, 2013) found that, in 
comparison to adult female drinkers (aged ≥18-years), adult male drinkers were more likely to 
report drinking at least every second day during the past four weeks (19% versus 11%). Males 
were also more likely to report drinking ≥7 standard drinks on their most recent drinking day 
(35% versus 26%).  Similar gender differences are seen in New Zealand’s older adult 
population. Data from the 2010 HWR survey (Towers, Sheridan et al., 2017) indicates that 
 
2 AUDIT-C scores are yielded based on participant responses to three items assessing 1) typical drinking 
frequency (never, monthly or less, 2-4 times monthly, 2-3 times weekly, ≥4 or more times weekly); 2) quantity of 
drinks consumed on a typical drinking day (1-2, 3-4, 5-6, 7-9, ≥10); and 3) frequency of binge drinking as defined 
by ≥6 drinks consumed on a single occasion (never, less than monthly, weekly, daily or almost daily).  Scores on 
each item range from 0-4, total scores range from 0-12, and an overall score of ≥4 is indicative of hazardous 
drinking (Bush et al., 1998; Dawson et al., 2005).  
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approximately 39% of older male drinkers and 29% of older female drinkers consume alcohol 
4 or more times weekly. This study also found that female drinkers were more likely to drink 
two or less drinks on a typical drinking day (82% versus 46%), and less likely to consume 5 or 
more drinks per drinking day (6% versus 26%).  Overall, these findings indicate New Zealand 
males tend to drink more often and consume more alcohol per occasion than females, and that 
these differences continue into older adulthood.  
2.3.e: Differences across countries in older adult drinking patterns 
Towers, Minicuci et al. (2017) compared survey data on older adult drinking patterns collected 
in nine countries, including New Zealand, England, the United States (US), China, Ghana, 
India, Mexico, Russian Federation, and South Africa.  Among the countries included in the 
analyses, New Zealand had the second highest rate of past year drinkers (83%), which was only 
slightly lower than the rate observed in England (87%).  This study also found that rates of 
heavy drinking3 among older drinkers living in New Zealand (18%) were comparable to those 
living in England (17%), and considerably higher than the rates observed in many other 
countries (except China and South Africa). Moreover, while higher rates of heavy drinking 
were observed among drinkers living in China (31%) and South Africa (23%), population rates 
of alcohol use were much lower in both of these countries in comparison to New Zealand.  
Heavy drinkers therefore made up a larger portion of the older adult population in New Zealand 
(14%) than in China (11%) and South Africa (6%).  Overall, these findings indicate the 
prevalence of alcohol use and heavy drinking by older adults in New Zealand is similar to 
England, and higher than most other countries (Towers, Minicuci et al., 2017).  
 
3 Towers et al. (2017) defined heavy drinking as ≥5 drinks on ≥3 days per week for men, and ≥3 drinks on ≥3 
days per week for women.  
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2.4: DRINKING MOTIVES: WHY DO OLDER ADULTS DRINK? 
Research highlights that, in New Zealand, there are concerning levels of alcohol use in older 
adults (Stevenson et al., 2015; Towers et al., 2011; Towers, Sheridan et al., 2018). In order to 
develop health or policy responses to change these drinking trends, it is important to understand 
why such drinking occurs in the first place. A study by Khan et al. (2006) exploring drinking 
motives in a sample of 100 New Zealand drinkers aged ≤65 years found that the most 
commonly endorsed reasons for drinking were related to social enhancement (e.g., drinking to 
be social), mood regulation (e.g., drinking to relax) and eating practices (e.g., drinking before 
meals). Similarly, a study of older adults living in Finland (Immonen et al., 2011) found that 
‘having fun or celebrating’ and ‘social reasons’ were the most commonly endorsed drinking 
motives among participants. This Finnish study also found ‘at-risk’ drinkers4 were more likely 
to endorse drinking for mood regulation purposes (most commonly to relieve depression, 
loneliness, or anxiety). The findings of these studies therefore indicate that many older adults 
drink for social reasons, and that drinking to regulate mood is also common among older adults, 
particularly those engaging in hazardous (or ‘risky’) drinking patterns. 
2.5: EFFECTS OF ALCOHOL ON OLDER ADULTS’ HEALTH AND WELLBEING 
One of the factors that is of paramount interest in international research on older adult’s alcohol 
consumption is the effect that alcohol has on the health.  This subsection reviews literature into 
the associations of alcohol use and health outcomes. Research indicating moderate drinking is 
associated with a variety of desirable health outcomes is discussed first, followed by a summary 
of the health risks associated with alcohol use during older adulthood.  
 
4 Immonen et al. (2011) defined ‘at-risk’ drinkers as those who reported consuming >7 drinks weekly, ≥5 drinks 
per typical drinking day, or ≥3 drinks on multiple days during a typical week 
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2.5.a: Relationship between moderate drinking and health  
Epidemiological studies consistently show an inverted relationship between alcohol 
consumption and health, where moderate drinking is associated with better outcomes than 
abstinence or heavy drinking across a range of dimensions such as cardiovascular health (de 
Gaetano et al., 2002; Foerster et al., 2009; Matsumoto et al., 2014; Ronksley et al., 2011; Shai 
et al., 2004), cognitive functioning (Lang et al., 2007), and depressive symptoms  (Chan et al., 
2009; Coulson et al., 2014; Rodgers et al., 2000). While such findings are often interpreted as 
evidence for the health benefits of moderate drinking, it is possible that such findings reflect 
important existing sociodemographic and behavioural differences between moderate drinkers 
and abstainers (Fekjaer, 2013; Naimi et al., 2005).  For example, Scott et al. (2020) found the 
relationship between moderate drinking and fewer depressive symptoms was explained by 
increased social interaction among older moderate drinkers.  Similarly, Towers, Philipp et al. 
(2018) found that the relationship between moderate drinking and physical health was 
substantially reduced among older women and completely eliminated among older men when 
a control measure of socioeconomic status (SES) was included in their analysis. These results 
suggest the association between moderate drinking and positive health outcomes is largely the 
result of confounding variables rather than a causal relationship. In the absence of potential 
health benefits, it is important to understand whether older drinkers are placing themselves at 
increased risk of alcohol-related harm due to their patterns of consumption.   
2.5.b: Risks associated with drinking in older adults 
Physiological changes that occur during later life appear to increase older adult’s vulnerability 
to many adverse health consequences of alcohol consumption.  Body water content decreases 
during older adulthood, leaving a smaller volume of fluid across which consumed alcohol is 
distributed (Moore et al., 2007). Additionally, production of the enzyme alcohol-
dehydrogenase (ADH), which is involved alcohol metabolism, decreases in later life (Moore 
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et al., 2007).  Due to these changes in body-mass and metabolism, older adults generally show 
higher blood alcohol levels (BALs) in response to consumption relative to younger or middle-
aged adults (Davies & Bowen, 1999; Jones & Neri, 1989; Pozzato et al., 1995). Older adults 
who misuse alcohol have heightened risk of cognitive impairment due to the acceleration of 
age-related declines in white matter (Sorg et al., 2015; Thomas & Rockwood, 2001).  Alcohol 
misuse among older adults also increases risk of hip fracture due to lowered bone density and 
increased likelihood of falling because of the effect alcohol has on factors such as reaction time 
and balance (Yuan et al., 2001). Many chronic conditions that can be caused or exacerbated by 
alcohol (e.g., cirrhosis, dementia, pancreatitis, and gastritis) are highly prevalent in older 
populations (Moore et al., 1999). Unsurprisingly, rising alcohol consumption in older adults 
around the world is correlated with increasing rates of alcohol use disorders in older adults 
(Han et al., 2017) and alcohol-related hospitalisations of older drinkers (Sacco et al., 2015).  
One of the most fundamental risks associated with drinking during older adulthood is the 
potential for harm associated with concomitant alcohol and medication use. With advancing 
age and associated onset of health morbidity, older adults are more likely to use one or more 
medications with the potential to cause an adverse alcohol-medication interaction (AMI) when 
used concomitantly with alcohol (alcohol-interactive (AI) medications) (Moore et al., 2007).  
While rates of AI-medication use in the New Zealand population are currently unknown, the 
prevalence of AI-medication use in a large US community sample was 43% among adults aged 
≥20 years and 78% among those aged ≥65 years (Breslow et al., 2015). Moreover, health risks 
posed by heightened rates of AI-medication use among older populations are compounded by 
increased susceptibility to AMI related harm due to age-related physiological changes that 
typically occur during older adulthood (Moore et al., 2007).  
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2.6: SUMMARY  
Alcohol consumption is highly prevalent among older adults living in New Zealand, with many 
older New Zealanders engaging in potentially harmful drinking patterns (Stevenson et al., 
2015; Towers el al., 2011; Towers, Sheridan et al.,2018). Survey studies conducted in New 
Zealand and abroad indicate drinking motives relating to both social enhancement and mood 
regulation are common among older adults (Immonen et al., 2011; Khan et al., 2006), with 
mood regulation related drinking motives being most common among those engaging in 
potentially harmful drinking patterns (Immonen et al., 2011). Several studies have found 
evidence for an association between moderate drinking and desirable health outcomes (Chan 
et al., 2009; Coulson et al., 2014; de Gaetano et al., 2002; Foerster et al., 2009; Lang et al., 
2007; Matsumoto et al., 2014; Rodgers et al., 2000; Ronksley et al., 2011; Shai et al., 2004), 
however this relationship likely reflects sociodemographic differences between groups who 
abstain, drink moderately and drink heavily, rather than a causal association (Fekjaer, 2013; 
Naimi et al., 2005; Scott et al., 2020; Towers, Philipp, et al., 2018).  Risks of alcohol-related 
harm increase with age due to age-related changes in body mass, metabolism and illness 
susceptibility (Davies & Bowen, 1999; Jones & Neri, 1989; Moore et al., 1999 ; Mukamal et 
al., 2006; Pozzato et al., 1995; Sorg et al., 2015; Thomas & Rockwood, 2001; Yuan et al., 
2001).  In particular, the combination of increasing morbidity and ongoing alcohol use places 
older drinkers at heightened risk of harm due to their increased likelihood of using one or more 
AI-medications, and increased susceptibility to AMIs (Moore et al., 2007).  
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CHAPTER 3: ALCOHOL-MEDICATION INTERACTION 
PROCESSES  
An understanding of the harm posed by concomitant alcohol and AI-medication use 
(‘concomitant alcohol/AI-medication use’ hereafter) among older adults requires consideration 
of the nature of alcohol-medication interactions (AMIs).  There are three broad categories of 
AMI processes. Firstly, alcohol can reduce the therapeutic effectiveness of many medications 
by exacerbating the condition they are used to treat (Moore et al., 2007). Secondly, alcohol can 
enhance the effects of many medications directly – these are known as pharmacodynamic 
interactions. Thirdly, pharmacokinetic interactions can occur between alcohol and certain 
medications, which involve interferences in normal drug absorption, distribution, and 
metabolism (Adams, 1995; Moore et al., 2007; Nagaraj et al., 2017; Weatherman & Crabb, 
1999).  
3.1: ALCOHOL EXACERBATING CONDITIONS 
Many conditions known to be exacerbated by alcohol are common in older populations, such 
as cognitive impairment, depression, diabetes mellitus, gastrointestinal problems, gout, 
hypertension, and insomnia (Moore et al., 2007).  The use of alcohol by older adults with such 
conditions can have an indirect effect on the effectiveness of medication treatment. 
Specifically, as medication doses are selected based on the degree of morbidity (i.e., higher 
doses for more serious conditions), alcohol use may undermine the effectiveness of a 
prescribed medication dose by exacerbating the seriousness of the condition being treated 
(Moore et al., 2007).  
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3.2: PHARMACODYNAMIC INTERACTIONS 
Alcohol can have pharmacodynamic interactions with medications that have similar effects to 
those caused by alcohol. For example, both alcohol and non-steroidal anti-inflammatory drugs 
(NSAIDs) such as aspirin and ibuprofen can cause gastrointestinal (GI) bleeding independently 
of one another. As a result, GI-bleeding risk is higher among persons using both alcohol and 
NSAIDs than those using only alcohol or only NSAIDs (Kaufman et al., 1999).  Similarly, 
sedation and orthostatic hypotension are common effects of alcohol. Drugs that can cause 
sedation (e.g. benzodiazepines) and hypotension (e.g. barbiturates) can therefore exacerbate 
these effects of alcohol, and in turn increase the likelihood of alcohol-related falls (Moore, 
2007). The risks of pharmacodynamic alcohol medication interactions are particularly relevant 
to older populations, as susceptibility to GI-bleeding increases with age (Moore, 2007), as does 
the likelihood of injury due to an alcohol-related fall (Stenbacka et al., 2002).   
3.3: PHARMACOKINETIC INTERACTIONS 
Pharmacokinetic interactions can occur between alcohol and a range of medications. Such 
interactions can occur due to interferences in a) the initial metabolism of alcohol in the stomach 
and liver (first-pass metabolism), b) the concentration of alcohol and/or medication through the 
body (distribution), and c) the final stage of alcohol and/or medication metabolism in the liver 
(hepatic metabolism).   
3.3.a: First-pass metabolism  
First-pass metabolism of alcohol refers to the initial stage at which alcohol is broken down by 
the body before reaching systemic circulation (i.e. the bloodstream) (Sharma et al., 1995). This 
first-pass metabolism process occurs in the stomach soon after ingestion.  While alcohol is 
being absorbed from the gastrointestinal tract into the bloodstream (a process called gastric 
emptying), a small amount of alcohol is metabolized in the stomach by the enzyme ADH. The 
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remaining alcohol is then transported to the liver where it is metabolised further (Moore et al., 
2007; Sharma et al., 1995).  Some medications interfere with the first-pass metabolism of 
alcohol by inhibiting ADH activity in the stomach (e.g. acetylsalicylic acid; histamine H2 
receptor antagonists) or by increasing the rate of gastric emptying (e.g. metoclopramide). Such 
interactions cause increased blood alcohol levels (BALs) relative to alcohol consumption 
quantity, and are more likely to occur in older persons because ADH levels diminish with age 
(Moore, et al., 2007).  
3.3.b: Distribution  
Following first-pass metabolism, alcohol is distributed from the liver throughout the body 
water. Changes in the ratios of body fat and body water which normally occur with aging have 
an important impact on the distribution of alcohol (Moore et al., 2007; Weatherman & Crabb, 
1999). Specifically, older adults typically have higher body fat ratios and lower body water 
ratios than younger adults, and therefore tend to have higher BALs relative to alcohol 
consumption volume (Davies & Bowen, 1999; Jones & Neri, 1989).  Additionally, higher body 
fat ratio can increase the half-life of fat-soluble sedative drugs, such as benzodiazepines.  
Therefore, older adults who use alcohol and fat-soluble sedatives concomitantly may 
experience prolonged and increased sedation (Moore et al., 2007; Weatherman & Crabb, 1999).   
3.3.c: Hepatic metabolism  
Following distribution, alcohol is transported back to the liver and metabolised. This final stage 
in alcohol metabolism is called hepatic metabolism. While there are several pathways through 
which hepatic metabolism of alcohol may occur, key enzymes implicated in pharmacokinetic 
AMIs involving hepatic metabolism interference include ADH and cytochrome P450 (CPY) 
enzymes (Adams, 1995; Moore et al., 2007; Nagaraj et al, 2017; Weatherman & Crabb, 1999).   
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For people who drink occasionally, ADH metabolizes most of the alcohol that reaches the liver.  
When alcohol is metabolized by ADH, it is converted into a chemical that is toxic to the liver 
called acetaldehyde, which is then further metabolized by aldehyde dehydrogenase (ALDH).   
A medication used for alcohol aversion therapy called disulfiram (commonly known as 
‘Antabuse’) acts by inhibiting ALDH. Alcohol use during the course of disulfiram treatment 
elicits highly unpleasant symptoms (e.g. facial flushing, nausea, headache, and dyspnea) 
resulting from acetaldehyde accumulation (Adams, 1995; Moore et al., 2007; Nagaraj et al, 
2017; Weatherman & Crabb, 1999).  Disulfiram is not typically prescribed to older adults 
because the consequences of this type of AMI may be more serious in older adult populations 
(Adams, 1995). However, disulfiram-like interactions can occur between alcohol and other 
medications that inhibit ALDH activity, such as metronidazole (NZF, 2017).   
AMIs involving interferences in CPY activity can occur when alcohol is used with medications 
that are metabolized by CPY enzymes (e.g. warfarin, benzodiazepines, phenytoin).  For people 
who drink moderately, CPY enzymes metabolize a small fraction of alcohol that reaches the 
liver. However, regular heavy drinking can increase CPY enzyme activity 10-fold, which can 
result in a need for higher medication doses to achieve desired therapeutic effects (Moore et 
al., 2007).  Episodic heavy drinking can deplete CPY enzymes, in turn increasing risks of 
medication overdose and alcohol poisoning (Moore et al., 2007; Weatherman & Crabb, 1999). 
Older persons may be particularly sensitive to these interactions because hepatic drug 
metabolism efficiency appears to decrease by up to 30% in older adulthood due to age related 
CPY enzyme impairment (Heuberger, 2012).   
3.4: SUMMARY 
In addition to the generally greater risks associated with alcohol use for older adults discussed 
in the previous chapter, alcohol use poses significant risk for older adults with medicated health 
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conditions (Moore et al., 2007). Alcohol may interfere with the therapeutic effects of 
medications by exacerbating the health condition they are used to treat. The harmful effects of 
alcohol may be exacerbated by medications which have similar effects to those caused by 
alcohol such as GI-bleeding, sedation, and hypotension.  Other alcohol-medication interactions 
may result from interferences in the metabolism and distribution of alcohol and/or medications.  
Due to age-related changes in illness susceptibility, body-mass, and metabolism, older adults 
are particularly susceptible to alcohol-medication interactions (Adams, 1995; Moore et al., 
2007; Nagaraj et al, 2017; Weatherman & Crabb, 1999). This places them at considerably 
higher risk of alcohol-related harm even for levels of drinking that may be considered non-
hazardous for other age-groups or for healthier cohorts (Towers, Sheridan et al., 2018). The next 
chapter reviews research exploring the rate at which older adults may be exposed to AMIs. 
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CHAPTER 4: PREVALENCE OF AMI EXPOSURE & THE 
CONCOMITANT USE OF ALCOHOL AND AI-MEDICATION 
BY OLDER ADULTS 
The previous chapter discussed the nature of AMIs, and highlighted that older adults are more 
vulnerable to AMI related harm relative to younger cohorts due to the physiological changes 
that occur with aging.  To further explore the AMI related harm posed to older adults, this 
chapter reviews research exploring the prevalence of potential AMI exposure in older adult 
populations.  Research into AMI related healthcare utilization is discussed first, followed by a 
review of survey research exploring rates of older adults who use of both alcohol and AI-
medications.   
4.1: AMI-RELATED HEALTHCARE UTILISATION RATES 
While published data on the rate of AMI exposure in New Zealand is currently unavailable, 
hospital records show that the prevalence of AMIs is increasing in the US. The annual rates per 
capita of emergency department visits resulting from AMIs in the US doubled between 2005 
and 2011 (Castle et al., 2016), and an analysis of hospital discharge records in the US state of 
Kentucky found a 187% increase in AMI-related hospital admissions among adults aged 50+ 
between 2001 and 2012 (Zanjani et al., 2016).  These findings indicate growth in the public 
health burden resulting from concomitant alcohol/AI-medication use. However, many cases of 
concomitant alcohol/AI-medication use may not result in ED visits or hospitalisation. 
Therefore, to get a sense of the prevalence of concomitant alcohol/medication use among older 
adults, findings from survey studies must also be considered. 
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4.2: ESTIMATED PREVALENCE OF CONCOMITANT ALCOHOL/AI-MEDICATION USE 
BASED ON SURVEY DATA 
A number of survey studies exploring the prevalence of concomitant alcohol/AI-medication 
use have been conducted in the US (e.g., Breslow et al., 2015), Europe (e.g., Immonen et al., 
2013), and Australia (Ilomäki et al., 2008). Data on medication use within community samples 
can be derived either by self-report measures or administrative data resources such as 
pharmaceutical dispensing records. However, self-report measures are necessary when 
assessing the prevalence of concomitant alcohol use by AI-medication users, because 
information on rates, frequency and quantity of alcohol use are not available via other sources 
for general community samples. There are also several methodological issues apparent in this 
field which impact upon the inferences drawn about rates of concomitant alcohol/AI-
medication use. It is therefore necessary to briefly highlight these methodological issues before 
discussing the results of survey studies exploring the prevalence of concomitant alcohol/AI-
medication use.  
4.2.a: Methodological considerations  
Some researchers have examined only a narrow range of medications, such as 
sedative/hypnotic medications (Bye et al., 2017; Ilomäki et al., 2008) and other classes of 
psychotropic drugs (Du et al., 2016; Wolf et al., 2017), when providing estimated rates of 
concomitant use.  Consequently, prevalence estimates provided by these studies are limited to 
AMIs attributable to these classes of medications and the populations who use them.   However, 
studies including a wide variety of medications in their analyses are difficult to compare due 
to differing populations of interest, and studies variously reporting information relating to a) 
rates of alcohol use among AI-medication users, b) rates of AI-medication use among drinkers, 
or c) overall sample rates of individuals identified as both drinkers and AI-medication users 
(i.e. concomitant users). Moreover, the research designs employed in such studies infer 
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concomitant use by measuring alcohol use and medication use separately, rather than directly 
assessing concomitant use with a single measure. For example, Qato et al. (2015) inferred 
concomitant alcohol/AI-medication based on survey questions regarding drinking frequency 
(alcohol measure), and by having participants provide containers of any medications they used 
regularly (medication use measure). Furthermore, any attempts to compare the findings of these 
studies are complicated by differences in specific measures and measurement thresholds used 
to identify drinkers and medication users. Consequently, the population prevalence of 
concomitant alcohol/AI-medication use is likely to be overestimated by studies using highly 
inclusive measurement thresholds and underestimated by those adopting more stringent 
thresholds. See chapter 10 for a more comprehensive review of survey research methods used 
to identify rates of concomitant alcohol/AI-medication use.  
4.2.b: Results of survey data analyses  
The results of six studies exploring rates of concomitant alcohol/AI-medication use using 
survey data from older adult samples in the US (Breslow et al., 2015; Pringle et al., 2005; Qato 
et al., 2015), Finland (Aira et al., 2005; Immonen et al., 2013) and Ireland (Cousins et al., 2014) 
are reviewed here.  These studies are most relevant because they included a wide range of 
medication classes in their analyses (rather than focusing on a few potentially AI drug classes) 
and thus provide the best available evidence on the population prevalence of potential AMIs. 
As these studies have important methodological differences, their respective sample and 
measurement characteristics are summarized in Table 1, and the implications of their research 
designs are considered as their findings are discussed. This discussion is structured in terms of 
the reported rates of 1) alcohol use among study participants who are AI-medication users 2) 
AI-medication use in study participants who consume alcohol, 3) study participants identified 
as users of both alcohol and AI-medications (i.e., concomitant alcohol/AI-medication users), 
and 4) observed relationships between alcohol use and AI-medication use.    
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Table 1: Methodological Characteristics of Reviewed Survey Studies Reporting on Rates of Concomitant Alcohol/AI-Medication Use 
Author Sample Characteristics Medication use measure AI-Medication 
Identification Resource(s) 




Aira et al., 2005 523 community 
dwelling adults aged 
≥75 years living in 
Finland 
Prescription sheets for 
medications in current 
use were provided by 
participants 
N/A Interview questions 
about past year 
drinking quantity and 
frequency 
Regular medication 
use at survey 
completion date 
(includes AI and 
non-AI medications) 
≥1 drink weekly 
during past year 
Immonen et al., 
2013 
2,100 community 
dwelling adults aged 




by their doctors 
 





questionnaire from the 
AUDIT (Saunders et 
al., 1993) and NIAAA 
(2007) guidelines 
AI-medication in use 
at survey completion 
date 
≥ drink monthly 
Cousins et al., 
2014 
3,815 community 
dwelling adults aged 




medications they used 
“on a regular basis, like 
every day or every week” 
Stockley’s Drug 




2013); and the Irish 
Medicines Formulary 
(2013) 
CAGE (Ewing, 1984; 
Buchsbaum et al., 
1992) and questions 
regarding past 6-
month frequency and 
quantity of 
consumption 
AI-medication use at 
survey completion 
date 
≥1 drink during 
past 6 months 
Notes: SFINX = The Swedish, Finnish, INteraction X-referencing; NIAAA = National Institute on Alcohol Abuse, & Alcoholism; AUDIT = Alcohol Use Disorders 
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Table 1: Continued 
Author Sample Characteristics Medication use measure AI-Medication 
Identification Resource(s) 




Breslow et al., 
2015 
26,657 community 
dwelling adults living in 
the US aged 20+; 
includes an older adult 
subsample (age ≥65 
years) 
One question about past 
month medication use, 








Weathermon and Crabb, 
(1999) 
Questions about past 




during past month 
≥1 drink during 





Pringle et al., 
2005 
83,321 adults aged ≥65 
living in the US and 
receiving medical 
benefits offered to older 





First DataBank (2004) 
 
Questions about 
drinking quantity and 
frequency, and 
drinking status (e.g. 
former drinker) 
AI-medication 




Qato et al., 2015 2,975 community 
dwelling adults aged 
≥57 living in the US 
Participants provided 
containers of medications 
they used regularly 
Thomson Micromedex 
database (cited in Qato et 
al., 2015) 
Questions about 
drinking quantity and 
frequency 
Regular AI-
medication use at 
survey completion 
≥1 drink weekly 
during past 3 
months 
Note: NIAAA = National Institute on Alcohol Abuse, & Alcoholism 
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Alcohol use among AI-medication users 
Reported rates of alcohol use among older AI-medication users range from approximately 20% 
in the US (Pringle et al., 2005) to approximately 60% in both Ireland (Cousins et al., 2014) and 
Finland (Immonen et al., 2013). However, these studies have important methodological 
differences which limit their interpretation and generalisability across countries. With regards 
to sampling, participants in the US study were substantially older than those participating in 
the other two studies. In addition, the US sample consisted exclusively of participants receiving 
pharmaceutical benefits offered to those within a low-income bracket, whereas the other two 
studies included nationally representative community samples. As both older age and lower 
SES have been associated with reduced alcohol use (Moos et al., 2005; Moore et al., 2005; 
Towers, Philipp et al., 2018), the lower rate of drinking in the US sample may reflect these 
differences. With regards to measurement differences, while the Finnish and US studies used 
similar thresholds to define participants as drinkers (those drinking at least monthly), the 
drinking criteria used in the Irish study was much more inclusive in comparison (those drinking 
during the past six months).  Consequently, the results of the latter study may provide an 
overestimation of concomitant alcohol use among AI-medication users.   
AI-medication use among drinkers 
Reported rates of AI-medication use among older drinkers range from 77% in the US (Breslow 
et al., 2015) to 87% in Finland (Aira et al., 2005). However, these findings cannot be seen as 
indicative of population differences between the US and Finland due to important sampling 
and measurement differences between the studies (see Table 1). With regards to sampling 
differences, participants included in the Finish sample were older than those participating in 
the US study (≥75 years vs. ≥65 years). Given that the likelihood of AI-medication use 
increases with age (Moore et al., 2007), age differences likely contribute to the differing results 
between these studies.  With regards to measurement differences, the US study only included 
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medications identified as AI in the analysis, whereas the Finish study did not exclude non-AI-
medications. In addition, while participants identified as drinkers in the Finnish study reported 
using alcohol at least weekly, the inclusion criteria used to identify drinkers in the US sample 
required participants to report drinking at least once during the past year and at least 12 drinks 
during their lifetime.  To summarize, the findings of these studies are not directly comparable 
due to age differences between to the two samples, and methodological differences in the 
identification of both alcohol users and AI-medication users.   
Rates of concomitant alcohol/AI-medication use  
Two US studies have reported on total sample rates of participants identified as both drinkers 
and AI-medication users. These studies indicate rates of concomitant alcohol/AI-medication 
use by older adults range from approximately 20% (Qato et al., 2015) to approximately 35% 
(Breslow et al., 2015). One important difference between these studies relates to the age of 
participants (Table 1), as Breslow et al. (2015) had an older sample than Qato et al. (2015).  
Both studies had similar designs in terms of AI-medication use identification, although a key 
measurement difference between these studies relates to drinking thresholds used to identify 
drinkers (Table 1). Qato et al. (2015) defined drinkers as those who reported using alcohol at 
least weekly, whereas participants identified as drinkers by Breslow et al. (2015) reported 
drinking during the past year. Therefore, the classification method used by Breslow et al. 
(2015) likely overestimated concomitant alcohol/AI-medication use, relative to the 
comparatively stringent classification method employed by Qato et al. (2015).   
Relationships between alcohol use and AI-medication use 
Five studies reviewed here explored relationships between alcohol use and AI-medication use 
among participants. Three studies (Breslow et al., 2015; Immonen et al., 2013; Qato et al., 
2015) found that AI-medication use was significantly less common among drinkers when 
compared to non-drinkers, one study (Cousins et al., 2014; Immonen et al., 2013) found that 
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alcohol use was significantly less common among those using AI-medications, and one study 
(Pringle et al., 2005) found that individuals using multiple AI-medications were significantly 
less likely to consume alcohol. To summarize, a negative association between alcohol use and 
AI-medication use is a consistent finding in survey studies including a wide variety of AI-
medications in their analysis.  
4.3: SUMMARY  
Published data relating to the prevalence of, and potential for, AMI exposure in New Zealand’s 
older adult population is currently unavailable. While US research shows increasing rates of 
AMI related ED visits and hospital admissions (Castle et al., 2016; Zanjani et al., 2016), 
estimates of rates of concomitant AI-alcohol use in community samples of older adults vary 
greatly. Studies conducted in the US and Europe suggest a) 20%-60% of older AI-medication 
users use alcohol, b) 77%-87% older of drinkers use AI-medications, and c) one-in-five to one-
in-three older adults use alcohol and AI-medications concomitantly (Aira et al., 2005; Breslow 
et al., 2015; Cousins et al., 2014; Immonen et al., 2013; Pringle et al., 2005; Qato et al., 2015). 
This variation likely reflects differences in methods used across studies, with key issues 
including the sources of data, the base population of interest, and the measurement and 
operationalisation of AI medication use, alcohol use, and concomitant alcohol/medication use. 
One consistent finding across survey studies exploring concomitant alcohol/AI-medication use, 
is that alcohol use is negatively associated with AI-medication use (Breslow et al, 2015; 
Cousins et al., 2014; Pringle et al., 2005; Qato et al., 2015). The next chapter reviews research 




41 | P a g e  
 
CHAPTER 5: MOTIVATING FACTORS UNDERLYING 
DRINKING BEHAVIOUR AMONG AI-MEDICATION USERS 
Research exploring the concomitant use of alcohol with a wide range of AI-medications 
consistently shows that AI-medication users are less likely to drink than non-users of AI-
medications (Breslow et al, 2015; Cousins et al., 2014; Pringle et al., 2005; Qato et al., 2015). 
This suggests many older adults alter their alcohol intake to accommodate their medication 
regimes. However, the high rates of concomitant alcohol/AI-medication use reported across 
survey studies show that many older adults continue to drink despite using AI-medications.  
This chapter reviews literature exploring the motivating factors underlying drinking behaviour 
among older AI-medication users, and highlights research suggesting healthy changes in 
drinking behaviour may be particularly difficult for older AI-medication users with mental 
health problems such as depression.  
5.1: AMI-RELATED KNOWLEDGE    
Perhaps unsurprisingly, some research findings suggest knowledge about the potential adverse 
impact of concomitant alcohol/AI-medication use on health motivates changes in drinking 
behaviour among many AI-medication users.  A qualitative analysis by Gavens et al. (2016) 
found that older persons who reduced their alcohol intake following chronic illness onset often 
cited discussions about potential AMIs with health professionals as motivation for drinking 
behaviour changes. Similarly, a survey study by Zanjani et al. (2013) found that, when 
compared to non-drinkers, older drinkers identified fewer AI-medications when completing a 
quiz (i.e., a list containing both AI and non-AI-medications) and had less knowledge of the 
potential alcohol-interactivity of medications they used personally.  Another survey study by 
Wilkinson et al. (2016) found that older adults were more receptive to information relating to 
alcohol-medication interactions than other types of alcohol safety information, such as 
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recommended drinking guidelines and more general health risks of alcohol.  Overall, these 
findings suggest that knowledge of the potential for alcohol to interact with medication is a 
strong motivator for changes in drinking behaviour for many older adults, perhaps even more 
so than other forms of alcohol safety information. 
If AMI related health knowledge is associated with lower alcohol consumption, one 
might reasonably assume the provision of AMI related health information would facilitate 
reductions in alcohol consumption among adults taking potentially AI-medications.  
Accordingly, interventions aimed at reducing AMI exposure have focused on educating older 
adults about the risks associated with concomitant alcohol/AI-medication use in pharmacy 
settings (Benza et al., 2010; Zanjani et al., 2018a, 2018b, 2018c).  These interventions have 
been shown to effectively increase older adults’ AMI awareness at immediate post-test (Benza, 
et al., 2010; Zanjani et al., 2018a, 2018b) and three-month follow-up (Zanjani et al., 2018c). 
However, despite having positive effects on AMI awareness, educational interventions appear 
to have little effect on drinking intentions at post-test (Zanjani et al., 2018b) and have actually 
been associated with decreased intentions to reduce alcohol consumption at three-month 
follow-up (Zanjani et al., 2018c). In other words, while educational interventions appear to 
effectively increase older adults’ AMI related awareness, simply providing AMI related 
information does not appear to facilitate desired changes in alcohol consumption and may 
actually have an adverse effect on drinking behaviour.    
5.2: INFORMATION AVOIDANCE 
The findings relating to AMI knowledge and drinking behaviour reviewed thus far seem 
somewhat contradictory. While the likelihood of alcohol use appears to be lower among older 
AI-medication users who are aware of the potential for AMI related harm, increasing older 
adults’ awareness of AMI risks does not appear to facilitate healthy changes in drinking 
behaviour. A possible explanation for this discrepancy is that AI-medication users who change 
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their drinking behaviour in response to health information are more likely to have sought 
information about AMI risks than those less inclined to respond to such information. For 
example, Zanjani et al. (2013) found that older drinkers displayed less willingness to discuss 
the potential for AMI related harm with friends and family. Similarly, Gavens et al. (2016) 
found that many older chronically ill drinkers avoided discussing alcohol-related harm with 
health professionals and others rationalised their drinking with selective interpretations of 
health information, placing greater importance on evidence that health problems are unrelated 
to alcohol use.  Additionally, a qualitative analysis by Zanjani, Allen, Smith et al. (2018) found 
pharmacy staff often cited denial of personal AMI risk as a key barrier to healthy changes in 
drinking behaviour among older adults.  Overall, these findings highlight the possibility that 
some AI-medication users who do not alter their alcohol intake may actively avoid and/or 
dismiss information relating to AMI risks. 
According to a review by Sweeny et al. (2010) exploring motivators of information 
avoidance in multiple contexts, people typically avoid information that challenges cherished 
beliefs and identifies a need for unwanted action or change. In the context of concomitant 
alcohol/AI-medication use, such information might be that which challenges beliefs about 
alcohol-related harm and highlights a need for reduced alcohol consumption.  Barriers to 
changes in drinking behaviour may therefore serve to motivate avoidance of AMI related 
information for many older adults and may also prevent exposure to AMI information from 
leading to reduced alcohol consumption.  
5.3: MENTAL HEALTH RELATED BARRIERS TO DRINKING BEHAVIOUR CHANGE 
There is some evidence indicating barriers to drinking behaviour change may be heightened 
among older AI-medication users suffering from mental health problems. Firstly, the observed 
negative association between alcohol use and AI-medication use (Breslow et al, 2015; Cousins 
et al., 2014; Pringle et al., 2005; Qato et al., 2015) is less evident in studies focusing on 
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medications commonly used to treat psychiatric difficulties (e.g., Bye & Rossow, 2017; 
Ilomäki et al., 2008, 2013).  For example, research from the US has shown that antidepressants 
are the most commonly used class of AI-medication among older drinkers (Qato et al., 2015), 
and are among the more commonly involved drug classes in AMI related emergency 
department visits (Castle et al., 2016). Secondly, a survey study of mental health service users 
conducted by Cheng et al. (2018) found that nearly half of the sample reported having used 
alcohol and psychotropic medications concomitantly despite having considered the risk of AMI 
prior to alcohol consumption (it is notable that antidepressants were the most commonly used 
medication class among participants in this study).   Finally, qualitative findings suggest 
alcohol is often used to alleviate negative affect among chronically ill older adults (Gavens et 
al., 2016) and to ‘self-medicate’ depressive symptoms among older medication users (Haighton 
et al., 2018). To summarize, these findings suggest reliance on alcohol as an affect-regulation 
strategy may prevent changes in drinking behaviour among older adults with mental health 
problems, particularly those experiencing symptoms of depression.  
5.4: SUMMARY  
Research into factors motivating concomitant alcohol/medication use suggests older AI-
medication users who drink typically have less knowledge of AMI risks than those who abstain 
from alcohol (Zanjani et al., 2013). However, interventions aim to educate older adults about 
AMI risks do not appear to motivate healthy changes in alcohol consumption, despite 
effectively enhancing awareness of AMI related harm (Benza et al., 2010; Zanjani et al., 2018a, 
2018b, 2018c).  Other research findings suggest this discrepancy may be due to avoidance 
and/or denial of AMI-related information among older drinkers who are less inclined to change 
their drinking behaviour in response to health information (Gavens et al., 2016; Zanjani et al., 
2012; Zanjani, Allen, Smith et al., 2018). There is therefore a need to identify barriers to 
drinking behaviour change among AI-medication users.  
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There is also evidence that mental health factors such as depression may hinder drinking 
behaviour change among AI-medication users. Alcohol use is common among users of 
medications used to treat psychiatric conditions such as depression (Bye & Rossow, 2017; 
Ilomäki et al., 2008, 2013; Qato et al., 2015), and users of mental health services often report 
using alcohol and medications concomitantly despite being aware of the potential for AMI 
related harm (Cheng et al., 2018).  Additionally, qualitative research indicates older AI-
medication users may often use alcohol to regulate emotion and/or ‘self-medicate’ symptoms 
of depression (Gavens et al., 2016; Haighton et al., 2018).  The next chapter aims to explain 
these findings using theories of health behaviour and alcohol use.  
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CHAPTER 6: MOTIVATIONAL THEORIES OF HEALTH 
BEHAVIOUR AND ALCOHOL USE 
The research reviewed in the previous chapter provided a starting point to form hypotheses for 
the second study conducted in the present thesis.  This chapter aims to contextualize these 
findings using motivational theories of health behaviour and alcohol consumption.   
6.1: SOCIAL COGNITIVE THEORIES OF HEALTH BEHAVIOUR: MOTIVATION TO 
CHANGE  
The term health behaviour broadly refers to any behaviour performed in the service of 
preventing adverse health outcomes and/or promoting health and well-being (Norman & 
Conner, 2005).  Altering alcohol consumption to reduce risk of AMI is therefore an example 
of health behaviour that is highly relevant to the present thesis.  Several social cognitive 
theories attempt to explain the way cognitive factors (e.g., thoughts, beliefs, attitudes) influence 
health behaviour engagement (Norman & Conner, 2005; Sutton, 2000). These theories may 
therefore provide insight into psychological factors motivating changes in drinking patterns 
among AI-medication users.  
 Social cognitive theories of health behaviour can generally be divided into two 
groups: Motivational models focus on identifying predictors of health behaviour at single 
points in time; and stage models focus on identifying the processes through which health 
behaviours change over time (Sutton, 2000).  The appeal of stage models is their consideration 
of factors determining whether adopted health behaviours are maintained. However, the 
components of stage models are not easily applied to cross-sectional research (Sutton, 2000). 
The present subsection therefore focuses on dominant motivational health behaviour models 
including Self-Efficacy Theory (SET) (Bandura, 1982); the Health Belief Model (HBM) (Janz 
& Becker, 1984; Rosenstock, 1974; Rosenstock et al., 1988); Protection Motivation Theory 
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(PMT) Maddux, & Rogers, 1983; Rogers, 1975); and the Theory of Planned Behaviour (TPB) 
(Ajzen, 1991).  The key constructs and general tenets of these theories are summarized in Table 
2.   
6.1.a: Evaluation of models in relation to AMI related health behaviour 
Overall, there is substantial overlap between the theories included in Table 2. Each model 
assumes that people are future oriented, and that behaviour is influenced by personal 
evaluations of the pros and cons of possible courses of action (Sutton, 2002).  The primary 
point of difference between these models relates to specific construct definition.  Lippke and 
Ziegelmann (2008) therefore argue that the value of each social cognitive model often depends 
on the specific health behaviour in question. Therefore, the present subsection seeks to identify 
which model best provides a parsimonious account of the findings discussed in chapter 5. 
 
Table 2: Motivational Models of Health Behaviour: Key Constructs and General Tenets 
Model Key constructs General tenet of the model 
SET Outcome expectancies: beliefs about the positive 
and negative consequences of a given behaviour 
(e.g. physical health outcomes; social and self-
evaluative outcomes) 
Self-efficacy: an individual’s beliefs about their 
ability to successfully perform a given behaviour 
Health behaviour is more likely if 
one a) expects the resulting 
positive consequences to outweigh 
the negative consequences and b) 
has high self-efficacy beliefs in 
relation to the health behaviour. 
HBM Cue of action: any stimuli that draws attention to 
the threat of adverse health outcomes and in turn 
initiates decision making processes about health 
behaviour 
Perceived susceptibility: beliefs about personal 
vulnerability to a given adverse health outcome  
Perceived severity: beliefs about the potential 
severity of an adverse health outcome 
Perceived benefits: beliefs about the effectiveness 
of health behaviours  
Perceived barriers: beliefs about potential 
downsides of health behaviour engagement 
Self-efficacy: an individual’s beliefs about their 
ability to successfully perform a health behaviour 
Health behaviour is more likely if 
one a) perceives the threat of 
illness/harm to be high, b) believes 
the resulting positive 
consequences outweigh the 
negative consequences, and c) has 
high self-efficacy beliefs in 
relation to the behaviour. 
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Table 2: Continued  
Model Key constructs General tenet of the model 
PMT Protection motivation: motivation to protect oneself 
against adverse health outcomes 
Adaptive responses (to threat): adopting health 
behaviour 
Maladaptive responses: responding to threat of 
illness/harm in a way that does not reduce risk (e.g. 
denial of risk) 
Response costs: perceived negative aspects of 
performing adaptive behaviour 
Rewards: perceived positive/rewarding aspects of 
maladaptive behaviour 
Vulnerability appraisal: beliefs about personal 
vulnerability to a given adverse health outcome 
Severity appraisal: beliefs about the potential 
severity of an adverse health outcome 
Response efficacy: the perceived 
usefulness/effectiveness of a health behaviour 
Self-efficacy: an individual’s beliefs about their 
ability to successfully perform a health behaviour 
Health behaviour is more likely if 
one a) perceives the threat of 
illness/harm to be high, b) believes 
the rewarding aspects of 
maladaptive behaviours to be 
minimal, c) perceives the costs of 
health behaviour to be small, d) 
believes health behaviour will 
mitigate threat and/or promote 
health, and e) has high self-
efficacy beliefs in relation to the 
behaviour 
. 
TPB Intentions: the intention to perform a given 
behaviour  
Attitudes: personal evaluations a given behaviour 
Behavioural beliefs: beliefs about the consequences 
of a given behaviour, which are thought to 
underpin one’s attitude toward that behaviour 
Subjective norms: perceived expectations of other 
people regarding the behaviour 
Normative beliefs: beliefs about others’ 
expectations, which are thought to underpin one’s 
subjective norm in relation to health behaviour. 
Perceived behavioural control: the perceived level 
of ease/difficulty in performing a health behaviour  
Control beliefs: beliefs that formulate one’s 
perceived behavioural control 
Health behaviour is more likely if 
one a) believes the positive 
consequences outweigh the 
negative consequences; b) 
believes the health behaviour is 
evaluated positively by important 
others’, and c) perceives the 
behaviour to be relatively easy to 
perform (similar to self-efficacy 
beliefs) 
 
Awareness of AMI risk motivates health behaviour change  
A key research finding discussed in the previous chapter is that knowledge of potential AMI 
risks appears to motivate many older adults to reduce their alcohol intake (Gavens et al., 2016; 
Wilkinson et al., 2016; Zanjani et al., 2013).   The idea that awareness of the potential threat of 
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illness or harm motivates health behaviour is implicit in all of the social cognitive models 
reviewed (e.g., outcome expectancies in SET; behavioural beliefs in TRA/TPB).  However, 
only two models (HBM; PMT) include specific constructs relating to perceived threat of 
adverse health outcomes (perceived susceptibility/severity; vulnerability/severity appraisals; 
see Table 2).   
Information avoidance and denial of risk among concomitant AI-medication users 
Another key research finding is that alcohol use among AI-medication users is often associated 
with a range of avoidant coping strategies, such as avoiding AMI related health information 
(Gavens et al., 2016; Zanjani et al., 2013) and denying personal AMI-risk (Zanjani, Allen, 
Smith et al., 2018).   Among the reviewed social cognitive theories of health behaviour (Table 
2), PMT is the only model with a specific construct that accurately captures this behaviour (i.e., 
maladaptive responses).   
Mental health and self-medication as barriers to change  
Each model in Table 2 includes constructs that partially explain findings suggesting self-
medication is often barrier to drinking behaviour change among AI-medication users with 
mental health issues such as depression (e.g., Cheng et al., 2018; Gavens et al., 2016; Haighton 
et al., 2018).  For example, self-medication may influence one’s expectations about alcohol use 
(outcome expectancies; rewards; behavioural beliefs) and reduced drinking (outcome 
expectancies; perceived barriers; response costs; behavioural beliefs). Additionally, reliance 
on alcohol to regulate affect may influence the extent to which one feels capable of change 
(self-efficacy; perceived behavioural control).   However, health behaviour theories do not 
directly explain the relationship between depression and self-medication via alcohol use.  
  
50 | P a g e  
 
6.1.b: Protection Motivation Theory (PMT) 
Among the social cognitive health behaviour theories reviewed in this chapter (Table 2), 
Rogers’ (1975) PMT appears to provide the best parsimonious account of the research reviewed 
in chapter 5.  PMT was developed to explain the way people respond to information about 
health-related threat.  The model defines responses to such information as either adaptive 
responses (i.e. adopting a recommended health promoting behaviour) or maladaptive 
responses (e.g. avoidance, wishful thinking, denial). These responses are thought to depend on 
one’s level of protection motivation (the intention to perform a recommended health 
behaviour), with higher protection motivation increasing the likelihood of adaptive responses. 
Two independent fear appraisal processes are thought to influence protection motivation, 
including threat appraisals and coping appraisals.  The threat appraisal process involves an 
evaluation of severity (of the adverse health outcome) and vulnerability (personal susceptibility 
to the adverse health outcome). Protection motivation is thought to increase when threat is 
perceived to be high, unless there is some advantage in performing maladaptive behaviour 
(rewards). The coping appraisal process includes response-efficacy (the perceived usefulness 
of a health promoting behaviour) and self-efficacy (beliefs about personal ability to successfully 
perform a given behaviour).  Protection motivation is thought to increase when response-
efficacy and self-efficacy are perceived to be high, unless the cost of health behaviour 
engagement (response cost) is perceived as being too great (Maddux, & Rogers 1983; Rogers, 
1975).   
Overall, PMT (Maddux & Rogers, 1983; Rogers, 1975) includes constructs conceptualizing 
perceived health threat as a motivator for health behaviour change (severity/vulnerability), 
which supports research indicating awareness of AMI risk is associated with reduced alcohol 
consumption (Gavens et al., 2016; Wilkinson et al., 2016; Zanjani et al., 2013).  The construct 
of maladaptive responses captures the avoidant coping strategies associated with continued 
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alcohol use among older AI-medication users (Gavens et al., 2016; Zangani et al., 2013, 
2018d). Additionally, PMT includes several constructs (rewards, response costs, self-efficacy) 
which explain how self-medication with alcohol may prevent changes in drinking patterns 
(Gavens et al., 2016; Haighton et al., 2018).  However, none of the health behaviour theories 
reviewed (including PMT) explains why self-medication with alcohol is commonly reported 
among AI-medication users with depression (Haighton et al., 2018). The following subsection 
therefore discusses this relationship in relation to motivational theories of alcohol use.   
6.2: THEORIES OF ALCOHOL USE: MOTIVATION TO DRINK 
Motivational models of alcohol use conceptualize drinking as a strategic behaviour for 
regulating affect (Cooper et al., 1995; Cox & Klinger, 1988). The motivational model proposed 
by Cooper et al. (1995) distinguishes between coping motives (drinking to escape, avoid, or 
alleviate unpleasant emotions) and enhancing motives (drinking to increase positive emotional 
and/or social experiences).   
Coping and enhancing motives appear to differ in terms of both antecedents and consequences. 
Factors which are predictive of enhancing motives include positive alcohol expectancies 
relating to social/emotional enhancement, sensation seeking tendencies, and positive affect. In 
contrast, positive expectations about the tension reduction properties of alcohol, avoidant 
coping tendencies, emotional dysregulation, and higher negative affect appear predictive of 
coping motives (Cooper et al., 1995).  Given that emotional dysregulation and negative affect 
are core features of most emotional disorders (Hofmann et al., 2012), Cooper’s model may help 
to explain the potential relationship between depression and alcohol/AI-medication use.  
With regards to consequences, coping motives appear more predictive of alcohol dependence 
than enhancing motives (Cooper et al., 1992; 1995). Cooper et al. (1995) suggest this is because 
the motivational consequences of negative affect are considerably more powerful than those of 
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positive affect.  Individuals who predominantly use alcohol for coping motives may therefore 
become reliant on alcohol to regulate unpleasant emotions that occur in everyday life.  In 
contrast, individuals who drink for enhancing motives are able to exert greater personal control 
over their alcohol consumption, and choose to drink when they see fit (Cooper et al., 1995).  
This model therefore provides further support the idea that self-medication (or drinking to 
cope) may lower alcohol related self-efficacy among AI-medication users.     
6.3: SUMMARY 
The present chapter aimed to identify theories that help explain the motivational factors 
underlying drinking behaviour among older adults who use AI-medications.  Protection 
motivation theory (Maddux & Rogers, 1983; Rogers, 1975) includes several constructs that 
help explain research findings implicating AMI related knowledge, avoidant coping strategies, 
and self-medication with alcohol as common factors influencing drinking behaviour among 
AI-medication users.  Cooper’s motivational model of alcohol use (Cooper et al., 1992; 1995) 
provides further explanation of a potential relationship between self-medication related 
drinking motives and concomitant alcohol/AI-medication use. Additionally, Cooper’s model 
also helps explain why self-medication with alcohol may be more common among AI-
medication users with depression.   The next chapter reviews relevant literature relating to the 
occurrence of depression during older adulthood.  
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CHAPTER 7: DEPRESSION DURING OLDER ADULTHOOD 
As discussed in section 5.3, research findings indicate concomitant alcohol use may be more 
common among older AI-medication users with depression. The present chapter therefore 
reviews relevant literature into depression during older adulthood.  This includes discussion of 
a) the term ‘late-life depression’, b) key symptoms of late-life depression, c) the prevalence of 
depression among older adults, d) the aetiology of late-life depression, and e) common factors 
associated with both depression and AI-medication use.  
7.1: DEFINING LATE-LIFE DEPRESSION 
Generally speaking, the term late-life depression refers to depression that is experienced during 
older adulthood.  This includes depression with onset during older adulthood (late-onset late-
life depression), and depression that persists during older adulthood from earlier life (early-
onset late-life depression).  More specifically, late-life depression is often used to refer to the 
occurrence of depressive syndromes during older adulthood (Alexopulos, 2005), such as those 
described by the Diagnostic and Statistical Manual for Mental Disorders (DSM) (American 
Psychiatric Association, 2013). When used in this way, the term usually refers to Major 
Depressive Disorder (MDD), but may also describe other unipolar depressive disorders such 
as dysthymia. Additionally, late-life depression may also refer to patterns of depressive 
symptoms falling below the threshold required for an MDD diagnosis (Fiske et al.,2009; Meeks 
et al., 2011; Rodda et al., 2011), sometimes referred to as ‘sub-threshold depression’ (SubD). 
While less severe than MDD, SubD greatly reduces health and quality of life among older 
adults, and is approximately 2-3 times more prevalent than major depression in older adult 
populations (Meeks et al., 2011).   
  
54 | P a g e  
 
7.2: SYMPTOMS OF DEPRESSION IN OLDER ADULTHOOD  
Depressed mood and a loss of interest in normally pleasurable activities (anhedonia) are 
generally considered to be the core features of depression, and the presence of one of these 
symptoms is required for a diagnosis of MDD (American Psychiatric Association, 2013). 
Additional depressive symptoms include cognitive disturbances (e.g. difficulty concentrating, 
negative thoughts, feelings of worthlessness, hopelessness, or suicidal ideation); psychomotor 
agitation (e.g. irritability, restlessness) or retardation (e.g. flat affect, slowed body movements); 
vegetative symptoms (e.g. sleep disturbance, eating disturbance, changes in body weight, loss 
of energy, fatigue, or reduced sexual desire); and anxiety symptoms (Stefanis & Stefanis, 
1999). 
While the overall symptom presentation of depression can be similar for younger and older 
adults (Chiu et al., 2003), the likelihood of certain symptoms appears to change during older 
adulthood. Depressive symptoms that appear more common among older adults include 
impaired cognitive processing speed, executive dysfunction (Butters et al., 2004), early 
morning wakening, fatigue, hopelessness (Christensen et al., 1999), anxiety, irritability, and 
somatic symptoms (Taylor, 2014).  Dysphoria and feelings of worthlessness or guilt appear to 
be less common in older persons (Gallo et al., 1994, 1997).    
 
7.3: PREVALENCE OF LATE-LIFE DEPRESSION  
While the current prevalence of late-life depression in New Zealand is unclear, data collected 
from the 2002/3 New Zealand Mental Health Survey indicated the past 12-month prevalence 
of MDD was 5.2% among New Zealanders aged 45-65 and 1.7% among those aged 65+ (Wells 
et al., 2006).  However, according to The World Health Organisation (WHO), the global 
prevalence of depression has risen in recent years, and depression is now the leading global 
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cause of poor health and disability (WHO, 2017a). Additionally, while rates of depression were 
once less prevalent in older populations (Byers et al., 2010; Henderson et al., 1998; Wells et 
al., 2006), recent estimates suggest the prevalence of depression peaks between the ages of 55-
74 (WHO, 2017b). This shift may be partially explained by changes in rates of late-life 
depression risk factors (discussed in the next subsection), given that rates of chronic illness, 
disability, and poor self-rated health are considerably higher among the baby-boomers than 
previous generations (King et al., 2013).   
7.4: AETIOLOGY OF LATE-LIFE DEPRESSION 
Late-life depression has been described as “the quintessential biopsychosocial disorder” (Aziz 
& Steffens, 2013, p. 511).  In other words, a broad range of biological, psychological, and 
social variables appear to be involved in the aetiology of late-life depression.  Some factors 
appear associated with increased vulnerability to late-life depression (i.e., risk factors), while 
others are associated with decreased late-life depression vulnerability (i.e., protective factors). 
However, the significance of certain risk factors appears to differ depending on the age at which 
symptoms of depression first appear. Specifically, non-genetic biological factors appear to be 
the most significant risk factors associated with depression that arises during older adulthood 
(late-onset late-life depression), whereas psychosocial and genetic factors appear to have 
greater association with depression arising prior to older adulthood (early-onset late-life 
depression) (Fiske et al., 2009).       
7.4.a: Psychosocial factors 
Several psychological factors (e.g., neuroticism, rumination, and avoidant coping styles) 
appear to increase risk of depression across all stages of the lifespan, including older adulthood 
(Fiske et al., 2009).  There are also a variety of social factors which appear to increase risk of 
depression across the lifespan, such as stressful events (e.g., bereavement, divorce), lower SES, 
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and decreased social support (Fiske et al., 2009; Rodda et al., 2011).  Interestingly, while the 
occurrence of many social risk factors for depression increases during later life, the relative 
impact of these factors on the occurrence of depression appears to be stronger during younger 
and middle adulthood than during older adulthood (Fiske et al., 2009; Rodda et al., 2011).  This 
may partially be due to the predictability of particular social risk factors during later life (Rodda 
et al., 2011).   For example, adjusting to the death of a spouse can be particularly difficult 
during midlife, as this is typically an unexpected event at this stage of life.  In contrast, older 
adults who experience spousal bereavement are more likely to have prepared themselves for 
this event, and may therefore be better able to adjust to life without their spouse (Rodda et al., 
2011).      There is also some evidence that certain psychological resilience factors increase 
during older adulthood, and this may reduce the impact of social risk factors on depression 
(Fiske et al., 2009).  In particular, older adults are more likely to utilize the cognitive strategy 
of ‘positive reappraisal’ in response to life stressors, and tend to focus more on emotionally 
meaningful and positive aspects of experience.  Therefore, older adults appear more likely to 
utilize cognitive strategies that foster effective emotional regulation, which may in turn protect 
against depression in response to social stressors (Fiske et al., 2009).  
7.4.b: Genetic factors  
Estimates of MDD heritability range from 28% (Fernandez-Pujals et al., 2015) to 38% (Kendler 
et al., 2006; Sullivan et al., 2000). However, genetic influence on the occurrence of depression 
appears to be less significant in depression with onset during older adulthood (Fiske et al., 
2009).   For example, a study by Tozzi et al. (2008) found that age of MDD onset was 
significantly earlier among those with a family history of depression, and that MDD with onset 
after age 50 years was not associated with depression among biological relatives.  Similarly, a 
large twin study by Kendler et al. (2005) found that early onset in twins with MDD increased 
likelihood of MDD occurrence in co-twins.  Given that approximately half of late-life 
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depression cases have a late-onset (Fiske et al., 2009), the influence of genetic vulnerability on 
rates of depression is likely to be lower in older populations than younger populations. 
7.4.c: Non-genetic biological risk-factors 
Theoretical models of late-life depression generally stress the importance of non-genetic 
biological risk factors (see Aziz & Steffens, 2013; Blazer & Hybels, 2005; Fiske et al., 2009). 
Normal age-related changes in neurotransmitter and endocrine activity may contribute to 
depressive symptoms (Blazer & Hybels, 2005), and physical conditions that increase 
vulnerability to depression are common in later life (Alexopolous, 2005; Aziz & Steffans, 
2013; Blazer, 2003; Blazer & Hybels, 2005; Fiske et al., 2009).  Some of the strongest 
predictors of late-life depression include poor self-rated health, physical disability or functional 
impairment, physical pain, sleep disturbance, and the presence of chronic illness (see Chang-
Quan et al., 2010; Cole & Dendukri, 2003; Djernes, 2006; Vink et al., 2008). While virtually 
any serious chronic health condition can contribute to the development of late-life depression 
(Fiske et al., 2009), specific illnesses identified as risk-factors include hypertension and 
hypotension (Vink et al., 2008), diabetes, respiratory disease, endocrinological disorders 
(Djernes, 2006), cardiovascular disease, cerebrovascular disease, Parkinson’s disease, and 
dementia (Djernes, 2006; Vink et al., 2008).   
7.5: PREVALENCE OF LATE-LIFE DEPRESSION AMONG AI-MEDICATION USERS 
Research exploring cross-sectional predictors of late-life depression show the prevalence of 
depression is heightened among older adults who use somatic and/or psychotropic medications 
(Djernes, 2006; Vink et al., 2008).  Moreover, many of the non-genetic biological risk factors 
for depression described above likely go hand-in-hand with AI-medication use. For example, 
sedative medications used to treat sleep disturbances interact with alcohol by enhancing the 
sedating effects of both drugs; many pain killers used to treat physical pain may interact with 
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alcohol, and medication used to treat many chronic conditions associated with late-life 
depression (e.g., diabetes, respiratory disease, dementia, Parkinson’s disease) may interact with 
alcohol (Moore et al., 2007).   It is therefore likely that the prevalence of depression is 
heightened among older adults using AI-medications due to heightened prevalence of 
depression risk factors in this population.   
7.6: SUMMARY  
Late-life depression refers to experiences of depressive symptoms that occur during older 
adulthood.  Biological factors are of particular significance to the aetiology of late-life 
depression, many of which are likely to be associated with AI-medication use. Therefore, 
depression is likely to be common among older adults who use AI-medications. Given the 
evidence for an association between depression and alcohol use among older AI-medication 
users (Cheng et al., 2018; Gavens et al., 2016; Haighton et al., 2018), further research exploring 
the potential moderating effects of depression on the relationship between AI-medication use 
and alcohol use is warranted.  
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CHAPTER 8: SUMMARY AND RESEARCH GAPS 
Cross-national comparisons of survey data indicate New Zealand has one of the highest rates 
of alcohol use by older adults globally (Towers et al., 2017).  Given that vulnerability to alcohol 
related harm increases during older adulthood (Davies & Bowen, 1999; Jones & Neri, 1989; 
Moore et al., 1999 ; Mukamal et al., 2006; Pozzato et al., 1995; Sorg et al., 2015; Thomas & 
Rockwood, 2001; Yuan et al., 2001), there is a need for research into the prevalence and impact 
of alcohol related health issues in New Zealand’s rapidly growing older adult population.   One 
key issue is the potential harm posed to older adults using both alcohol and AI-medication 
(Moore et al., 2007).  Older adults are more likely to use AI-medications than younger cohorts, 
and are more susceptible to AMI related harm due to age related changes in body mass and 
metabolism (Adams, 1995; Moore et al., 2007; Nagaraj et al, 2017; Weatherman & Crabb, 
1999).  Analyses of survey data indicates a high prevalence of concomitant alcohol/AI-
medication use among older adults living in the US (e.g., Breslow et al., 2015; Qato et al., 
2015) and Europe (e.g., Cousins et al., 2014).  However, the prevalence of AMI risk among 
New Zealand older adults is currently unknown.  There is therefore a need for research 
exploring the prevalence and associated public health burden of concomitant alcohol/AI-
medication use by older adults in New Zealand.  
There is also a need to explore motivating factors underlying differences in alcohol use among 
older AI-medication users, as this may help inform interventions aimed at reducing AMI 
related harm.   Existing research indicates awareness of personal AMI related harm is a key 
factor associated with reduced alcohol use among older AI-medication users (Gavens et al., 
2016; Wilkinson et al., 2016; Zanjani et al., 2013), whereas avoidant coping strategies (such as 
information avoidance, wishful thinking, and denial) may be associated with unsafe 
alcohol/AI-medication use (Gavens et al., 2016; Zanjani, Allen, Smith et al., 2018). There is 
also some evidence suggesting drinking motivated for the purpose of self-medication may 
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prevent changes in alcohol use among AI-medication users with mental health issues, 
particularly depression (Cheng et al., 2018; Gavens et al., 2016; Haighton et al., 2018).  
Moreover, a variety of conditions which are often treated with AI-medications are also 
associated with late-life depression (Djernes, 2006; Moore et al., 2007; Vink et al., 2008). 
Therefore, the prevalence of depression may be heightened among older adults who use AI-
medications. However, the potential moderating effects of depression on the relationship 
between alcohol use and AI-medication use have not been explored in a large community 
sample.    Further research is therefore needed into the potential relationships between alcohol 
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CHAPTER 9: THE PRESENT INVESTIGATION 
The present research aimed to expand existing knowledge relating to concomitant alcohol/AI-
medication use by older adults, while also addressing the research gaps discussed in chapter 8. 
Two cross-sectional analyses were conducted using survey data collected from the New 
Zealand Health, Work and Retirement study (Towers & Noone, 2007; Towers & Stevenson, 
2014), and linked national pharmaceutical dispensing data accessed from the New Zealand 
Pharmaceutical Collection (Ministry of Health, 2015). These analyses explored a range of 
research questions relating to the prevalence and correlates of concomitant alcohol/AI-
medication use among New Zealand older adults, and hypotheses were informed by the 
literature reviewed in the previous chapters of this thesis.  These research questions and 
hypotheses are described below. The contents of subsequent chapters are then summarized. 
9.1: RESEARCH QUESTIONS AND HYPOTHESES 
9.1.a: Research questions  
1. What is the prevalence of concomitant alcohol/AI-medication use in New Zealand’s 
older adult population?  (explored in studies 1 and 2) 
2. Does concomitant alcohol/AI-medication use impact on physical health and healthcare 
utilization among older New Zealanders? (study 1) 
3. Is there a relationship between AI-medication use and alcohol use among New Zealand 
older adults, and do differences in AMI risks associated with various AI-medications 
influence the strength of this relationship? (study 2) 
4. Does depression moderate the potential relationship between AI-medication use and 
alcohol use?  (study 2) 
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9.1.b: Hypotheses for research question 2: 
In relation to the second research question, as outlined in chapter 3, research shows that 
vulnerability to AMI related harm increases during older adulthood. This led to hypotheses 1 
and 2.  
• Hypothesis 1: concomitant AI-medication use will be negatively associated with self-
reported physical health after controlling for associations of alcohol use and AI-
medication use individually  
• Hypothesis 2:  after controlling for the individual associations of AI-medication use 
and alcohol use, concomitant alcohol/AI-medication use will be positively associated 
with healthcare utilization   
9.1.c: Hypotheses for research question 3:  
Hypotheses in relation to the third research question were informed by literature reviewed in 
chapters 5 and 6, including research findings and theory (PMT). Previous research has 
consistently shown a negative association between AI-medication use and alcohol use.   
Awareness of personal AMI risk appears to motivate reduced alcohol consumption for many 
older AI-medication users, which supports the PMT proposition that appraisals of personal 
vulnerability to health threat often motivates health behaviour. Additionally, PMT would also 
suggest appraisals of the severity of health threat exert influence on health behaviour.  This led 
to hypotheses 3 and 4.   
• Hypothesis 3: AI-medication use will be negatively associated with alcohol use  
• Hypothesis 4: The strength of the hypothesized negative association between AI-
medication use and alcohol use will be strongest for AI-medications associated with 
higher AMI risks   
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9.1.d: Hypothesis for research question 4: 
The hypothesis in relation to research question four was informed by research reviewed in 
chapter 5 and theory reviewed in chapter 6 (PMT; Cooper’s drinking model), suggests 
depression may be associated with alcohol consumption for self-medication purposes (coping 
motives), which may in turn prevent changes in alcohol consumption by AI-medication users. 
This led to hypothesis 5: 
• Hypothesis 5: depression will weaken the hypothesized negative association between 
AI-medication use and alcohol use 
9.2: SUMMARY OF SUBSEQUENT CHAPTER CONTENT  
9.2.a: Summary of chapter 10 
The next chapter of the present thesis reviews the research designs implemented in previous 
survey studies exploring rates of concomitant alcohol/medication.  The purpose of chapter 10 
was to identify key strengths and limitations of various methods for measuring and classifying 
alcohol use, AI-medication use, and concomitant alcohol/AI-medication use. The conclusions 
drawn from this review were then used to inform the research designs implemented in the 
present project.  
9.2.b: Summary of chapter 11 
Chapter 11 is divided into two main sections.  The first section (11.1) establishes a research 
protocol for classifying the alcohol-interactivity potential of medications, and for using 
participants’ pharmaceutical records to measure AI-medication use in survey research.   The 
implementation of this research protocol in the present project is then described in section 11.2. 
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9.2.c: Summary of chapters 12 and 13 
The first study implemented in the present thesis is described in chapter 12, and the second 
study is described in chapter 13.  Both studies explored the prevalence of concomitant 
alcohol/AI-medication use among participants (research question 1). Study 1 (chapter 12) 
explored the hypothesized associations of concomitant alcohol/AI-medication use on physical 
health and healthcare utilization (i.e., hypotheses 1 and 2). Study 2 (chapter 13) explored the 
hypothesized relationships between alcohol use, AI-medication use, and depression (i.e., 
hypotheses 3, 4, and 5).  Each of these chapters include a discussion section covering topics 
specific to the research questions addressed in that study. Discussion topics specifically 
relevant to study 1 are covered in section 12.6, and topics relevant to study 2 are covered in 
section 13.6. As both studies explored the prevalence of concomitant alcohol/AI-medication 
use, much of the discussion relating to research question 1 is covered in chapter 14.  
9.2.d: Summary of chapter 14 
Chapter 14 begins with a general discussion of studies 1 and 2 (section 14.1), both of which 
explored the prevalence of concomitant alcohol/AI-medication use.  The sample characteristics 
and results of the two studies are compared first. Findings of the present research are then 
compared with those of other studies exploring the prevalence of concomitant alcohol/AI-
medication use in older adult populations, and methodological issues relating to both studies 
are discussed.  The second section of chapter 14 discusses the overall contribution of the present 
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CHAPTER 10: MEASURING CONCOMITANT ALCOHOL 
AND AI-MEDICATION USE: A REVIEW OF SURVEY 
RESEARCH DESIGNS 
Approaches to the operationalisation of concomitant alcohol-medication use have varied 
greatly across previous epidemiological studies. These methodological decisions have 
significant implications for the precision of related estimates. Evaluation of these research 
designs and their implications for estimates are an important part of understanding the 
limitations of the current research and improving estimates in the future. This chapter is a 
methodological review focusing on approaches to a) measuring and defining AI-medication 
use, b) measuring and defining alcohol use, and c) operationalizing concomitant alcohol/AI-
medication use.  Methods of identifying the potential alcohol-interactivity of medications are 
not discussed in the present chapter and are covered in chapter 11. This review focuses on 
measures used to identify participants who use both alcohol and medications in a close enough 
proximity of time for both substances to be present in the body simultaneously. Conclusions 
drawn from this review informed the methods of estimating concomitant alcohol/AI-
medication use utilized in the two studies included in the present thesis. 
10.1: STUDIES REVIEWED 
Eighteen studies are reviewed in this chapter. These studies were selected for review because 
they utilised survey data and aimed to estimate sample rates of potential concomitant 
alcohol/medication use. Seventeen studies (i.e., Aira et al., 2005; Breslow et al., 2015; Bye & 
Rossow, 2017; Cousins et al., 2014; del Rı́o et al., 1996; del Rio et al., 2002; Du et al., 2016; 
Forster et al., 1993; Ilomäki et al., 2008; Ilomäki et al., 2013; Immonen et al., 2013; Jalbert et 
al., 2008; John et al., 2007; Pringle et al., 2005; Qato et al., 2015; Swift et al., 2007; Veldhuizen 
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et al., 2009; Wolf et al., 2017) employed cross-sectional designs, and one study (i.e., Pringle et 
al., 2006) conducted a longitudinal analysis.    
10.2: MEASUREMENTS OF MEDICATION USE 
Appropriate assessment of medication use by participants in survey research projects require 
consideration of the methods used to collect data on medication use, and the criteria applied to 
define participants as medication users based on the data collected. Across the studies 
reviewed, three approaches to collecting data on medication use were utilized and these are 
presented in Table 3. Some relied solely on self-report survey questions about medication use 
(e.g., Immonen et al., 2013), while the majority had participants provide some verification of 
medication use, such as medication containers or prescription sheets for the medications 
reported (e.g., Breslow et al., 2015). Two studies (Pringle et al., 2005, 2006) identified 
medication use by accessing participants’ prescription medication claims records. Studies that 
either have participants provide verification of medication use or access prescription claims 
data are likely to have a lower risk of misclassification bias than those relying solely on self-
reports. This is because self-report measures are susceptible to recall issues and biased 
reporting, both in terms of medications used (Holton et al., 2017) and the timing and duration 
of their use (which are key factors in the identification of concomitant use, as will be discussed 
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Table 3: Methods of Identifying Participant Medication Use Utilized Among The 
Reviewed Studies 
Method of medication use identification Author(s)/year 
 Self-report survey questions Bye, & Rossow (2017); Del Rio et al. (1996); 
del Rı́o et al.(2002); Immonen et al. (2013); 
Swift et al. (2007) 
 
 Provision of medications, packages, or 
prescription sheets 
Aira et al. (2005); Breslow et al., 2015; 
Cousins et al., 2014; Du et al. (2016); Forster 
et al. (1993); Ilomäki et al. (2008) Ilomäki et 
al., 2013; Jalbert et al., 2008; John et al., 2007; 
Qato et al., 2015; Veldhuizen et al. (2009); 
Wolf et al. (2017)   
 
 Access to pharmaceutical claims records Pringle et al. (2005, 2006) 
   
 
Table 4 details the temporal criteria against which participants were classified as being 
users/non-users of medications. There was much variation across the reviewed studies 
regarding these temporal criteria. Some studies explored current medication use, which has 
typically been defined as any medication use within a specific timeframe (e.g, Breslow et al., 
2015). Other studies explored regular medication use and medication use as needed across 
unspecified timeframes (e.g. Cousins et al., 2014). One study (Bye et al., 2017) explored 
specific periods of continuous medication use (daily or almost daily use) as well as any 
medication use during the past year. Given that interactions between alcohol and medications 
require both substances to be used within a close enough time proximity for an interaction to 
occur, it is important for studies exploring concomitant alcohol/AI-medication use to carefully 
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Table 4: Criteria Used to Define Participants as Medication Users Among the Reviewed 
Studies 
Definition of medication use Author(s)/year 
Current medication use   
 Past 24 hours: Swift et al., 2007 
 Past 2- days Veldhuizen et al., 2009 
 Past week Du et al., 2016; John et al., 2007; Wolf et al., 2017 
 Past 2-weeks Del Rio et al., 1996, 2002 
 Past month Breslow et al., 2015; Jalbert et al., 2008 
 Past 45-days Pringle et al., 2005, 2006 
 Timeframe unspecified Forester et al., 1993 
   
Regular medication use   
 Timeframe unspecified Aira et al., 2005; Cousins et al., 2014; Qato et al., 2015 
   
Regular or as needed medication use  
 Timeframe unspecified Ilomäki et al., 2008; Ilomäki et al., 2013 
   
As needed medication use  
 Timeframe unspecified Aira et al., 2005 
   
Any medication use  
 Past year Bye et al., 2017 
   
Continuous use (daily or almost daily use)  
 1-4 weeks during past year 
 
Bye et al., 2017 
 >4 weeks during past year Bye et al., 2017 
 
10.3: MEASUREMENTS OF ALCOHOL USE 
As with measures of medication use, the initial consideration for the identification of alcohol 
use relates to the methods of data-collection. All studies reviewed here relied on self-report 
methods to determine use of alcohol. Most studies used one of three methods to measure 
alcohol consumption; 1) non-standardised survey questions about quantity and frequency of 
alcohol use; 2) standardised alcohol use screening tools; or 3) a combination of standardised 
screening tools and non-standardized drinking quantity and/or frequency questions (Table 5). 
While non-standardized measures may provide information relating to alcohol consumption 
quantity and frequency, it is difficult to determine the accuracy of non-standardised measures 
as they lack important information such as reliability, validity, sensitivity, and specificity 
(Kimberlin & Winterstein, 2008). Moreover, the ability to compare findings across studies may 
be hampered by such ad-hoc measures. Studies using standardised measures to determine 
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alcohol use among participants therefore have clear advantages over those relying solely on 
non-standardized survey questions.   
 
Table 5 Alcohol Use Measures Utilized in Previous Studies 
Measures Author(s)/year 
  
Non-standardized quantity/frequency questions 
 
 
 Past week John et al., 2007; Veldhuizen et 
al., 2009 
   
 Past two-weeks Del Rio et al., 1996, 2002 
   
 Past year Aira et al., 2005; Breslow et al., 
2015 Ilomäki et al., 2008; Jalbert 
et al., 2008 
   
 Unspecified timeframe Pringle et al., 2005, 2006; Qato et 
al., 2015 
   
Other non-standardized measures 
 
 
 Question about (any) alcohol use (past 24 hours) Swift et al., 2007 
   
 Self-reported qualitative drinking categories (e.g. non-
drinker, former-drinker, regular-drinker) 
Forester et a., 1993; Pringle et al., 
2005, 2006 
   
Standardized measures only 
 
 
 FFQ Du et al., 2016; Wolf et al., 2017 
 
 AUDIT and NIAAA guidelines Immonen et al., 2013 
   
Standardized measures and non-standardized measures  
 
 
 AUDIT and past year frequency questions 
 
Bye et al., 2017 
 CAGE and past year quantity/frequency questions 
 
Ilomäki et al., 2013 
 CAGE and past 6-month quantity/frequency questions Cousins et al., 2014 
Measure abbreviations: FFQ = Food Frequency Questionnaire (Haftenberger et al., 2010); AUDIT = 
Alcohol Use Disorders Identification Test (Saunders et al. 1993); CAGE = Cut-down, Annoyed, Guilty, 
Eye-opener (Ewing,1984): NIAAA = National Institute for Alcohol Abuse and Alcoholism 
 
In addition to the variability in instruments used to identify alcohol use across the reviewed 
studies, there is also much variation regarding the criteria used to define participants as alcohol 
users (Table 6). One study reported on alcohol use in relation to problematic drinking groups 
such as daily drinkers and binge drinkers (Ilomäki et al., 2013). Conversely, some studies 
reported on regular drinking (e.g. Bye et al., 2017), and others required participants to report 
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having used alcohol within a specific period of time prior to survey completion (e.g. Cousins 
et al., 2014). While the utility of different alcohol use thresholds depends on the specific 
research question being asked, having clearly defined inclusion criteria helps ensure 
information gathered is meaningful. As for medication use, the temporal criteria against which 
participants are classified in terms of alcohol use has similar a methodological impact and is a 
key consideration when determining concomitant use. 
Table 6 Minimum Level of Alcohol Consumption Required to Qualify as a Drinker 
Lowest drinking thresholds  Author(s)/year 
 
Problematic drinking groups only 
 
  
 Daily drinking = alcohol consumed daily 
(past year) 
 
 Ilomäki et al., 2013 




 Binge drinking = 5+ drinks at least once 
monthly (past year) 
 
  
 Problem drinking = CAGE score of 2 or 
more 
  
    
Regular drinking groups only 
 
  
 At least two drinking days weekly (past 
year) 
 Ilomäki et al., 2008 
    
 At least one drinking day weekly 
(unspecified timeframe)  
 Qato et al., 2015 
    
 At least one drinking day monthly 
 
  
 Past year  Bye et al., 2017; Immonen et al., 
2013 
 
 Unspecified timeframe  Pringle et al., 2005, 2006 
    
Any alcohol use within a specific timeframe 
 
  
 Past week 
 
 Veldhuizen et al., 2009 
 Past 2 weeks 
 
 Del Rio et al., 1996, 2002 
 Past 6-months 
 
 Cousins et al., 2014 
 Past year  Aira et al., 2005; Breslow et al., 





71 | P a g e  
 
10.4: OPERATIONALIZED MEASURES OF CONCOMITANT ALCOHOL/MEDICATION 
USE 
Key to the operationalization of any epidemiological concept in prevalence studies is the 
identification of measurement thresholds that are both sensitive5 and specific6 (Loong, 2003). 
In other words, the quality of an outcome measure depends on its ability to successfully identify 
true-positive and true-negative cases while avoiding false-negative and false-positive case 
identification.  Therefore, evaluating the sensitivity and specificity of a research design requires 
a clearly defined outcome or phenomenon of interest.  
As studies exploring concomitant alcohol/medication use are primarily concerned with risk of 
AMI exposure, Breslow et al. (2015) argue that operationalized measures should aim to identify 
participants who use alcohol and medications either simultaneously or within a close enough 
time proximity for an AMI to occur. Sensitivity would therefore refer to the extent to which a 
threshold is maximally able to capture participants who do use alcohol and AI-medication 
within a timeframe that that puts them at risk of AMI exposure. In contrast, specificity would 
refer to the extent to which a threshold is maximally able to capture participants who do not 
use alcohol and medication within a timeframe that puts them at risk of AMI exposure. In this 
regard, designs with highly flexible inclusion criteria would likely provide the highly sensitive 
estimates (i.e., criteria prioritise capture of exposed persons at the risk of capturing non-
exposed persons), whereas those using highly stringent inclusion criteria would provide highly 
specific estimates (i.e., criteria prioritise capture exposed persons at the risk of missing some 
exposed persons). For example, a measure which defined every participant who had used 
 
5 Sensitivity estimates are concerned with the ability of a given classification measure to accurately identify true 
positive cases and minimize false negative case identification within a sample or population 
 
6 Specificity refers to the ability of a given classification measure to minimize false positive case identification 
and maximise the identification of true negative cases. 
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alcohol at any time in their life and medication at any time in their life as a concomitant user 
would have perfect sensitivity because every true positive case would be included. However, 
such a measure would likely falsely identify a large number of participants as concomitant 
users, and thus would have very poor specificity.  
To address this key issue, this section of the present chapter evaluates various operationalised 
measures of concomitant alcohol/medication use. The aim of this discussion is to identify 
methods of maximizing both sensitivity and specificity based on the operationalisation of 
concomitant alcohol/medication use proposed by Breslow et al. (2015), i.e., the use of alcohol 
and medication within a timeframe that poses risk of AMI exposure. While this task is 
complicated by differences in half-lives between various medications (which present differing 
windows of opportunity for AMIs), additional considerations include the time windows within 
which alcohol and medication use are measured, and the frequency at which alcohol is 
consumed.  The methodological strengths and/or limitations of three studies (Bye et al., 2017; 
Cousins et al., 2014; Wolf et al., 2017) are outlined below to illustrate both these issues as they 
appear in the literature and inform the rationale for the definitions adopted in the current 
research.   
10.4.a: Example of a highly sensitive research design 
Cousins et al. (2014) estimated the prevalence of concomitant alcohol/AI-medication use by 
conducting a cross-sectional analysis of a sample of older adults (aged ≥60 years) using data 
collected by the Irish Longitudinal Study of Aging (TILDA). In this study, concomitant 
alcohol/AI-medication users were defined as those who a) were identified as regular AI-
medication users across an unspecified timeframe, and b) reported using alcohol during the 
past six-months.  As the drinking threshold utilized in this inclusion criteria was relatively low 
(i.e. any alcohol during the past six months), the operationalisation of concomitant alcohol/AI-
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medication use utilized by Cousins et al. (2014) is likely to capture most of the true-positive 
cases within their sample. This study therefore provides an example of a highly sensitive 
research design for the identification of concomitant alcohol/AI-medication use. However, this 
design is also likely to yield a high number of false-positive cases, as many participants 
identified as at-risk using this design may not use alcohol and AI-medication concomitantly. 
In other words, the operationalisation of concomitant alcohol/AI-medication use adopted by 
Cousins et al. (2014) likely achieves high sensitivity at the expense of decreased specificity, by 
casting a ‘wider net’, so to speak.  
10.4.b: Example of a highly specific research design 
Wolf et al. (2017) explored rates of concomitant alcohol/psychotropic-medication use among 
older adults (aged 60-79 years) using data collected in two German National Health Surveys.  
The operationalized definition of concomitant alcohol/medication use utilized in this study 
included a) self-reported daily alcohol use (past year), and b) past 7-day psychotropic drug use.  
Due to the highly stringent drinking threshold utilized in this study, the likelihood of an 
individual being incorrectly identified as a concomitant alcohol/medication user based on these 
criteria is relatively low. However, it is also unlikely that all concomitant users would be 
identified using such a design, particularly those who do not drink daily. This study therefore 
provides an example of an operationalized concomitant alcohol/medication use measurement 
with high specificity and low sensitivity. 
10.4.c: Example of a research design providing estimates with both high sensitivity and 
high specificity 
While no study reviewed here provides a single measurement of concomitant 
alcohol/medication use that can be considered high in both sensitivity and specificity, studies 
providing multiple measures of concomitant use are able to provide a clearer overall estimate. 
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For example, Bye et al. (2017) provided the following estimates of concomitant alcohol and 
sedative/hypnotic drug use: 1) rates of individuals reporting the use of alcohol and the use of 
sedative hypnotics during the past year; 2) rates of individuals reporting frequent alcohol use 
(at least once weekly, past year) and short continuous sedative/hypnotic drug use (1-4 
consecutive weeks of daily or almost daily use during the past year), or reporting infrequent 
alcohol use (1–3 times monthly, past year) and long continuous sedative/hypnotic drug use 
(self-report, at least one month of daily or almost daily use, past year), or engaging in frequent 
alcohol use and long-continuous sedative/hypnotic drug use.  The first estimate utilized in this 
study is likely to have high sensitivity and low specificity (due to its flexible inclusion criteria), 
and the second is likely to have high specificity and low sensitivity (due to its stringent 
inclusion criteria). In doing so, this design is likely to provide an underestimate and an 
overestimate of concomitant use, and it is therefore reasonable to infer that the actual 
population prevalence falls somewhere between these two measurements. This approach 
therefore may have greater utility for public health research and planning than research designs 
providing a single estimate 
10.5: CONCLUSIONS  
The present chapter reviewed methods of measuring alcohol use, medication use, and 
concomitant alcohol/medication use that have been applied in survey studies exploring research 
questions relating to AMI risk among participants.  The purpose of this chapter was to identify 
key methodological principles to inform the study designs implemented in the present research 
(see chapters 12-13).   Five key points were identified from this discussion, which are listed 
below (section 10.5.a). The application of these methodological considerations to the present 
research is then discussed in section 10.5.b.  
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10.5.a: Key points raised in this chapter 
1. Given that self-report measures of medication use may be susceptible to problems such 
as biased reporting and recall issues, risk of medication use misclassification may be 
reduced by accessing participants’ medication containers, prescription sheets, or 
pharmaceutical dispensing records  
2. Standardized alcohol use questionnaires have clear advantages over ad hoc measures, 
which lack empirical support for their utility and do not facilitate comparisons across 
studies 
3. As the likelihood of simultaneous alcohol and AI-medication use increases with 
repeated use of both substances over time, drinking frequency may be a better indicator 
of concomitant use than drinking quantity 
4. Measures of AI-medication use and alcohol use that include appropriate temporal 
criteria may enhance measurement precision when estimating the potential for AMI, as 
this helps to infer the likelihood that both substances are taken in a close enough 
proximity of time for an interaction to occur. 
5. It is extremely difficult to provide a single estimate of concomitant alcohol/AI-
medication use that has both sensitivity and specificity. As such, studies that provide 
multiple estimates, based on differing levels of drinking frequency by AI-medication 
users, may have greater utility for public health research and planning  
10.5.b: How this chapter informed the present research  
The present research aimed to explore rates of concomitant alcohol/AI-medication use in a 
large sample of New Zealand older adults, using existing survey data collected by the Health 
Work and Retirement (HWR) Study (Towers & Noone, 2007; Towers & Stevenson, 2014). The 
methodological considerations listed in the previous subsection (10.5.a) informed the design 
of the present research in the following ways. In light of the first point listed above, the present 
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research made use of an HWR project in which consenting participants survey data was linked 
with their national health records (HWR Data-Linkage Project) (Allen 2014). This enabled 
medication use to be measured by accessing participants pharmaceutical dispensing records, 
which is a key strength of the present research.  Another strength of the present research, in 
relation to the second point listed, was the use of the AUDIT-C (Bush et al., 1998), which is a 
standardized measure of alcohol consumption.   In light of the third point listed, the present 
research utilized a single item from the AUDIT-C, which assesses how often an individual 
typically consumes alcohol (i.e., drinking frequency). However, in relation to the fourth point 
listed, a key limitation of the AUDIT-C is that it does not specify a timeframe across which 
drinking frequency is assessed. To compensate for the potential problems this issue may create 
in terms of specificity, the present research focused on measuring regular AI-medication use 
across a specified timeframe, which is a more conservative approach than focusing on current 
use only. In relation to the fifth point listed, the present research aimed to provide multiple 
estimates of concomitant alcohol/AI-medication use based on drinking frequency among 
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CHAPTER 11: IDENTIFYING PARTICPANT AI-
MEDICATION USE USING PHARMACUETICAL CLAIMS 
DATA: PROTOCOL AND METHODOLOGY  
The current research required extensive planning, primarily due to the complex procedures 
required when incorporating research and administrative data sources (i.e., national 
pharmaceutical record collections). In addition to the methodological considerations reviewed 
in chapter 10, it was necessary to develop a research protocol providing clear guidelines for a) 
classifying AI-medications in research, and b) using pharmaceutical claims records to identify 
medication users among survey participants. Relevant literature was reviewed to ensure 
methodological decisions were empirically supported and/or carefully modelled on methods 
adopted by other researchers. The protocol was then developed by the author, submitted for 
peer review7, and implemented by the author. This chapter details the research protocol 
developed for the present thesis, it’s rationale, and describes the implementation of procedures 
used to identify AI-medication use among survey participants using pharmaceutical claims 
records. 
11.1: RESEARCH PROTOCOL 
This section of the present chapter establishes a research protocol for determining the potential 
alcohol-interactivity of medications, and for using pharmaceutical claims data to identify 
medication use in survey research.  The first subsection discusses the classification of AI-
medications, and the categorization of AI-medications based on their associated levels of AMI 
 
7 With thanks to reviewers Professor Janie Sheridan and Dr David Newcombe from the Centre for Addiction 
Research, University of Auckland 
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risk. The second subsection discusses methods of identifying current and regular medication 
use by accessing survey participants pharmaceutical claims records.  
11.1.a: Identifying AI-medications to explore concomitant alcohol/AI-medication use  
Decisions about AI-medication identification and categorisation implemented in the present 
research protocol were informed by methods adopted in previous studies exploring 
concomitant alcohol/AI-medication use. Four studies in this field (namely, Breslow et al., 
2015; Cousins et al., 2014; Immonen et al., 2013; Qato et al., 2015) were selected for review 
because they 1) included a wide variety of medications in their analyses and 2) provided 
reference to the specific resources they used to identify potentially AI-medications.  Key 
considerations included decisions about how many resources indicating the potential for 
medications to have an adverse drug-interaction with alcohol should be used to identify AI-
medications, and the specific inclusion criteria used for defining and categorizing AI-
medications in terms of the risk they present for AMI. Three approaches to AI-medication 
identification were used across the four studies reviewed.  
The simplest method for identifying AI-medications used among the reviewed studies is to 
utilize a single drug-interaction identification resource (i.e., a resource for assessing the 
clinical effects of drug interactions) (Grannell, 2020). This method, which was adopted by 
Immonen et al. (2013) and Qato et al. (2015), may have limitations in terms of sensitivity and/or 
specificity depending on the specific resource utilized. Barrons (2004) compared various drug 
interaction identification compendia by assessing search outputs of 80 drug pairs, 40 of which 
represented clinically significant drug interactions. Each resource falsely identified at least one 
drug pair as a clinically significant drug interaction and/or failed to identify at least one 
clinically significant drug interaction. These results highlight the possibility that the use of a 
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single resource could lead to false positive and/or false negative identification of AI-
medications. 
Another approach, which was adopted by Cousins et al. (2014), is to use multiple drug-
interaction identification resources and define drugs as AI when identified as such by at least 
one resource. The benefit of this approach is a reduced likelihood of false negative AI-
medication identification, as any AI-medications missed by one resource are likely to be 
identified by another.  However, the shortcoming of this approach is the increased likelihood 
of false positive AI-medication identification as any medications incorrectly identified as 
alcohol-interactive in any resource used would be incorrectly be defined as AI in the study.  In 
other words, this method likely to have high sensitivity, but its specificity may be 
compromised. 
A third approach to AI-medication identification, adopted by Breslow et al. (2015), is to use 
multiple drug-interaction identification resources and define drugs as AI when identified as 
such by more than one resource. The benefit of this method is a reduced likelihood of false 
positive AI-medication identification, as it is likely that medications incorrectly identified as 
alcohol-interactive in one resource will not be identified as alcohol-interactive in others.  
However, the shortcoming of this method is increased the likelihood of false negative AI-
medication identification, as AI-medications missed by one resource might be defined as non-
AI in the study. In other words, this method is likely to have high specificity, but its sensitivity 
may be compromised.    
Approach to AI-medication identification adopted in the present research 
The present research used only one drug-interaction resource to identify AI-medications for 
three reasons. Firstly, potential limitations of specificity and sensitivity cannot be fully 
addressed by using multiple resources because inclusion criteria aimed at increasing sensitivity 
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would likely reduce specificity while criteria aimed at increasing specificity would likely lead 
to reduced sensitivity.  Secondly, as health behaviour models indicate that increased potential 
for an adverse AMI will have consequences for alcohol use, AI-medications in this project 
were categorized into ordinal groups of differing levels of alcohol-interactivity. As such, the 
use of multiple resources could lead to inconsistency in reporting on AI-medication use overall, 
and AI-medication use by interactivity severity.  This is because some medications might be 
defined as AI based on information gained from one or more resources, yet not identified as 
AI by the resource used to identify interactivity severity. As a result, the overall total of AI-
medications included in the analyses would be greater than the combined total of AI-
medications across AI-medication severity categories. Finally, drug interaction notifications to 
GPs and Pharmacists in New Zealand are generated from one resource (the New Zealand 
Formulary (NZF)), which takes the form of a coloured sticker placed by pharmacists on the 
medication packaging.  This single resource therefore provides the best indicator of patient 
behaviours in New Zealand.  
Thus, for consistency and comparability with existing literature, inclusion criteria for 
identifying and categorizing AI-medications in the present research are based on those used by 
other authors. The inclusion criteria for defining AI-medications adopted in the present 
research are based on those used by Cousins et al. (2014), who defined AI-medications as those 
having “specified alcohol interactivity and/or […] a cautionary warning and/or 
recommendation for advisory labels [related to alcohol use]” (p.1473).  These criteria were 
selected as a model in the present research because they are clearly defined and can easily be 
applied to a single drug-interaction identification resource. The criteria developed for 
categorizing AI-medications into multiple levels of alcohol interactivity in the present research 
were designed to resemble those used by Qato et al. (2015) as this was the only study selected 
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for review that included such categories.  AI-medication severity categories utilized in the Qato 
et al. (2015) study included the following:  
• Contraindicated AI-medications: medications contraindicated for use with alcohol 
• Major AI-medications: those capable of causing interactions that are life threatening 
or that require medical attention 
• Moderate AI-medications: medications capable of causing interactions in which the 
therapeutic effects of the medication are reduced through the exacerbation of the 
individual’s condition 
• Mild AI-medications: medications capable of causing alcohol-interactions with 
limited clinical significance  
11.1.b: Using pharmaceutical claims to identify AI-medication users 
Another key consideration for the present research relates to methods of identifying medication 
use among survey participants based on pharmaceutical claims, which enables detailed 
assessments of the timing and duration of AI-medication use. Specifically, the present research 
aimed to identify participants who a) were current users of AI-medications at the time they 
responded to the survey, and b) had used AI-medications regularly for an extended period prior 
to survey completion. These decisions were informed by literature comparing alternative 
methods of identifying current medication use based on pharmaceutical claims and previously 
adopted research designs aimed at identifying regular medication use based on pharmaceutical 
claims.   
Fixed-window and legend-time measures of current medication use 
There are two main methods of identifying current medication use based on pharmaceutical 
claims data. The ‘fixed-window method’ assumes any medications dispensed within a fixed 
number of days prior to survey response are in current use. The ‘legend-time method’ infers 
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current use when the number of days for which a medication is supplied is greater than or equal 
to the number of days between dispensing date and response date (Lau et al., 1997).  The 
accuracy of each of these methods appears to vary across certain medication classes. Sensitivity 
and specificity estimates suggest the fixed-window method is at least as accurate as the legend-
time method in identifying current use of most drugs and more accurate in identifying current 
use of many drugs. However, the legend-time method appears to have higher sensitivity and 
specificity as a measure of current antibiotic use (Lau et al., 1997; Nielsen et al., 2008).  
Utilizing the legend-time method for antibiotics and the fixed window method for all other 
medications may therefore maximize accurate current medication use identification.  
Optimal time intervals for fixed-window current medication use identification   
A key consideration when using the fixed-window method is the size of the specified time 
window in which pharmaceutical dispensations are considered to be in current use. Studies 
comparing fixed-window time intervals suggest a 90-day fixed-window has optimal sensitivity 
and specificity for identifying current medication use for most drug classes (King et al. 2001; 
Lau et al., 1997; Pit et al., 2008). However, a 30-day fixed window appears to be the best 
method (with regards to sensitivity/specificity) for identifying current use of non-steroidal anti-
inflammatory drugs (NSAID’s) and benzodiazepines (Pit et al., 2008). To achieve the optimum 
accuracy of current medication use, the present research utilized a) the legend-time method to 
identify current antibiotic use, b) a 30-day fixed window approach to identify current use of 
benzodiazepines and NSAIDs, and c) a 90-day fixed window approach to identify the current 
use of all other medications. 
Regular medication use identification  
Previous data-linkage studies have defined regular medication use by multiple dispensings 
within a six-month fixed window. Regular medication use was defined by three dispensings 
over the past six months in a study of older adults living in Ireland (Richardson et al., 2013). 
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Another study of older veterans living in Australia defined regular medication use as at least 
one dispensing in the past 3 months (indicating current use), and at least one other dispensing 
occurring during the three months preceding the past three months (Roughead et al., 2010).  
While the studies just described provide a basic guideline for the identification of regular 
medication use using data-linkage methods, medications prescribed in Australia and Ireland 
are usually dispensed in one-month supplies.  A six-month time-window would likely be 
insufficient in the context of New Zealand, where most medicines can be dispensed in 3 month 
supplies, and may often last slightly longer than 3 months due to issues with compliance (e.g. 
occasionally forgetting to take medication). The present research therefore defines regular AI-
medication use as multiple dispensings within a 244-day (8-months) fixed window, with at 
least one dispensing occurring within a timeframe indicative of current medication use (i.e. 
legend time for antibiotics; 30-day fixed window for NSAIDs and benzodiazepines; 90-day 
fixed window for all other medications) and at least one dispensing that does not indicate 
current use.   
11.2:  METHODOLOGY 
This section of the present chapter discusses the implementation of the research protocol 
described above.  All of the described procedures were carried out using SPSS software. The 
first subsection (11.2.a) describes the data sources used in the present research. This includes 
survey data provided by the Health, Work and Retirement (HWR) Study (Towers & Noone, 
2007; Towers & Stevenson, 2014), pharmaceutical claims data provided by the New Zealand 
Pharmaceutical Collection (PHARMS) (Ministry of Health, 2015), and AI-medication 
identification data provided by NZF (NZF, 2017).  Methods of classifying AI-medications 
within the NZF data and PHARMS data are discussed in the second subsection (11.2.b), and 
the third subsection (11.2.c) describes methods used to identify AI-medications within the 
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PHARMS data.  Methods of establishing regular AI-medication use among HRW participants 
are then described in the fourth subsection (11.2.d).    
11.2.a: Data sources  
Survey data: The Health Work & Retirement Study (HWR) 
Survey data analysed in the present research was gathered from The New Zealand, Health, 
Work, and Retirement (HWR) Study, which is a large ongoing nationally representative survey 
of older adults living in New Zealand.  Data from the 2006 HWR survey (Towers & Noone, 
2007) was analysed in study 1, and study 2 analysed the data from the 2010 HWR survey 
(Towers & Stevenson, 2014). Both studies included a subset of participants who consented to 
have their survey data linked with their national health records as part of the HWR Data-
Linkage Project (Allen, 2016). This enabled participant medication use to be ascertained by 
accessing their pharmaceutical claims records. Details regarding HWR participant recruitment, 
data-linkage recruitment, and the characteristics of the final study samples are described in 
chapters 12 (study 1) and 13 (study 2).   
Pharmaceutical claims data: The New Zealand Pharmaceutical Collection (PHARMS)  
Pharmaceutical data obtained in the HWR data-linkage project is collected via the New Zealand 
Pharmaceutical collection (PHARMS), a data collection system run by the New Zealand 
Ministry of Health and the Pharmaceutical Management Agency (PHARMAC) that compiles 
information regarding claims of subsidized pharmaceutical dispensings in New Zealand 
(Ministry of Health, 2015). This includes records of a) prescribed community pharmaceuticals 
by a retail pharmacy or to an outpatient by a hospital pharmacy b) prescribed hospital pharmacy 
pharmaceuticals distributed by retail pharmacies, and c) prescribed community 
pharmaceuticals used for non-subsidized purposes distributed under Special Authority 
Application. The PHARMS data does not capture information relating to medication used by 
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inpatients within hospitals, medications used for non-subsidized purposes without Special 
Authority Application, or medications distributed at costs below the minimum price eligible 
for PHARMAC subsidization8 (Horsburgh et al., 2009).   
Drug-interaction identification resource: The New Zealand Formulary (NZF) 
Data on AI-medications were provided by the NZF. This resource is commonly used among 
New Zealand healthcare professionals and was selected to increase relevance of results in the 
context of New Zealand. The NZF is an online resource designed to provide New Zealand 
healthcare professionals with medication information and practice guidance that is clinically 
validated, with the aim of aiding in safe and effective medication selection for individual 
patients (NZF, 2017).  The drug interaction information provided by NZF is derived from 
Stockley’s Interaction Alerts, a computerised version of Stockley’s Drug Interactions, which 
is the most comprehensive and complete drug interaction index available (Stockley’s Drug 
Interactions, 2017). The NZF provides two categorical variables relating to potential 
interactions between drugs: 1) the ‘severity key’, which relates to the severity of a potential 
drug interaction (see Table 7); and 2) the ‘action key’, which provides practice guidelines based 
largely on the likelihood of a potential drug interaction (see Table 8).   
 
Table 7: NZF Severity Key Ordinal Categories 
Output Indication 
Nothing expected  For interactions that are unlikely to result in an effect, or for drugs pairs where 
no interaction occurs. 
Mild  For interactions that could result in an effect that is mild and unlikely to unduly 
concern or incapacitate the majority of patients. 
Moderate  For interactions that could result in an effect that may either cause considerable 
distress or partially incapacitate a patient. These interactions are unlikely to be 
life-threatening or result in long-term effects. 
Severe  For interactions that could totally incapacitate a patient or result in either a 
permanent detrimental effect or a life-threatening event. 
 
 
8 Dispensings are not eligible for subsidization when the cost of the medicine is lower than that of the patient 
contribution (Horsburgh et al., 2009).  For most subsidized medications, the prescription charge to the patient is 
$5 (Ministry of Health, 2018) 
  




Table 8: NZF Action Key Ordinal Categories 
Output Indication 
No action  For interactions where close follow up or monitoring are probably not automatically 
warranted due to the low probability of an interaction, but where more information is 
given in the event of a problem 
Information  For interactions where close follow up or monitoring are probably not automatically 
warranted due to the low probability of an interaction, but where more information is 
given in the event of a problem 
Monitor  For interactions where the drug pair is valuable and no compensatory action is possible, 
but the patient needs to be monitored to assess the outcome. 
For interactions where biochemical or therapeutic drug monitoring is recommended and 
further action may be needed based on the results 
Adjust  For interactions where the interaction can be accommodated, but where it is 
recommended that either one of the drugs is changed, or the dose is altered on initiating 
the combination. 
Avoid  For interactions where a drug combination is best avoided. This will mainly be used to 
highlight contraindicated drug pairs. 
 
11.2.b: Classifying AI-medications within the NZF data  
NZF was used to identify AI-medications with inclusion criteria based on those used previously 
by Cousins et al. (2014). Specifically, AI-medications were defined as those referred to as 
having potential alcohol-interactivity, those including a cautionary warning against alcohol 
use, and/or those including some sort of recommendation regarding alcohol consumption.  The 
NZF severity key variable was used to identify medications with specified alcohol interactivity 
(i.e., severity key = ‘mild’, ‘moderate’, or ‘severe’), and the action key variable was used to 
identify medications with an alcohol-related warning or recommendation (i.e. action key = 
‘information’, ‘monitor’, ‘adjust’, or ‘avoid’). Medications with a ‘nothing expected’ severity 
key output and a ‘no action’ action key output were therefore flagged as non-AI-medications. 
The methods of AI-medication and non-AI-medication identification based on NZF variable 









Table 9: AI-Medication and Non-AI-medication NZF Severity and Action Key Outputs   
NZF Severity key  NZF Action key  AI Classification 




No action, information, monitor, 
adjust, or avoid 
 
= AI-medication 
Nothing expected + Information, monitor, adjust, or avoid 
 
= AI-medication 
Nothing expected + No action 
 
= Non-AI-medication 
NZF severity and action key variables were used to assign AI-medications to ordinal categories 
of varying alcohol-interactivity levels. These categories included contraindicated (medications 
contraindicated for use with alcohol); major (interactions with detrimental effects that may be 
permanent or life-threatening; or interactions that may result in significant distress or 
incapacitation, and the likelihood of interaction is high enough to warrant close monitoring or 
dosage adjustment); moderate (interactions that may result in significant distress or 
incapacitation, but the likelihood of interaction is not high enough to warrant close monitoring 
or dosage adjustment); and mild AI-medications (potential interactions are of little clinical 
significance). The NZF severity key and action key outputs used to identify medications within 
each of these categories are shown in Table 10. 
Table 10: Categorisation of AI-medications Levels of Alcohol-Interactivity Potential 
Based on NZF Severity and Action Key Variables 
NZF Severity key  NZF Action key  Severity Categorisation 
Nothing expected, 
mild, moderate, or 
severe 
+ Avoid = Contraindicated AI-medication 
Severe, or moderate + Monitor, or adjust = Major AI-medication 
Moderate + No action, information = Moderate AI-medication 
Mild + No action, information = Mild AI-medication 
Nothing expected + Information = Mild AI-medication 
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11.2.c: Matching NZF data with PHARMS data   
Identification of medications listed in the PHARMS data indicated as being AI by the NZF was 
carried out using SPSS software. Medications identified as being AI in the NZF data were 
matched with medications listed in the PHARMS data through string variables containing the 
chemical names of medications generally used by both datasets. Specific differences in the way 
medication chemical names were documented in each of these data sources were addressed 
during data cleaning procedures. This subsection describes the differences between chemical 
medication name entries within the PHARMS and NZF datasets, the data-cleaning procedures 
used to address these differences, and the methods used to match these datasets.  All PHARMS 
medications that were identified as being AI by the NZF are listed in Appendix-A. This 
includes information relating to PHARMS chemical names, medication ids, brand names, and 
brand codes; AI-severity classification; and where applicable, medications classified as 
benzodiazepines, NSAIDs, or antibiotics.  
NZF and PHARMS differences in medication chemical name documentation   
Initially, medication chemical names within the NZF and PHARMS datasets were not 
compatible due to differences in documentation between the two data sources. The differences 
were that: 
• All chemical names listed in the NZF data referred to a single substance (e.g. aspirin), 
whereas some chemical name entries in the PHARMS data referred to multiple 
substances (e.g. aspirin with paracetamol and codeine), 
• Chemical names included in the NZF data typically contained only the active 
ingredient of each drug (e.g. abacavir), whereas the PHARMS data often included 
documentation of specific preparation salts (e.g. abacavir sulphate), 
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• Chemical names were documented using lowercase letters only within the NZF data 
(e.g. aspirin), whereas entries in the PHARMS data began with capital letters (e.g. 
Aspirin), and 
• The NZF chemical medication name entries included an indication of whether the 
medication is for topical or systemic use - e.g. “suvorexant (systemic)” or “tacrolimus 
(topical)”.  
Data cleaning procedures were developed to address these issues so that automated scripts 
could be used to match chemical medication names between the two data sources.  
Data cleaning 
SPSS string variable functions were used to manipulate chemical medication names within the 
NZF and PHARMS datasets. Topical/systemic use indications were removed from the NZF 
data, and rare cases of chemical entries containing multiple substrings (e.g. isosorbide 
mononitrate) were flagged. The second substring of these cases were then removed so that each 
chemical name within the NZF data contained only a single word (e.g. isosorbide). All NZF 
cases containing multiple substrings were manually checked following automated data 
cleaning processes and corrections were made where necessary.   
Cleaning of the chemical names documented in the PHARMS data involved removal of all 
capital letters (because the NZF entries contained only lowercase letters).  The following 
preparation salts were identified within the PHARMS data using two resources (drugs.com, 
2018; Wiedmann & Naqwi; 2016) and deleted: acetate; bromide; calcium; carbonate; citrate; 
decanoate; estolate; fumarate; hydrochloride; maleate; mesylate; pamoate; phosphate; 
potassium; sodium; succinate; sulfate; sulphate; and tartrate. Two new variables were then 
created for cases containing multiple chemical ingredients. The substrings ‘and’ ‘with’ and ‘,’ 
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(which had separated substrings representing different active ingredient within a single 
medication) were then removed.   
Data Matching 
Automated scripts were generated to match drugs identified within the NZF and PHARMS 
datasets. Matches were considered finalized when strings within the cleaned datasets matched 
exactly. In some cases, strings within the NZF data matched with single substrings in PHARMS 
data entries containing multiple substrings. In such cases, these matches were checked 
manually and corrected accordingly. See Appendix B for a list of automatically and manually 
corrected matches of chemical medication names between the NZF and PHARMS datasets.    
11.2.d: Using PHARMS data to identify AI-medication users within the HWR samples 
Once AI-medications were identified within the PHARMS data, the final task was to identify 
AI-medication users within the HWR samples.    This process involved three key steps: 1) 
identifying current AI-medication users; 2) identifying which current AI-medication users 
could also be defined as regular AI-medication users; 3) assigning regular AI-medication users 
into groups based on the AI-medication severity categories described previously.   
Identifying current AI-medication users  
As discussed in section 11.1.b, the definition of current medication use adopted in the present 
research varied for specific medication classes (benzodiazepines, NSAIDs, and antibiotics).  
The PHARMS data included a drug classification system adapted from the Anatomical 
Therapeutic Chemical (ATC) medicines (World Health Organization, n.d.).    This enabled for 
antibiotic and NSAIDs to be identified easily within the PHARMS data, as there were specific 
categories corresponding to these drug classes. However, the modified version of ATC used in 
the PHARMS data did not include a category that directly captured the class of 
benzodiazepines.  This issue was resolved by comparing benzodiazepines listed in the standard 
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ATC system9 against the chemical names of medications included in the PHARMS data.  The 
following medications were then defined as benzodiazepines:  alprazolam; bromazepam; 
chlordiazepoxide hydrochloride; clobazam; clonazepam; diazepam; flunitrazepam; 
loprazolam mesylate; lorazepam; lormetazepam; midazolam; nitrazepam; oxazepam; 
temazepam; triazolam; zopiclone.  Once benzodiazepines, NSAIDs, and antibiotic drugs were 
identified, an overall categorisation of current AI-medication use was calculated using the 
legend-time10 method for antibiotics; a 30-day fixed-window11 method for NSAIDs and 
benzodiazepines; and a 90-day fixed-window12 for method for all other medications.   
Identifying regular AI-medication users   
As discussed in section 11.1.b, the present research defined regular AI-medication use as a) at 
least one medication dispensing indicative of current AI-medication use, and b) at least one 
other AI-medication dispensing within an 8-month fixed window.  However, the research 
questions for this project related to AI-medication use in general, rather than specific classes 
of AI-medications. A decision therefore needed to be made about whether each dispensing 
must reflect a single medication (e.g., 2 dispensing of lorazepam), or whether multiple 
dispensings of different AI-medications could also constitute regular AI-medication use (e.g., 
1 lorazepam dispensing and 1 codeine dispensing).   The latter option was selected for the 
following reasons. The present research is based on the assumption that risk of AMI increases 
with frequency of AI-medication use over time (see Chapter 10). As such, AMI risk among 
 
9 https://www.whocc.no/atc_ddd_index/  
10 Legend-time method: data-linkage method of identifying current medication use. Infers current use when the 
number of days for which the medication is supplied is greater than or equal to the number of days between 
medication dispensing date and survey response date 
11 30-day fixed window: data-linkage method of identifying current medication use. Infers current use when a 
medication is dispensed during the past 30 days prior to survey response date  
12 90-day fixed window: data-linkage method of identifying current medication use. Infers current use when a 
medication is dispensed during the past 90 days prior to survey response date 
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current AI-medication users is considered higher for those who used AI-medications in the 
recent past, even if the specific medications used were different.  Moreover, by focusing on 
regular AI-medication use rather than current use, the present research already adopted a 
conservative approach to estimating the prevalence of concomitant alcohol/AI-medication use. 
Excluding cases of regular use on such a technicality would therefore unnecessarily reduce 
measurement sensitivity.    
Categorizing regular AI-medication users 
Another decision then needed to be made about how to apply the AI-medication severity 
categories (i.e., mild, moderate, major/contraindicated) when regular use is identified based on 
multiple dispensings of different medications.   This issue was resolved by using medications 
in current use to assign AI-medication users into their respective AI-medication severity 
groups.  The classification of regular AI-medication use across severity categories adopted in 
the present research is shown in Table 11.   
 
Table 11: Dispensing Records of AI-Medication User Groups 
AI-Medication User 
Groups 
Pharmaceutical Dispensings Received by Participants 
Current use* Past 244 days 




At least one contraindicated AI-
medication 
At least one AI-medication (mild, 
moderate, major, or contraindicated) 
Major AI-medication 
users 
At least one major AI-medication, and no 
contraindicated AI-medications 




At least one moderate AI-medication, 
and no major or contraindicated AI-
medications 
At least one AI-medication 
Mild AI-medication 
users 
At least one mild AI-medication, and no 
moderate, major, or contraindicated AI-
medications 
At least one AI-medication 
Note: *current use = legend time for antibiotics; 30-day fixed-window for benzodiazepines & NSAIDs; 90-day 
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CHAPTER 12: CONCOMITANT ALCOHOL & ALCOHOL-
INTERACTIVE MEDICATION USE BY OLDER NEW 
ZEALANDERS: EXPLORING THE IMPACT ON HEALTH 
AND HEALTHCARE UTILISATION (STUDY 1) 
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12.1: ABSTRACT 
Background: Vulnerability to alcohol-medication interactions (AMIs) increases during older 
adulthood due to age related changes in body mass, metabolism, and illness susceptibility. High 
rates of concomitant alcohol and alcohol-interactive (AI) medication use have been observed 
among older adults living in the United States and Europe, however the prevalence of this issue 
in New Zealand’s older adult population is currently unknown. Additionally, only a small 
number of observational studies have explored the public health impact of AMIs.  Objectives: 
This study explored the prevalence of concomitant alcohol/AI-medication use among older 
New Zealanders, and the impact of concomitant alcohol/AI-medication use on self-rated 
physical health and healthcare utilisation.  Design and Methods: This study included a large 
community sample of New Zealand older adults, and involved secondary analysis of survey 
data and pharmaceutical claims records. Sample weights were applied to survey data to 
increase representativeness to New Zealand’s older adult population.  Associations between 
variables of interest were explored using one hierarchical multiple regression model and two 
hierarchical logistic regression models. Results: One-in-four participants used alcohol and AI-
medications concomitantly.  Concomitant alcohol/AI-medication use was not significantly 
associated with self-rated health or healthcare utilisation. Discussion: The results of the present 
study indicate a substantial portion of New Zealand’s older adult population are at risk of AMI. 
Non-significant findings of the present study likely reflect measurement issues, and should 
therefore be interpreted with caution. Future research exploring the public health burden of 
concomitant alcohol/AI-medication use should include longitudinal outcome measures that are 
specific to the effects of AMI. 
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12.2: INTRODUCTION 
As discussed in chapter 3, interactions between alcohol and medications can increase risks of 
overdosing, cause a number of serious side effects such as gastrointestinal bleeding and 
psychomotor impairment, and interfere with the therapeutic effects of medication treatment 
regimens (Adams, 1995; Moore, Whiteman, & Ward, 2007; Weathermon & Crabb, 1999).  
These risks are of particular concern for older adults, as this population are more likely to be 
using medications with the potential to interact negatively with alcohol, and are particularly 
sensitive to the effects of alcohol-medication interactions (AMIs) due to age-related changes 
in body mass and metabolism (Moore et al., 2007).   
Cross-sectional survey findings suggest concomitant alcohol/AI-medication use is common 
among community dwelling older adults living in the United States (US) and Europe (Aira et 
al., 2005; Breslow et al., 2015; Cousins et al., 2014; Immonen et al., 2013; Qato et al., 2015). 
For example, Qato et al. (2015) found that approximately one-in-five participants from their 
sample of United States older adults reported using alcohol and AI-medications regularly. 
While equivalent data directly identifying the rate of AMIs in New Zealand’s older adult 
population is currently unavailable, findings from recent research suggests that older adult 
potential exposure to AMIs may be a significant issue in New Zealand.  For example, cross 
national comparisons of survey findings indicate that older adults living in New Zealander tend 
to drink more often and in greater quantity per occasion than those living in other countries 
such as the US, China, and Russia (Towers et al., 2017). Moreover, research by the Health 
Quality and Safety Commission (2018) suggests approximately 35% of New Zealander’s aged 
≥65 years use 5 or more long-term medications for their health conditions. As such, the 
prevalence of concomitant alcohol/AI-medication use by older New Zealanders is an issue that 
warrants investigation.    
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There is also need for survey research identifying potential relationships between concomitant 
alcohol/AI-medication use and adverse health outcomes. A recent systemic review of 20 
studies reporting on concomitant alcohol/AI-medication use found that only four studies 
reviewed included information about potential AMI related adverse health outcomes (Holton 
et al., 2017). This included three studies reporting on associations between alcohol/AI-
medication use and falls (Immonen et al.,2013; Sheahan et al., 1995; Wong et al., 2016), and 
one study reporting on AMI related hospital admissions (Onder et al., 2002). Overall, the range 
of potential concomitant alcohol/AI-medication use health associations explored to date is low, 
and there is a need for further research investigating other ways alcohol/AI-medication use may 
affect public health.     
12.3: THE PRESENT STUDY 
12.3.a: Aims 
The present study aimed to address the gaps in the literature outlined above by a) exploring the 
prevalence of concomitant alcohol/AI-medication use in a community sample of New Zealand 
older adults, and b) investigating the potential impact of concomitant alcohol/AI-medication 
use on self-rated physical health and healthcare utilization.  
12.3.b: Hypotheses  
Given that vulnerability to AMI-related harm appears to increase during older adulthood, the 
present study had the following hypotheses.  
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1. After controlling for relevant demographic variables (i.e. SES13) and the individual 
effects of alcohol use and AI-medication use, concomitant alcohol/AI-medication use 
will be negatively associated with self-rated physical health  
2. Concomitant alcohol/AI-medication use will be positively associated with healthcare 
utilization, after controlling for SES and the individual effects of alcohol use and AI-
medication use 
12.4: METHODS 
12.4.a: Participants  
Health, Work & Retirement Survey: 2006 data wave  
Survey data analysed in the present study was collected in the initial 2006 data wave of New 
Zealand Health Work, and Retirement (HWR) study, which is a large ongoing longitudinal 
survey of older adults living in New Zealand.  HWR participants were recruited through 
random selection from the New Zealand electoral roll.  To ensure New Zealand’s Māori 
population were adequately represented in the survey, an oversample of persons indicated as 
being of Māori decent on the electoral role was undertaken.  Surveys were posted to 13,045 
New Zealanders aged 55-70 years, with 5,264 surveys being posted to individuals from the 
general population, and 7,781 being posted to individuals of Māori descent. The response rate 
in the initial data wave was 51.1%, with surveys returned by 6,662 individuals. This included 
3,108 individuals from the general sample (59% response rate), and 3554 individuals (46% 
response rate) from the Māori sub-sample (Towers & Noone, 2007).  The present study sample 
 
13 Towers, Philipp, Dulin, and Allen (2016) found that the relationship between moderate drinking and physical 
health was substantially reduced among older women and completely eliminated among older men when a control 
measure of SES was included in their analysis. 
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included a subset of the 2006 HWR cohort who consented for their survey data to be linked 
with their national health records as part of the HWR data linkage project (Allen, 2016).   
HWR Data-Linkage Project 
In 2014, written informed consent to data-linkage was sought from participants recruited in the 
initial 2006 data wave and remained in the longitudinal study. A second approach to data-
linkage consent occurred in 2015 and included those who did not respond in the 2014 approach, 
yet were active participants in the 2014 survey (i.e., they responded to the survey, had not 
withdrawn from the study, and were not indicated as being deceased by national mortality 
records or other notification to the study). Consent was sought from 2,158 participants across 
the two approaches – 1,403 participants consented to data-linkage, 188 declined, and 567 did 
not respond. Minimum identifiers of consenting participants (name, gender, and date of birth) 
were provided to the Ministry of Health Analytic Services (formerly New Zealand Health 
Information Service) and a direct-match strategy was implemented to link to participants’ 
National Health Index (NHI) number. Data were then matched by the Ministry of Health 
Analytic Services to health records based on NHI number, before all identifying information 
were removed and records assigned a new identification number for the purposes of linkage to 
HWR study survey data (Allen, 2016). Of the 1,403 participants who consented to data-linkage, 
1,324 were matched successfully to an NHI number.  
Final unweighted and weighted samples  
The present study sample included 1,319 participants from the 2006 HWR study (Towers & 
Noone, 2007), who participated in the HWR data-linkage project (Allen, 2016), and responded 
to a survey item assessing drinking frequency (19.8% of the original random sample). This 
included 629 male participants (47.7%) and 690 female participants (52.3%).  Ages ranged 
from 54-70 years, and the mean age of the sample was 61.1 years (SD= 4.5 years).  A total of 
344 participants (26.1%) were aged ≥65 years.  For analyses addressing research questions 
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about the prevalence of concomitant alcohol/AI-medication use, the sample was weighted (by 
ethnicity, gender, and age) to adjust for oversampling and ensure representativeness to the 
population of New Zealanders aged 55-70 (see Stevenson, 2015). The weighted sample 
consisted of 1,720 participants, 860 of whom were male (50.0%) and 860 were female (50.0%). 
Ages in the weighted sample ranged from 54-70 years, and the mean age was 61.6 years (SD= 
4.5 years).   A total of 507 participants (29.4%) in the weighted sample were aged ≥65 years.  
12.4.b: Measures 
AI-medication use 
Participants’ pharmaceutical claims records were used to determine AI-medication use within 
the sample. This data was derived from the New Zealand Pharmaceutical Collection 
(PHARMS). The New Zealand Formulary (NZF) was used to identify AI-medications14 within 
the PHARMS data and categorize them into ordinal groups of varying alcohol-interactivity 
levels (mild15, moderate16, major17, and contraindicated18). The specific methods of identifying 
and categorizing AI-medications within the PHARMS data based on information provided by 
the NZF are detailed in the Chapter 11.2. 
Participants were identified as AI-medication users if their pharmaceutical claims records 
indicated they a) were currently using AI-medication(s) at the time of survey completion, and 
b) had used AI-medication(s) on a regular basis prior to survey completion. The research 
 
14 AI-medications: those referred to as having potential alcohol-interactivity, those including a cautionary warning 
against alcohol use, and/or those including some sort of recommendation regarding alcohol consumption. 
15 Mild AI-medications: potential interactions are of little clinical significance. 
16 Moderate AI-medications: interactions may result in significant distress or incapacitation, but the likelihood of 
interaction is not high enough to warrant close monitoring or dosage adjustment. 
17 Major AI-medications: for interactions with detrimental effects that may be permanent or life-threatening OR 
interactions that may result in significant distress or incapacitation and the likelihood of interaction is high enough 
to warrant close monitoring or dosage adjustment. 
18 Contraindicated AI-medications: medications contraindicated for use with alcohol. 
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protocol developed for this project informed the specific methods used to determine which 
participants could be defined as AI-medication users based on this definition (see chapter 11.1 
and 11.2). Briefly, current use of antibiotics was determined using the legend-time method; 
current use of NSAIDs and benzodiazepines was determined using a 30-day fixed-window; 
and current use of all other medications (excluding antibiotics, NSAIDs, and benzodiazepines) 
was determined using a 90-day fixed-window.  Participants were defined as current regular AI-
medication users if they were (1) identified as currently using AI-medications based on the 
criteria just described, and 2) dispensed at least one other AI-medication supply during the past 
244 days (prior to survey completion) that was not in current use at the time of survey 
completion.  AI-medication users were then assigned to one of three groups (mild, moderate, 
and major/contraindicated AI-medication users) based on the highest alcohol-interactivity level 
of medications in current use (see Table 12).  For some analyses, moderate and 
major/contraindicated AI-medication use categories were also combined to identify 
participants using AI-medications with the potential to cause a clinically significant AMI 
(clinically significant AI-medication users).  
Table 12: Pharmaceutical Dispensing Records of Participants Defined as Mild, Moderate, 
or Major/Contraindicated AI-Medication Users 
AI-Medication User 
Groups 
Pharmaceutical dispensing by participant 
Current use Past 244 days 
(not in current use) 
Major/Contraindicated 
AI-medication users* 
At least one major or contraindicated 
AI-medication 
At least one AI-medication (mild, 




At least one moderate AI-
medication, and no major or 
contraindicated AI-medications 
At least one AI-medication 
Mild AI-medication 
users 
At least one mild AI-medication, and 
no moderate, major, or 
contraindicated AI-medications 
At least one AI-medication 
Note: Current use = Legend time for antibiotics; 30-day fixed-window for benzodiazepines & NSAIDs; 90-
day fixed-window for all other drugs. 
Note: *clinically significant AI-medication users   
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Alcohol use  
The HWR survey includes the Alcohol Use Disorders Identification Test – C (AUDIT-C, Bush 
et al., 1998), which consists of three items assessing alcohol consumption patterns; specifically, 
the quantity and frequency of alcohol use, as well as binge drinking frequency.  The present 
study used the AUDIT-C frequency item to measure alcohol use among participants. Those 
who reported using alcohol ‘never’ or ‘monthly or less’ were defined as minimal/non-drinkers, 
and regular drinkers were defined as those who reported drinking at least twice monthly.  
Responses on the AUDIT-C frequency item were then used to categorize regular drinkers as 
either light/moderate-drinkers (those who reported using alcohol ‘2-4 times monthly’ or ‘2-3 
times weekly’) or heavy-drinkers (those who reported using alcohol ‘4 or more times weekly’).  
Physical health 
The 2006 HWR survey included items of the SF12v2 (Ware et al., 2000), a self-report 
questionnaire that assesses a range of specific physical and mental health dimensions 
represented in separate subscales. The SF12v2 also produces two overall subscale scores 
relating to general physical and mental health dimensions.  Subscale scores range from 0-100 
(M=50, SD=10). The present study used the general physical health SF12v2 subscale to 
measure HWR participants’ physical health. Scoring of the SF12v2 was based on normative 
data gathered in a New Zealand population derived from the 2008 New Zealand General Social 
Survey and factor score coefficients derived from the 2006-07 New Zealand Health Survey 
(Frieling et al., 2013).  The SF12v2 physical health scale has shown good internal consistency 
(α >.80) in large samples of US adults aged ≥18 years (Cheak-Zamora et al., 2009) and older 
adults aged ≥65 years (Shah & Brown, 2020).  
Healthcare utilisation  
The 2006 HWR survey included healthcare utilisation items originally developed for the New 
Zealand Taking The Pulse (TTP) survey, a nationally representative survey run by the New 
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Zealand Ministry of Health (1999) for population health monitoring.  The present study utilized 
TTP questions to measure past 12-month GP visits (≤2 to ≥3), and past 12-month emergency 
department (ED) visits and/or overnight hospital admissions (0 to ≥1).  The higher threshold 
of ≥3 GP visits was selected because subsidised medications used among participants are likely 
to have been prescribed by GPs. Past 12-month ED-visits and overnight hospital admissions 
(ED-visits/OHAs hereafter) were combined into a single dichotomous variable because it was 
impossible to determine whether reported ED visits and overnight hospital admissions resulted 
from separate or single events (i.e. ED visits that also result in overnight admission to hospital).   
Demographic variables 
In light of the association of SES with alcohol use, participant SES was measured using the 
economic living standard index short-form (ELSI-sf): a 25-item self-report measure of 
consumption capacity, economic social restrictions, and material wealth in New Zealand 
(Jensen et al.,2005). The ELSI-sf authors reported high internal consistency (α <.80) for this 
measure in a large New Zealand community sample (Jensen et al., 2005). Raw scores on the 
ELSI-sf range from 0-31, with higher scores indicating higher SES.  ELSI-sf scores were also 
categorised into three levels of living standards including ‘hardship’ (score of ≤16) 
‘comfortable’ (scores from 17-24) and ‘good' (score of ≥25). Other demographic variables 
included ethnicity, age, marital status, and education level. Ethnicity was defined as ‘New 
Zealand European’ (NZE), ‘Māori’, or ‘Other’. Age groups included '54-59 years', '60-64 
years', and '65-70 years'. Marital status groups included ‘Married, Civil Union, or De Facto’, 
and ‘Other’.  Education level was defined as ‘Tertiary Education’ or ‘No Tertiary Education’.   
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12.4.c: Analyses 
All analyses were conducted using SPSS software. Descriptive statistics were used to describe 
sample rates and frequency of alcohol use, and characterise the demographic composition of 
the sample by alcohol use frequency category.     
To explore the prevalence of concomitant alcohol/AI-medication use, descriptive statistics 
were used to describe sample rates of AI-medication use, rates of alcohol use among AI-
medication users, and overall sample rates of concomitant AI-medication use.  These analyses 
were applied to the unweighted and weighted samples. Additionally, to enhance comparability 
of the present study with other studies exploring rates of concomitant alcohol/AI-medication 
use by older adults, these analyses were also applied to unweighted and weighted subsamples 
of participants aged ≥65 years.    
Hierarchical multiple regression was used to test the association of concomitant alcohol/AI-
medication and physical health. The SF12v2 physical component scale was entered as an 
outcome variable. ELSI-SF raw scores were entered at step 1 to control for the effect of living 
standards. Binary variables were entered at step 2 to control for the effects of alcohol use 
(‘minimal/non-drinkers’ versus ‘regular drinkers’) and AI-medication use (‘non-users’ and 
‘mild AI-medication users’ versus ‘clinically significant AI-medication users’19). These two 
variables were then entered as an interaction term variable (‘AI-medication use*alcohol use’) 
at step 3, to assess whether the association of AI-medication use with physical health differed 
with concomitant alcohol use. Missing cases were deleted pairwise to maximize statistical 
power of the available data.     R squared (R2) was used to assess the level of variance in physical 
health explained by predictor variables at each step in the model. Additional variance in 
 
19 Clinically significant AI-medications include moderate and major/contraindicated AI-medications. 
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physical health explained by predictors introduced at steps 2 and 3 was assessed using R 
squared change (ΔR2). Standardized beta values (β) were used to assess the direction and 
statistical significance (alpha level = <.05) of relationships between predictor variables and 
physical health.   
Two hierarchical logistic regression models were constructed to assess the main effects and 
interaction effects of alcohol use and AI-Medication use on the likelihood of past 12-month 
healthcare utilization. The outcome variable in the first of these models was past 12-month ED-
visits/OHAs (0 versus ≥1), and the outcome variable in the second model was past 12-month 
GP visits (≤2 versus ≥3). As with the multiple regression model described in the previous 
paragraph, the ELSI-SF scale was entered at step 1 to control for the effect of living standards, 
binary variables were entered at step 2 to control the effects of AI-medication use and of alcohol 
use, and an ‘AI-medication use*alcohol use’ interaction term was entered at step 3 to assess 
whether the association of AI-medication use with health service use differed with concomitant 
alcohol use. The goodness of fit both logistic regression models was assessed using Hosmer 
and Lemeshow Chi-squared tests (HLT). At each step of both logistic regression models, the 
variance in healthcare utilization explained by predictor variables was assessed using Cox and 
Snell R squared, and Nagelkerke R squared.  Beta values (B) were used to assess whether 
relationships between predictor variables and healthcare utilization outcome variables reached 
statistical significance (alpha level = <.05), and odds ratios (OR) were used to assess the extent 
to which predictor variables influenced the likelihood of past 12-month healthcare utilization.  
12.5: RESULTS 
12.5.a: Characteristics of drinkers  
Table 13 shows the demographic characteristics of the weighted sample (N = 1,720) overall 
and by drinking frequency category.  
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Table 13: Weighted Sample Characteristics by Drinking Frequency (N = 1,720) 
  
Total % of 
Sample 
Drinking Frequency (AUDIT-C) 













Gender     


















Age      






























Ethnicity      






























Education level     


















    Missing (n = 25.5) 1.5%    
Marital Status      
    Married, civil union,  



















    Missing (n = 15.8) 0.9%    
Living Standards     






























    Missing (n = 28.8) 1.7%    
 
Overall, 73.1% of the weighted sample (n = 1,258) reported using alcohol at least twice 
monthly (i.e., regular drinkers). Regular drinking was most common among participants who 
were male (79.8%), aged 60-64 years (75.1%), NZ European (74.1%), those with good 
economic living standards (78.6%), those with tertiary level education (83.3%), and those of 
married, civil union, or de facto marital status (75.6%). The weighted sample rate of heavy 
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drinking (alcohol use 4 or more times weekly) was 34% (n = 585).   Heavy drinking was more 
common among those who were male (44.4%), aged 60-64 (37.9%), of other ethnicity (40.8%), 
those with good living standards (40.2%), those with tertiary level education (48.3%), and those 
of married, civil union, or de facto marital status (36.2%).  The unweighted sample 
characteristics by drinking frequency is shown in Appendix-C (Table 30).   
12.5.b: Prevalence of concomitant alcohol/AI-medication use 
Table 14 presents the unweighted and weighted sample rates of concomitant alcohol/AI-
medication use. These results reflect a breakdown of the alcohol use patterns by a) the total 
sample; b) dichotomous samples reflecting ‘non-users of AI-medications’ and ‘AI-medication 
users’; and c) a breakdown of the sub-samples within the ‘AI-medication’ use group based on 
AI-medication severity categories.  Percentages are provided for overall sample rates of 
concomitant alcohol/AI-medication use, and for rates of alcohol use within AI-medication use 
samples and subsamples. The present study did not assess the statistical significance of the 
variation in alcohol use between AI-medication user groups, however this is explored in study 
2 (chapter 13). 
Rates of AI-medication use  
The unweighted and weighted sample rates of participants identified as current regular users 
of at least one AI-medication were 35.9% (n = 473), and 34.4% (n = 591.2) respectively. Within 
the unweighted sample, 146 (11.1%) participants were mild AI-medication users, 151 (11.4%) 
were moderate AI-medication users, and 176 (13.3%) were major/contraindicated AI-
medication users. Weighted sample rates of mild, moderate, and major/contraindicated AI-
medication use were 11.9%, 11.7%, and 10.7% respectively (Table 14).
  






Table 14: Unweighted and Weighted Sample Rates of Alcohol Use, AI-Medication Use, and Cncomitant Alcohol/AI-Medication Use 
Alcohol Use 




















AI-medication sample by potential 
interaction severity 
Mild Moderate Maj/Con*  Mild Moderate Maj/Con* 
Minimal/non-
drinkers  
             
416 236 180 40 61 79  461.9 282.4 179.5 43.2 67.4 68.9 
  %Sample 31.5% 17.9% 13.6% 3.0% 4.6% 6.0%  26.9% 16.4% 10.4% 2.5% 3.9% 4.0% 
  %AI-Medication  27.9% 38.1% 27.4% 40.4% 44.9%   25.0% 30.4% 21.0% 33.4% 37.4% 
Regular drinkers 903 610 293 106 90 97  1258.2 846.6 411.7 162.0 134.4 115.2 
  %Sample 68.5% 46.2% 22.2% 8.0% 6.8% 7.4%  73.1% 49.2% 23.9% 9.4% 7.8% 6.7% 
  %AI-Medication  72.1% 61.9% 72.6% 59.6% 55.1%   75.0% 69.6% 79.0% 66.6% 62.6% 
Light/moderate 509 342 167 50 55 62  673.2 453.5 29.7 64.4 81.7 73.6 
  %Sample 56.4% 25.9% 12.7% 8.0% 6.8% 7.4%  39.1% 26.4% 12.8% 3.7% 4.8% 4.3% 
  %AI-Medication  40.4% 35.3% 34.2% 36.4% 35.2%   40.2% 37.2% 31.4% 40.5% 40.0% 
Heavy 394 268 126 56 35 35  585.1 393.1 192.0 97.7 52.7 41.6 
  %Sample 43.6% 20.3% 9.6% 4.2% 2.7% 2.7%  34.0% 22.9% 11.2% 5.7% 3.1% 2.4% 
  %AI-Medication  31.7% 26.6% 38.4% 23.2% 19.9%   34.8% 32.5% 47.6% 26.2% 22.7% 
Total Sample 1,319 846 473 146 151 176  1,720.1 1,128.9 591.2 205.2 201.8 184.1 
  %Sample 100.0% 64.1% 35.9% 11.1% 11.4% 13.3%  100.0% 65.6% 34.4% 11.9% 11.7% 10.7% 
Notes: *This severity category includes major AI-medications, and contraindicated AI-medications (i.e., major/contraindicated AI-medications) 
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Rates of concomitant alcohol use among AI-medication users  
Of the 473 participants identified as current regular AI-medication users in the unweighted 
sample, 293 (61.9%) were identified as regular drinkers, and 126 (26.6%) were heavy drinkers. 
Among those identified as AI-medication users in the weighted sample, 69.6% were regular 
drinkers, with 32.5% being heavy drinkers (Table 14). 
Sample rates of concomitant alcohol.AI-medication use  
Unweighted and weighted sample rates of participants identified as both regular-drinkers and 
current regular AI-medication users (i.e., concomitant alcohol/AI-medication users) were 
22.2% and 23.9% respectively (Table 14).  A total of 187 participants in the unweighted sample 
(14.2%) were concomitant users of alcohol and AI-medications with the potential to cause a 
clinically significant AMI (i.e., moderate AI-medications, or major/contraindicated AI-
medications).  The weighted sample rate of participants identified as being at risk of a clinically 
significant AMI was 15.5% (n = 249.6).  
Concomitant alcohol/AI-medication use among participants aged ≥65 years 
A total of 344 participants within the unweighted sample were aged ≥65 years, 156 of whom 
(45.2%) were identified as current regular users of one or more AI-medications.  Within the 
weighted sample, 506.5 participants were aged ≥65 years, 43.3% of whom (n = 219.1) were 
AI-medication users.  The unweighted and weighted rates of regular drinking among AI-
medication users aged ≥65 years were 63.5% (n = 99) and 66.1% (n = 144.9) respectively. The 
overall prevalence of concomitant alcohol/AI-medication use among participants aged ≥65 
years was 28.8% in the unweighted sample, and 28.6% in the weighted sample. Among 
participants aged ≥65 years in the unweighted sample, 19.5% (n = 67) used alcohol 
concomitantly with AI-medications with the potential to cause a clinically significant AMI 
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(i.e., moderate, or major/contraindicated AI-medications). The rate of clinically significant 
AMI risk among those aged ≥65 years in the weighted sample was 18.3% (n = 92.5). 
12.5.c: Alcohol, AI-medication, and physical health  
Hierarchical multiple regression was used to assess a) the main effects of alcohol use and AI-
medication use on physical health (assessed by SF12-v2) after controlling for living standards 
(ELSI-sf scores), and b) the interaction of alcohol and AI-medication use on the prediction of 
health after controlling for living standards and the main effects of alcohol and AI-medication 
use. All participants (n = 1,319) had data available for alcohol use and AI-medication use; 
SF12-v2 data was available for 1,228 participants; ELSI-sf data was available for 1,291 
participants; and 1,204 participants had data for both the SF12-v2 and the ELSI-sf.   
Preliminary analyses showed the assumptions of normality, linearity, and homoscedasticity 
were not violated.  Assessment of multicollinearity showed no correlations between 
independent variables exceeding .70 (excluding those between the interaction term and main 
effects variables). A summary of the results from the hierarchical regression is presented in 
Table 15.  
Table 15: Multiple Regression Predicting Variance in Physical Health 
 
Step 1 Step 2 Step 3 
β R2 ΔR2 Β R2 ΔR2 β R2 ΔR2 
Model Predictors          
  Living Standards .33***   .28***   .28***   
  Alcohol use    .06*   .06*   
  AI-medication use    -.29***   -.27***   
  Alcohol use x AI-  
  medication use 
      -.02   
Model Summary  .111 .111***  .199 .088***  .199 .000 
Note: * p < .05; ** p < .01; *** p < .001 
Note: Living standards were determined based on continuous ELSI-sf scores 
Note: Alcohol use was coded as 0 for those using alcohol monthly or less (minimal/non-drinkers) 
and 1 for those using alcohol at least twice monthly (regular drinkers) 
Note: AI-Medication use was coded as 0 for non-users and Mild-AI-medication users and 1 for those 
using moderate or major/contraindicated AI-medications 
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Living standards was entered at step 1 and explained 11.1% of the variance in physical health. 
After entry of alcohol use and AI-medication use variables at step 2, the variance of the model 
was 19.9%, F (3, 1200) = 99.30, p < .001. The two variables explained an additional 8.8% of 
the variance in physical health after controlling for living standards, R squared change = .09, F 
change (2, 1200) = 65.75, p < .001.  After entry of an interaction term variable at step 3 (alcohol 
use * AI-medication use), the total variance of the model as a whole remained at 19.9% F (3, 
1199) = 74.47, p < .001. The addition of the interaction term explained 0.00% of the variance 
in physical health after controlling for living standards and the main effects of alcohol use and 
AI-medication use, R squared change = .00, F change (1, 1199) = .187, p .665.  
In the final model, statistically significant predictors of physical health included living 
standards, alcohol use, and AI-medication use, with living standards recording a higher beta 
value (beta = .28, p <.001) than AI-medication use (beta = -.27, p < .001), and alcohol use (beta 
= .06, p = .04).   The variance in physical health explained by living standards, alcohol use, AI-
medication use, and the interaction term was 7.2%, 0.3%, 2.8%, and 0.0% respectively.   Figure 
1 displays the mean SF12-v2 scores for drinkers and non-drinkers across AI-medication user 
vs. non-user categories after controlling for the effects of variables entered in the model.   
 
 
Figure 1: Mean SF12-v2 Physical Component Scores Cross Alcohol Use and AI-
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12.5.d: Alcohol, AI-medication, and healthcare utilisation  
Two hierarchical logistic regression models assessed the main effects and interaction effects of 
alcohol use and AI-Medication use on the likelihood of past 12-month ED-visits/OHAs (≥1) 
and GP-visits (≥3). In both models, the living standards were entered as a control variable at 
step 1, Alcohol Use and AI-Medication Use were entered at step 2, and an interaction term 
(Alcohol Use * AI-medication Use) was entered at step 3. Summaries of the logistic regression 
models for ED-visits/OHAs and GP-visits are presented in Table 16 and Table 17 respectively.   
Emergency department visits and overnight hospital admissions (ED-visits/OHAs) 
Step 1 of the model for ED-visits/OHAs was statistically significant (X2 (1, N = 1,287) = 23.30, 
p <.001) indicating higher living standards were associated with a reduced risk of past year ED 
visits/OHAs. The ELSI-sf scale explained between 1.8% (Cox and Snell R2 square) and 3.0% 
(Nagelkerke R squared) of the variance in ED-visits/OHAs. The model was significantly 
improved by the addition of step 2 (block X2 (2, N = 1,287) = 26.27, p <.001; full model X2 (3, 
N = 1,287) = 49.47, p <.001), with the overall model at step 2 explaining between 3.8% (Cox 
and Snell R square) and 6.3% (Nagelkerke R squared) of the variance in ED-visits/OHAs (the 
additional variables therefore explained between 2.0% and 3.3% of the variance in ED-
visits/OHAs). The model was not significantly improved by the addition of step 3 (block X2 (1, 
N = 1,287) = 0.19, p =.658; full model X2 (4, N = 1,287) = 49.77, p <.001).  
The final model explained between 3.8% (Cox and Snell R square) and 6.4% (Nagelkerke R 
squared) of the variance in ED-visits/OHAs, correctly classified 83.2% of cases, and had 
adequate fit as indicated by non-significant HLT (X2 (8, N = 1,287) = 6.70, p =.570).  Significant 
predictors of ED-visits/OHAs in the final model (see Table 16) included living standards and 
AI-Medication use (p =<.001).  The OR for AI-Medication use was 2.50, indicating AI-
Medication users were 2.5 times more likely to report past year of ED-visits/OHAs than non-
users.  
  
112 | P a g e  
 
Table 16: Hierarchical Logistic Regression Model Predicting ≥1 Emergency Department 
Visits and/or Overnight Hospital Admissions During the Past Year (n = 1,287) 











 Living standards 
-.23*** 
0.79 
(0.72, 0.87) -.19*** 
0.82 
(0.75, 0.91) -.19*** 
0.82 
(0.75, 0.91) 





(0.68, 1.31) .00 
1.00 
(0.66, 1.52) 
 AI-medication   




(1.67, 3.13) .92*** 
2.50 
(1.51, 4.15) 
 Alcohol use*AI- 








Note: * p < .05; ** p < .01; *** p < .001 
Note: Living standards were determined based on ELSI-sf scores 
Note: Alcohol use was coded as 0 for those using alcohol monthly or less and 1 for those using 
alcohol at least twice monthly 
Note: AI-Medication use was coded as 0 for non-users and mild-AI-medication users and 1 for those 
using moderate or major/contraindicated AI-medications 
  
GP-visits 
Step 1 of the model for GP-visits was statistically significant (X2 (1, N = 1,287) = 15.66, p 
<.001), with the ELSI-sf scale explaining between 1.2% (Cox and Snell R square) and 1.6% 
(Nagelkerke R squared) of the variance in GP-visits. The model was significantly improved by 
the addition of step 2 (block X2 (2, N = 1,287) = 153.69, p <.001; full model X2 (3, N = 1,287) 
= 169.35, p <.001), with the overall model at step 2 explaining between 12.3% (Cox and Snell 
R squared) and 16.4% (Nagelkerke R squared) of the variance in GP-visits (the additional 
variables therefore explained between 11.1% and 14.8% of the variance in GP-visits). The 
model was not significantly improved by the addition of step 3 (block X2 (1, N = 1,287) = 0.22, 
p =.639; full model X2 (4, N = 1,287) = 169.57, p <.001).  
The final model explained between 12.3% (Cox and Snell R square) and 16.5% (Nagelkerke 
R squared) of the variance in GP-visits, correctly classified 65.3% of cases, and had adequate 
fit as indicated by non-significant HLT (X2 (7, N = 1,287) = 4.66, p =.701).  Significant 
predictors of GP visits in the final model (see Table 17) included living standards (p < .05) and 
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AI-medication use (p <.001). The OR for AI-Medication use was 5.27, indicating AI-
medication users were more than 5 times more likely to report ≥3 past year GP-visits than non-
users.   
Table 17: Hierarchical Logistic Regression Model Predicting ≥3 Past Year GP visits (n = 
1,287) 
























(0.74, 1.25) -.07 
.93 
(0.69, 1.25) 






(4.25, 7.82) 1.66*** 
5.26 
(3.25, 8.54) 
 Alcohol use*AI- 








Note: * p < .05; ** p < .01; *** p < .001 
Note: Living standards were determined based on ELSI-sf scores 
Note: Alcohol use was coded as 0 for those using alcohol monthly or less and 1 for those using alcohol at 
least twice monthly 
Note: AI-Medication use was coded as 0 for non-users and mild-AI-medication users and 1 for those using 
moderate or major/contraindicated AI-medications 
12.6: DISCUSSION 
This section discusses topics of particular relevance to study 1, as points of discussion that 
apply to both studies implemented in the present thesis are covered in chapter 14.   The results 
of the present study are summarized first.  The findings and methods of the present study are 
then compared to those of previous observational studies exploring similar research questions.   
Strengths and limitations specific to study 1 are then discussed, and conclusions are provided.  
12.6.a: Summary of results  
The present study explored the prevalence of concomitant alcohol/AI-medication use, and the 
impact of concomitant alcohol/AI-medication use on health and healthcare utilisation, in a 
sample of New Zealand older adults. Almost a quarter of participants aged 54-70 years were 
identified as being at risk of AMI, and approximately one-in-six were at risk of exposure to an 
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AMI of clinical significance.  Over one quarter of those aged 65-70 years were at risk of AMI, 
and approximately one-in-five were at risk of clinically significant AMI.  The hypothesized 
associations of concomitant alcohol/AI-medication use with health and health care utilization 
were not supported by the results.  After controlling for living standards, AI-medication use, 
and alcohol use, concomitant alcohol/AI-medication use was not a significant predictor of self-
rated physical health or past 12-month healthcare utilization.    
12.6.b: The present study in the context of existing observational research into 
concomitant alcohol/AI-medication use health outcomes 
Previous research findings  
To the authors knowledge, four other observational studies have explored associations of 
concomitant alcohol/AI-medication use on health outcomes in large older adult samples.  
Consistent with the present study, non-significant findings were reported in two studies 
examining the potential association between concomitant alcohol/AI-medication use and falls 
(Sheahan et al., 1995; Wong et al., 2016).   In contrast, Immonen et al. (2013) found that ‘at 
risk drinkers’ who used AI-medications were significantly more likely to report having fallen 
when intoxicated than those using non-AI-medications (13.8% vs 4.1%).  Similarly, Onder et 
al. (2002) found that recent alcohol consumption increased the odds of suffering an adverse 
drug reaction by 24% in a sample of older adults attending EDs across 81 hospitals in Italy.  
Differences in outcome measures  
The mixed findings described above may reflect differences in the outcome measures used 
between studies.   Specifically, the studies that found significant associations of concomitant 
alcohol/AI-medication use (Immonen et al., 2013; Onder et al., 2002) included specific 
outcome variables that were potentially more relevant to the effects of AMIs.  Immonen et al. 
(2013) used an outcome measure of alcohol-related falls, whereas Sheahan et al. (1995) and 
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Wong et al. (2016) included general measures of falls, and the health outcome measure used in 
the present study was even more broad (i.e., self-rated physical health).  Moreover, Onder et 
al. (2002) reported on adverse drug reaction related ED visits, whereas the healthcare utilization 
measures included in present study were much more general in comparison (i.e., past 12-month 
GP visits, ED-visits, and OHAs).    It is therefore possible that the health and healthcare 
utilization measures included in the present study were too broad to capture specific effects of 
concomitant alcohol/AI-medication use.   
Differences in drinking measures 
Alcohol use measurement differences may also contribute to the mixed results of observational 
studies reporting on concomitant alcohol/AI-medication related health outcomes.   The two 
studies reporting significant findings included alcohol measures that considered both drinking 
quantity and drinking frequency. Immonen et al. (2013) defined ‘risky drinkers’ as those 
consuming ˃ 7 drinks weekly, ≥5 drinks per typical drinking day, and/or ≥3 drinks at least twice 
weekly, and recent drinkers were defined as those consuming an average of ≥40g of alcohol 
per day prior to hospital admission in the study by Onder et al. (2002).  In contrast, the present 
study and the study by Sheahan et al. (1995) assessed drinking frequency only, and the drinking 
measure Wong et al. (2002) utilized (total drinks per month) was unable to specify typical 
drinking quantity or frequency with any level of accuracy (e.g., 30 drinks per month could 
reflect a variety of drinking quantity/frequency patterns).   
The present study focused on drinking frequency over drinking quantity because this was seen 
as being a more reliable predictor of simultaneous exposure to alcohol and AI-medications 
(Breslow et al., 2015).  However, the likelihood of simultaneous exposure causing an AMI is 
also depends on the amount of alcohol consumed and the class of AI-medication used (Moore 
et al., 2007). Given that drinking quantity was considered in both studies finding adverse health 
associations of concomitant alcohol/AI-medication use (Immonen et al., 2013; Onder et al., 
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2002), a focus on drinking frequency over drinking quantity might partially explain the non-
significant findings of the present study.    
12.6.c: Strengths and limitations20 
A key strength of the present study was the nationally representative sample, which increased 
the generalizability of the study findings to the population of New Zealanders aged 54-70 years. 
However, due to the age distribution of the study sample, the results are not easily generalized 
to the population of New Zealanders aged ≥65 years, which is generally considered the 
definition of older adulthood (Cannon, 2015).  The age of the study sample was therefore a key 
limitation of the present study.  The cross-sectional research design of the present study was 
also a potential limitation, given the nature of the research questions addressed.   Health 
behaviour theorists (e.g., Maddux & Rogers, 1983; Janz & Becker, 1984; Rogers, 1975; 
Rosenstock et al., 1988) argue that perceived personal vulnerability to a given adverse health 
outcome is often a strong motivator for health behaviour change. It would therefore be 
reasonable to assume that having significant alcohol related health problems, and/or 
experiencing an acute AMI requiring medical attention, would be sufficient motivation for 
many older adults to stop drinking.   Such cases would not be identified in the present study, 
as alcohol consumption was assessed at the time of survey completion, and the outcome 
variables were not measured longitudinally. Finally, the use of broad outcome variables that 
are non-specific to the effects of AMIs, and the overemphasis on drinking frequency over 
drinking quantity, were also potential limitations of the present study (as discussed previously 
in section 12.6.b). 
 
20 Several methodological strengths and limitations relating to measures of AI-medication use and alcohol use are 
discussed in Chapter 14, as these points also apply to study 2  
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12.6.d: Summary and conclusions 
A substantial portion of the present study sample were identified as users of both alcohol and 
AI-medications. Concomitant alcohol/AI-medication use was not associated with self-rated 
health, past-12-month GP visits, or past month ED-visits and/or OHAs. However, these 
findings should be interpreted with caution, given that the heightened risks of AMI related 
harm for older adults are well documented in the pharmacological literature (Moore et al., 
2002).  As discussed, the non-significant findings of the present study likely reflect 
methodological issues.  Future observational research into the health outcomes of concomitant 
alcohol/AI-medication use should include longitudinal outcome measures that are specific to 
the effects of AMI.  
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CHAPTER 13: RISK OF ALCOHOL-MEDICATION 
INTERACTIONS AMONG OLDER NEW ZEALANDERS: 
EXPLORING ASSOCIATIONS BETWEEN ALCOHOL USE, 
MEDICATION USE, AND DEPRESSION (STUDY 2) 
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13.1: ABSTRACT 
Background: Vulnerability to adverse alcohol-medication interactions (AMIs) increases 
during older adulthood. Existing research findings indicate awareness of AMI risks is 
associated with reduced alcohol consumption among AI-medication users, and mental health 
factors such as depression may be associated with concomitant use of alcohol and AI-
medication. Objectives:  This study explored associations between AI-medication use, alcohol 
use, concomitant alcohol/AI-medication use, and depression among older adults. Design and 
Methods: This study included a large community sample of New Zealand older adults, and 
involved secondary analysis of survey data and pharmaceutical claims records. Sample weights 
were applied to survey data to increase representativeness to New Zealand’s older adult 
population.  Associations between variables of interest were explored using Chi-squared tests 
and hierarchical logistic regression. Results: More than one-in-three participants were at risk 
of AMI. AI-medication use was associated with less alcohol use, with lower rates of alcohol 
use being seen among those using AI-medications associated with higher AMI-severity. 
Depression did not influence the association between AI-medication use and alcohol use. 
Discussion: Many New Zealand older adults are at risk of AMI exposure.  These risks may be 
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13.2: INTRODUCTION  
Interactions between alcohol and medications can increase risks of overdosing, cause a number 
of serious side effects such as gastrointestinal bleeding and psychomotor impairment, and may 
interfere with the therapeutic effects of medication treatment regimens (Adams, 1995; Moore, 
Whiteman, & Ward, 2007; Weathermon & Crabb, 1999).  These risks are of particular concern 
for older adults, as this population is more likely to be using medications with the potential to 
interact negatively with alcohol, and are particularly sensitive to the effects of alcohol-
medication interactions (AMI’s) due to age-related changes in body mass and metabolism 
(Moore et al., 2007).  Survey research exploring rates of alcohol and alcohol-interactive (AI) 
medication use among older adults has shown that, while AI-medication use is negatively 
associated with alcohol use, concomitant alcohol and AI-medication use is common among 
community dwelling older adults (Cousins et al., 2014; Breslow et al., 2015; Pringle et al., 
2005; Qato et al., 2015).   
Given the potential for alcohol related harm in older people, there is a need to identify factors 
underlying drinking behaviour among older AI-medication users that may inform intervention 
strategies aimed at reducing alcohol AMI exposure.  Existing research findings show that 
having knowledge about AMI risk is negatively associated with alcohol use by AI-medication 
users (Gavens et al., 2016; Zanjani et al., 2013). These findings support motivational theories 
of health behaviour that propose perceived health threat often facilitates healthy behaviour 
change (e.g. Rogers, 1983; Rosenstock, 1974).   
Conversely, avoidant coping strategies, such as avoidance of AMI related health information 
or denial of personal risk, appear to be associated with concomitant alcohol/AI-medication use 
(Gavens et al., 2016; Zanjani et al., 2013; Zanjani, Allen, Smith et al., 2018).  There is also 
evidence indicating alcohol use for self-medicating purposes may prevent healthy changes in 
drinking behaviour by AI-medication users with mental health problems, particularly those 
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with symptoms of depression (Gavens et al., 2016; Haighton et a., 2018). These findings 
support motivational models of alcohol use proposing that people with higher negative affect 
and avoidant coping styles often use alcohol to self-medicate, and that self-medication in turn 
reduces volitional control over alcohol consumption (Cooper et al., 1995).   
 
13.3: THE PRESENT STUDY 
13.3.a: Aims  
The present study analysed data from a nationwide survey of community dwelling older adults 
living in New Zealand. The aims of this study were to assess sample rates of concomitant 
alcohol/AI-medication use, and to explore the potential relationships between AI-medication 
use, alcohol use, and depression.  
13.3.b: Theoretical framework  
The theoretical framework adopted in the present study was based on health behaviour 
principles detailed in the Protection Motivation Theory (PMT) (Maddux & Rogers, 1983; 
Rogers, 1975) and Cooper’s two-factor motivational model of alcohol use (Cooper et al., 1995).  
These theories were selected because they provide a parsimonious account regarding factors 
underlying drinking behaviour among AI-medication users (see chapter 6). 
13.3.c: Hypotheses 
The study had three hypotheses 
• Firstly, based on previous epidemiological research showing a negative association 
between AI-medication use and alcohol use (Cousins et al., 2014; Breslow et al., 2015; 
Pringle et al., 2005; Qato et al., 2015), it was hypothesised that alcohol use would be 
less prevalent among AI-medication users than non-users of AI-medications.  
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• Secondly, it was hypothesised that alcohol use would be less common among 
participants using medications with higher levels of alcohol-interactivity than those 
using forms of AI-medication associated with milder AMIs. This hypothesis was based 
on the PMT principles of vulnerability and severity (Maddux & Rogers, 1983; Rogers, 
1975), as well as research findings suggesting older AI-medication users who stop 
drinking may do so in response to knowledge of AMI risks (Gavens et al., 2016; Zanjani 
et al., 2013).  
• Thirdly, it was hypothesized that depression would weaken the negative association 
between AI-medication use and alcohol use. This hypothesis was based on research 
suggesting some AI-medication users with depression may drink for self-medication 
purposes (Cheng et al., 2018; Gavens et al., 2016; Haighton, et al., 2018), PMT 
principles of self-efficacy and response costs, and the principle of ‘drinking to cope’ 
from Cooper’s motivational model of alcohol use (Cooper et al., 1995).  
13.4: METHOD 
13.4.a: Participants 
Health, Work and Retirement study (HWR) 2010  
The present study is a secondary analysis of data from the 2010 wave of the Health, Work and 
Retirement (HWR) study, which is a large ongoing nationally representative survey of older 
adults living in New Zealand that started in 2005.  The 2010 data-wave was used in the present 
study because this was the first HWR survey to include a measure of depressive symptoms.  
The cohort consists of participants recruited across two waves occurring in 2006 and 2010.  
Participants were randomly selected from the New Zealand electoral roll, and over sampling 
of those indicated as having Māori descent was undertaken to ensure adequate representation 
of New Zealand’s Māori (indigenous) population. Participants recruited in 2006 participated 
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in the initial HWR study, which originally consisted of 6,662 participants aged 55-70 years.  
The 2010 HWR recruitment wave aimed to increase representation of younger (aged 50-84 
years) and older (70-84) age groups within the sample.  The 2010 HWR sample consisted of 
3,305 New Zealand adults aged ≥48 years, 1,981 of whom were recruited in 2006 and 1,324 
were recruited in 2010 (Towers & Stevenson, 2014).  The present study includes a subsample 
of the 2010 HWR cohort who consented to having their survey data linked with their national 
health records as part of the HWR data-linkage project.  
Data-linkage  
The HWR data linkage project links consenting participants’ survey data with their national 
health records. In 2014, written informed consent was sought among participants of the 2010 
HWR study. A second approach to data linkage consent occurred in 2015 and included those 
who did not respond in the 2014 approach, yet were active participants in the 2014 HWR 
survey.  Consent was sought from 2,475 participants across the two approaches, 1,727 of whom 
consented to data linkage. Minimum identifiers of consenting participants (name, gender, and 
date of birth) were provided to the Ministry of Health Analytic Services (formerly New Zealand 
Health Information Service) and a direct-match strategy was implemented to link to 
participants’ National Health Index (NHI) number (Allen, 2016). Data were then matched by 
the Ministry of Health Analytic Services to health records based on NHI number, before all 
identifying information were removed and records assigned a new identification number for 
the purposes of linkage to HWR study research data.  Of the 1,727 participants who consented 
to data-linkage, 1,625 were matched successfully to their NHI (and were therefore able to 
participate in the data-linkage project). Among those successfully matched to their NHI, 1,191 
(73.3%) were recruited in 2006, and 434 (26.7%) were recruited in 2010. Table 18 shows the 
number of 2010 HWR participants who were approached for and consented to data linkage, 
and were successfully matched to their NHI number across both waves of recruitment. 
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Table 18: Process of Data-Linkage Recruitment Among 2010 HWR Participants 
 Wave of recruitment Total 
 2006 2010 
Total HWR 2010 sample 1,981 1,324 3,305 
Approached for data linkage  1,783 692 2,475 
Consented to data linkage 1,257 470 1,727 
Matched to NHI (final sample) 1,191 434 1,625 
 
Final unweighted and weighted samples  
The present study sample included 1,621 participants from the 2010 HWR study (Towers & 
Stevenson, 2014), who participated in the HWR data-linkage project (Allen, 2016), and 
responded to a survey item assessing drinking frequency (49.0% of the original random 
sample). This included 765 male participants (47.2%) and 856 female participants (52.8%).  
Ages ranged from 49-83 years, and the mean age of the sample was 63.4 years (SD= 6.1 years).  
A total of 710 participants (43.8%) were aged ≥65 years.  For analyses addressing research 
questions about the prevalence of concomitant alcohol/AI-medication use, the sample was 
weighted (by ethnicity, gender, and age) to adjust for oversampling and ensure 
representativeness to the population of New Zealand’s older adult population (see Stevenson, 
2015). The weighted sample consisted of 1,736 participants, 870 of whom were male (50.1%) 
and 866 were female (49.9%). Ages in the weighted sample ranged from 49-83 years, and the 
mean age was 63.5 years (SD= 6.0 years).   A total of 771 participants (44.4%) in the weighted 
sample were aged ≥65 years.  
13.4.b: Measures  
AI-medication use 
Participants’ pharmaceutical claims records were used to determine AI-medication use within 
the sample. This data was derived from the New Zealand Pharmaceutical Collection 
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(PHARMS). The New Zealand Formulary (NZF) was used to identify AI-medications21 within 
the PHARMS data and categorize them into ordinal groups of varying alcohol-interactivity 
levels (mild22, moderate23, major24, and contraindicated25). The specific methods of identifying 
and categorizing AI-medications within the PHARMS data based on information provided by 
the NZF are detailed in the Chapter 11.2.  
Participants were identified as AI-medication users if their pharmaceutical claims records 
indicated they a) were currently using AI-medication(s) at the time of survey completion, and 
b) had used AI-medication(s) on a regular basis prior to survey completion. The research 
protocol developed for this project informed the specific methods used to determine which 
participants could be defined as AI-medication users based on this definition (see Chapter 11.1 
and 11.2). Briefly, current use of antibiotics was determined using the legend-time method; 
current use of NSAIDs and benzodiazepines was determined using a 30-day fixed-window; 
and current use of all other medications (excluding antibiotics, NSAIDs, and benzodiazepines) 
was determined using a 90-day fixed-window.  Participants were defined as current regular AI-
medication users if they were (1) identified as currently using AI-medications based on the 
criteria just described, and 2) dispensed at least one other AI-medication supply during the past 
244 days (prior to survey completion) that was not in current use at the time of survey 
completion.  AI-medication users were then assigned to one of three groups (mild, moderate, 
and major/contraindicated AI-medication users) based on the highest alcohol-interactivity level 
 
21 AI-medications: those referred to as having potential alcohol-interactivity, those including a cautionary warning 
against alcohol use, and/or those including some sort of recommendation regarding alcohol consumption. 
22 Mild AI-medications: potential interactions are of little clinical significance. 
23 Moderate AI-medications: interactions may result in significant distress or incapacitation, but the likelihood of 
interaction is not high enough to warrant close monitoring or dosage adjustment. 
24 Major AI-medications: for interactions with detrimental effects that may be permanent or life-threatening OR 
interactions that may result in significant distress or incapacitation and the likelihood of interaction is high enough 
to warrant close monitoring or dosage adjustment. 
25 Contraindicated AI-medications: medications contraindicated for use with alcohol. 
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of medications in current use (Table 19). For some analyses, moderate and 
major/contraindicated AI-medication use categories were also combined to identify 
participants using AI-medications with the potential to cause a clinically significant AMI 
(clinically significant AI-medication users). 
 
Table 19: Pharmaceutical Dispensing Records of Participants Defined as Mild, Moderate, 
or Major/Contraindicated AI-Medication Users 
AI-Medication User 
Groups 
Pharmaceutical dispensing by participant 
Current use Past 244 days 
(not in current use) 
Major/Contraindicated 
AI-medication users* 
At least one major or contraindicated 
AI-medication 
At least one AI-medication (mild, 




At least one moderate AI-
medication, and no major or 
contraindicated AI-medications 
At least one AI-medication 
Mild AI-medication 
users 
At least one mild AI-medication, and 
no moderate, major, or 
contraindicated AI-medications 
At least one AI-medication 
Note: Current use = Legend time for antibiotics; 30-day fixed-window for benzodiazepines & NSAIDs; 90-
day fixed-window for all other drugs. 
Note: *clinically significant AI-medication users   
Alcohol use 
The HWR survey includes the Alcohol Use Disorders Identification Test – C (AUDIT-C, Bush 
et al., 1998), which consists of three items assessing alcohol consumption patterns; specifically, 
the quantity and frequency of alcohol use, as well as binge drinking frequency.  The present 
study used the AUDIT-C frequency item to measure alcohol use among participants. Those 
who reported using alcohol ‘never’ or ‘monthly or less’ were defined as minimal/non-drinkers, 
and regular drinkers were defined as those who reported drinking at least twice monthly.  
Responses on the AUDIT-C frequency item were then used to categorize regular drinkers as 
either light/moderate-drinkers (those who reported using alcohol ‘2-4 times monthly’ or ‘2-3 
times weekly’) or heavy-drinkers (those who reported using alcohol ‘4 or more times weekly’).  
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Depression  
Depression was measured with a shortened version of the Centre for Epidemiologic Studies 
Depression Scale (CES-D; Radloff, 1977), which includes 10 items selected for the assessment 
of depression in older people (CES-D-10) (Andersen et al., 1994).  Raw scores on the CES-D-
10 range from 0 – 30. The present study adopted a dichotomous scoring threshold of 10, which 
is recommended by Anderson et al. (1994), so that participants scoring below 10 were 
categorized as ‘not depressed’ and those scoring ≥10 were categorized as ‘depressed’.  The 
chronbach’s alpha coefficient for this measure was α = .82 in the present study sample.  
Demographic variables 
Participant SES was measured using the Economic Living Standard Index short form (ELSI-
sf), a 25-item self-report measure of consumption capacity, economic social restrictions, and 
material wealth (Jensen et al., 2005). This measure was included to control for the association 
between SES and alcohol consumption (see Scott et al., 2018; Towers, Philipp et al., 2018), 
when assessing relationships between alcohol use, AI-medication use, and depression. Raw 
scores on the ELSI-sf range from 0-31, with higher scores indicating higher SES.  ELSI-sf raw 
scores were also categorised into three levels of living standards (‘hardship’; ‘comfortable’; 
‘good'). Other demographic variables of interest included age, ethnicity, marital status, and 
education level. Age groups included '48-54 years', '55-64 years', '65-74 years', and ' ≥75 years'. 
Ethnicity was defined as ‘New Zealand European’ (NZE), ‘Māori’, or ‘Other’. Marital status 
groups included ‘Married, Civil Union, or De Facto’, and ‘Other’.  Education level was defined 
as ‘Tertiary Education’ or ‘No Tertiary Education’.   
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13.4.a: Analysis 
All analyses were conducted using SPSS software. Descriptive statistics were used to describe 
unweighted sample rates and frequency of alcohol use, and characterise the demographic 
composition of the unweighted sample by alcohol use frequency category. 
To explore the prevalence of concomitant alcohol/AI-medication use, descriptive statistics 
were used to describe sample rates of AI-medication use, rates of alcohol use among AI-
medication users, and overall sample rates of concomitant AI-medication use.  These analyses 
were applied to the total weighed sample, and to unweighted and weighted subsamples of 
participants aged ≥65 years.  The prevalence of concomitant alcohol/AI-medication use across 
the total unweighted sample was also explored when assessing the association between AI-
medication use and alcohol use, as discussed in the following two paragraphs.   
Hypothesized associations between AI-medication use and alcohol use were explored in the 
unweighted sample. To test the hypothesis that alcohol use would be less common among those 
using AI-medications, 2x2 chi-square test of independence was used to compare rates of 
minimal/non-drinker status versus light-moderate/heavy drinker status among users and non-
users of AI-medications. The effect size of the 2x2 chi-squared test was assessed using the Phi 
coefficient. A 3x2 chi-square test of independence was used to further explore this hypothesis 
across 3 drinking frequency categories. Cramer’s V was used to measure effect size of the 3x2 
Chi-squared test.  Standardized residuals were analysed to determine whether cells deviated 
from expected frequencies at <.05 (critical value of ±1.96) or <.01 (critical value of ±2.58) 
levels of significance.  
To test the hypothesis that alcohol use would be less common among those using AI-
medications with higher alcohol interactivity, a 4x2 chi-squared test of independence was used 
to compare rates of minimal/non-drinker status versus light-moderate/heavy drinker status 
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across AI-medication user severity categories. This was then further explored across the 
extended drinking frequency categories using a 4x3 chi-squared test of independence. Effect 
sizes were measured using Cramer’s V, and standardized residuals were used to determine 
whether cells deviated from expected frequencies at <.05 or <.01 levels of significance.  
A hierarchical logistic regression model was used to test the hypothesis that the predicted 
negative relationship between AI-medication use and alcohol use would be moderated by 
depression.  In this model, alcohol use was entered as binary outcome variable (regular drinkers 
versus minimal/non-drinkers).  ELSI-SF raw scores were entered at step 1 to a control for the 
effect of living standards. Binary variables were entered at step 2 to control for the main effects 
of AI-medication use (‘non-users’ and ‘mild AI-medication users’ versus ‘clinically significant 
AI-medication users’), and depression (CES-D-10 cut-off score of ≥10). These two variables 
were then entered as an interaction term variable (‘AI-medication use*depression’) at step 3, 
to whether the association of AI-medication use with alcohol use differed with the presence of 
depression. A Hosmer and Lemeshow Chi-squared test (HLT) was used to assess the regression 
model’s goodness of fit.  The variance in alcohol use explained by predictors at each step of 
the model was assessed using Cox and Snell R squared, and Nagelkerke R squared.  Beta values 
(B) were examined to assess whether relationships between predictor variables and alcohol use 
reached statistical significance (alpha level = <.05), and odds ratios (OR) were used to assess 
the extent to which predictor variables influenced the likelihood of alcohol use. 
13.5: RESULTS 
13.5.a: Characteristics of drinkers  
Table 20 shows the demographic characteristics of the weighted sample overall (N= 1,736), 
and by drinking frequency. The unweighted sample demographics by drinking frequency are 
shown in Appendix C (Table 31). 
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Table 20: Demographic Weighted Sample Characteristics Across Drinking Frequency 
Groups 
 Total % 
of 
Sample 














Gender     


















Age      






































Ethnicity    ‘  




























Education level     
    Tertiary   









    No tertiary  









Marital Status      
  Married, civil 




















Living Standards     
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A total of 1,210 participants (69.7%) were identified as regular drinkers (light/moderate and 
heavy), and 530 (30.5%) were heavy drinkers (alcohol use four or more times weekly). Regular 
drinking was most common among those who were male (86.5%), aged 55-64 (82.3%), NZ 
European (71.2%), educated at tertiary level (75.6%), those with good living standards 
(77.5%), and those who were of married, civil union, or de facto marital status (73.4%).  Rates 
of heavy drinking were highest among those who were male (37.1%), aged ≥75 years (32.1%), 
NZ European (32.1%), educated at tertiary level (37.2%), with good living standards (38.2%), 
and of married, civil union, or de facto marital status (32.7%).   
13.5.b: Weighted prevalence of concomitant alcohol/AI-medication use  
Table 21 presents the weighted sample rates of concomitant alcohol/AI-medication use. These 
results reflect a breakdown of the alcohol use patterns by a) the total sample; b) dichotomous 
samples reflecting ‘non-users of AI-medications’ and ‘AI-medication users’; and c) a 
breakdown of the sub-samples within the ‘AI-medication’ use group based on AI-medication 
severity categories.  Percentages are provided for overall sample rates of concomitant 
alcohol/AI-medication use, and for rates of alcohol use within AI-medication use 
samples/subsamples. 
Overall, 939 participants (54.1%) in the weighted sample were current regular users of at least 
one AI-medication, 66.3% of whom (n = 623) were regular drinkers. The rate of heavy drinking 
among AI-medication users in the weighted sample was 27.9% (n = 262). Across the total 
weighted sample, 623 participants (35.9%) were identified as being regular drinkers and 
current regular AI-medication users (Table 21).   A total of 439 participants in the weighted 
sample (25.3%) used alcohol concomitantly with AI-medications that pose risk of clinically 
significant AMI (i.e., moderate AI-medications, or major/contraindicated AI-medications).   
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AI-medication sample by potential 
interaction severity 
Mild Moderate Maj/Con* 
Minimal/non-
drinkers 
      
525.7 209.7 316.0 65.9 101.0 149.1 
%Sample 30.3% 12.1% 18.2% 3.8% 5.8% 8.6% 
%AI-Medication  26.3% 33.7% 26.5% 31.6% 40.3% 
Regular 
drinkers 1210.0 587.3 622.7 183.2 218.8 220.7 
%Sample 69.7% 33.8% 35.9% 10.6% 12.6% 12.7% 
%AI-Medication  73.7% 66.3% 73.5% 68.4% 59.7% 
Light/moderate 680.3 319.6 360.7 93.4 130.5 136.9 
%Sample 39.2% 18.4% 20.8% 5.4% 7.5% 7.9% 
%AI-Medication  40.1% 38.4% 37.5% 40.8% 37.0% 
Heavy 529.7 267.7 262.0 89.9 88.4 83.8 
%Sample 30.5% 15.4% 15.1% 5.2% 5.1% 4.8% 
%AI-Medication  33.6% 27.9% 36.1% 27.6% 22.7% 
Total Sample 1735.7 797.0 938.7 249.1 319.8 369.8 
%Sample 100.0% 45.9% 54.1% 14.4% 18.4% 21.3% 
       
Notes: *This severity category includes major AI-medications, and contraindicated AI-medications (i.e., 
major/contraindicated AI-medications) 
 
13.5.c: Concomitant alcohol/AI-medication Use among those aged ≥65 years in the 
Unweighted and Weighted samples 
A total of 710 participants within the unweighted sample were aged ≥65 years, 465 of whom 
(65.5%) were identified as current regular users of one or more AI-medications.  Within the 
weighted sample, 771 participants were aged ≥65 years, 63.6% of whom (n = 490) were AI-
medication users.  The unweighted and weighted rates of regular drinking among AI-
medication users aged ≥65 years were 62.4% (n = 290) and 67.3% (n = 330) respectively. The 
overall prevalence of concomitant alcohol/AI-medication use among participants aged ≥65 
years was 40.8% in the unweighted sample, and 42.8% in the weighted sample. Among 
participants aged ≥65 years in the unweighted sample, 28.3% (n = 201) used alcohol 
concomitantly with AI-medications with the potential to cause a clinically significant AMI 
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(i.e., moderate, or major/contraindicated AI-medications). The rate of clinically significant 
AMI risk among those aged ≥65 years in the weighted sample was 30.4% (n = 234). 
13.5.d: Unweighted prevalence of concomitant alcohol/AI-medication use: exploring the 
hypothesized associations between AI-medication use and alcohol use  
Rates of AI-medication use 
Across the total unweighted sample, 897 participants (55.3%) used at least one AI-medication 
regularly, with the remaining 724 participants (44.7%) identified as non-users. The unweighted 
sample rates of mild, moderate, and major/contraindicated AI-medication use were 14.6% (n 
= 237), 17.5% (n = 283), and 23.2% (n = 377), respectively.  
Alcohol consumption by users vs. non-users (binary AI-medication use) 
The unweighted sample rate of participants identified as both drinkers and AI-medication users 
was 34.0% (551 participants). A chi-square test of independence showed the rate of alcohol 
use was significantly lower among AI-medication users (61.4%) than non-users of AI-
medications (72.4%), X2 (1, N = 1,621) = 21.50, p <.001, phi = 0.11. When this relationship 
was explored by drinking frequency category (Table 22), comparison of standardized residuals 
indicated rates of minimal/non-drinker status were significantly lower than expected among 
non-users of AI-medications (p < .01) and significantly higher than expected among AI-
medication users (p < .05); X2 (2, N = 1,621) = 21.82, p <.001, Cramer’s V = .12. However, no 
significant deviations from expected frequencies were observed across light/moderate and 
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Drinking Frequency (AUDIT-C) 

















Note: Values in parentheses represent standardized residuals; * p <.05; ** p <.01 
Alcohol consumption by mild, moderate, and major/contraindicated AI-medication users 
The sample rates of participants identified as both regular drinkers (light/moderate or heavy) 
and users of mild, moderate, and major/contraindicated AI-medications were 10.5%, 11.3%, 
and 12.2% respectively. The respective sample rates of participants identified as both 
light/moderate drinkers and users of mild, moderate, or major/contraindicated AI-medications 
were 5.6%, 6.9%, and 7.8%. The sample rates of participants identified as both heavy-drinkers 
and users of mild, moderate, major/contraindicated AI-medications were 4.9%, 4.4%, and 4.4% 
respectively.  
A chi-square test of independence showed significant differences in alcohol use across AI-
medication user severity categories (Table 23), X2 (3, N = 1,621) = 47.48, p <.001, Cramer’s 
V = 0.17. Standardized residuals showed rates of non-drinker status were significantly lower 
than expected among those not using AI-medications and significantly higher than expected 
among major/contraindicated AI-medication users (p < .01), while rates of drinker status were 
significantly higher than expected among those not using AI-medications (p <.05) and 
significantly lower than expected among those using major/contraindicated AI-medications. 
When this relationship was further explored across drinking frequency categories (X2 (6, N = 
1,621) = 52.21, p <.001, Cramer’s V = 0.13), the rate of heavy drinking was significantly lower 
than expected among major/contraindicated AI-medication users only (p <.01), and rates of 
light/moderate drinking did not deviate significantly from expected frequencies across AI-
medication use categories (see Table 24).   
  




Table 23: AI-Medication Severity by Binary Drinking: Chi-Squared Test 























Note: values in parenthesis represent standardized residuals; * <.05; **<.01 
Note: X2 (3, N = 1,621) = 47.48, p <.001, phi = .17. 
 
Table 24: AI-Medication Severity by Drinking Frequency: Chi-Squared Test 
AI-Medication User 
Severity Categories 




























Notes: values in parenthesis represent standardized residuals; * <.05; **<.01 
Note: X2 (6, N = 1,621) = 52.21, p <.001, phi = .179. 
 
13.5.e: Interaction of AI-medication use and depression in the prediction of alcohol use 
A hierarchical logistic regression model assessed the main effects and interaction effects of AI-
medication use and depression on the likelihood of alcohol use. Living standards was entered 
as a control variable at step 1, AI-medication use and depression were entered at step 2, and 
the interaction term (AI-medication use*depression) entered at step 3. The results of this model 
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Table 25: Hierarchical Logistic Regression Model Assessing Interaction Effects of AI-
Medication Use and Depression on Alcohol Use 
Predictor and Step B S.E Wald df P OR 
95 % CI for OR p X2 Block 
(N = 1,488) Lower Upper 
Step 1              
  Living    
  Standards .33 .04 78.35 1 <.001 1.39 1.30 1.50 p <.001 
Step 2           
  Living  
  Standards .30 .04 52.83 1 <.001 1.35 1.25 1.47 p <.001 
  AI-Medication  -.46 .12 15.30 1 <.001 .63 .50 .79  
  Depression -.03 .15 .03 1 .86 .97 .72 1.32  
Step 3          
  Living  
  Standards .30 .04 52.92 1 <.001 1.35 1.25 1.47 p =.638 
  AI-Medication -.43 .13 10.67 1 <.01 .65 .50 .84  
  Depression .05 .23 .05 1 .82 1.06 .67 1.67  
  AI-Medication *  
  Depression 
 
-.14 .29 .22 1 .64 .87 .49 1.54 
 
 
As shown in Table 25, step 1 of the model was statistically significant (χ2 (1, N = 1,488) = 
82.12, p = <.001), with ELSI-sf scores explaining between 5.4% (Cox and Snell R square) and 
7.5% (Nagelkerke R square) of the variance in alcohol use. The model of alcohol use was 
significantly improved with the addition of step 2 (block: X2 (2, N = 1,488) = 15.83, p <.001; 
full model: X2 (3, N = 1,488) = 97.95, p <.001), with the overall model at step 2 explaining 
between 6.4% (Cox and Snell R square) and 8.8% (Nagelkerke R square) of the variance in 
alcohol use (the additional variables therefore explained between 1% and 1.3% of the variance 
in alcohol use). The model was not significantly improved with the addition of step 3 (block 
X2 (1, N = 1,488) = 0.22, p =.638; full model X2 (4, N = 1,488) = 98.12, p <.001). The final 
model explained between 6.4% (Cox and Snell R Square) and 8.9% (Nagelkerke R Square) of 
the variance in alcohol use, and had adequate fit as indicated by non-significant HLT (X2 (7, N 
= 1,488) = 4.18, p = .758). The only significant predictors of alcohol use in the final model 
were living standards and AI-medication use. 
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13.6: DISCUSSION 
This section discusses topics of particular relevance to study 2, and points of discussion that 
apply to both studies implemented in the present thesis are covered in chapter 14.   The present 
study explored the prevalence of concomitant alcohol/AI-medication use in a sample of New 
Zealand older adults, and assessed the potential relationships between AI-medication use, 
alcohol use, and depression.  Approximately two thirds of the sample reported using alcohol at 
least two days monthly, and just over half of the sample used at least one AI-medication 
regularly.  More than one third of participants aged 49-83 years were at risk of AMI exposure, 
and approximately one quarter were at risk of suffering an adverse AMI of clinical significance. 
Among those aged ≥65 years, approximately two-in-five participants were at risk of AMI, and 
more than one-in-four were at risk of a clinically significant AMI.   
13.6.a: Hypothesized relationships between alcohol use and AI-medication use  
The hypothesis that alcohol use would be less common among those using AI-medications was 
supported, as participants identified as AI-medication users were significantly less likely than 
non-users of AI-medications to report using alcohol two or more times monthly. This finding 
is consistent with previous studies exploring rates of concomitant alcohol/AI-medication use 
among older adults in the US and Ireland (Cousins et al., 2014; Breslow et al., 2015; Pringle et 
al., 2005; Qato et al., 2015).  
The hypothesis that AI-medications with higher levels of alcohol-interactivity would be 
associated with less alcohol use was generally supported by the results.  Rates of self-reported 
alcohol use (at least twice monthly) were significantly lower among those using AI-
medications identified as having the highest level of alcohol-interactivity (i.e. 
major/contraindicated AI-medications).  When this association was explored across drinking 
frequency groups, the data showed that those using medications identified as highly alcohol-
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interactive were significantly less likely to report heavy drinking (four days weekly), but rates 
of light-moderate drinking (two days monthly to three days weekly) did not differ significantly 
across AI-medication severity groups. 
Given that the AI-medication severity categories utilized in this study were identified using the 
same drug-interaction identification system used by New Zealand prescribers and pharmacists, 
it is likely that some of the participants identified major/contraindicated AI-medication users 
in this study would have been advised about AMI risks from their prescribers.  As such, the 
observed negative association between alcohol use and major/contraindicated AI-medication 
use is consistent with previous studies indicating AMI related knowledge leads to reduced 
alcohol use (Gavens et al., 2016; Zanjani et al., 2013), as well as the principles of severity and 
vulnerability described by PMT (Maddux & Rogers, 1983; Rogers, 1975).  
13.6.b: Hypothesized moderator role of depression  
The hypothesis that depression would moderate the hypothesized negative association between 
AI-medication use and alcohol use was not supported by the results. After controlling for living 
standards, depression was not a significant predictor of concomitant alcohol use by AI-
medication users.  While these results do not support findings of previous studies implicating 
self-medication as a motivator for alcohol use among AI-medication users (e.g., Gavens et al., 
2016; Haighton, et al., 2018), it should be noted that drinking motives were not directly 
measured in the present study.  Although drinking to alleviate distress is common among 
people with depression (Bolton et al., 2009; Boschloo et al., 2012 Brown & Stewart, 2008), it 
cannot be assumed that all people with depression self-medicate with alcohol, or that drinking 
to cope occurs exclusively in the context of depression. As such, the non-significant findings 
of the present study should not be interpreted as evidence against the role of self-medication in 
concomitant alcohol/AI-medication use. 
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13.6.c: Strengths and limitations  
A key strength of the present study was the nationally representative sample, which increases 
the generalizability of the findings to the population of New Zealanders aged 48-83 years.  
Additionally, in comparison to the sample included in study 1 (see sections 12.4.c and 12.6.c), 
the present study sample was more representative of the population of New Zealanders aged 
≥65 years, which is generally considered the definition of older adulthood.  The age distribution 
of the sample was therefore a key strength of the present study.   As stated previously, a 
potential limitation of the present study was that a measure of drinking motives was not 
included in the analysis.   
13.6.d: Summary and conclusions  
The results of this study indicate that many New Zealand older adults are at risk of AMI related 
harm.  Providing older adults with information about the risks of combined alcohol/AI-
medication use may help mitigate their risk of AMI exposure. Such interventions should 
emphasize information about heightened susceptibility to AMIs during older adulthood, and 
the severity of AMI related harm.   However, previous research indicates the effectiveness of 
educational interventions aimed at reducing AMI risk are often limited (Zanjani et al., 2018a, 
2018b, 2018c).  Therefore, after providing AI-medication users with appropriate AMI-related 
health warnings, clinicians should continue screening for alcohol use at follow-up 
appointments and provide further intervention when needed. Future survey research exploring 
factors underlying concomitant alcohol/AI-medication use should utilize measures that directly 
assess participants’ reasons for drinking, such as the older adult version of The Drinking 
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CHAPTER 14: GENERAL DISCUSSION 
The present chapter consist of three sections. The first section (14.1) includes a general 
discussion of topics relevant to both studies included in the present thesis.  Discussion topics 
of particular relevance to study 1 were covered in chapter 12 (section 12.6), and topics 
particularly relevant to study 2 were discussed in chapter 13 (section 13.6).  Section 14.1 
therefore focuses on the prevalence of concomitant alcohol/AI-medication use, as this issue 
was explored in both studies. The second section of this chapter (14.2) summarizes the main 
contributions of the present thesis, and conclusions relating the project overall are then 
summarized in the final section (14.3).   
14.1: DISCUSSION OF STUDIES 1 & 2  
The first research question of the present project - “What is the prevalence of concomitant 
alcohol/AI-medication use in New Zealand’s older adult population?” - was explored in both 
study 1 and study 2. Both studies utilized the same methods of answering this question, and 
there were notable differences in the results of the two studies.  Before making inferences about 
the meaning of these differing results, it is important to consider potential demographic 
differences between the two samples.  Therefore, the characteristics of the two study samples 
are discussed, followed by a comparison of the findings (14.1.a). The results of the present 
research are then compared with those of other studies exploring the prevalence of concomitant 
alcohol/AI-medication use (14.1.b), and methodological strengths and limitations of studies 1 
and 2 are discussed (14.1.c).  
14.1.a: Summary and comparison of study 1 & study 2  
Sample characteristics  
As discussed in chapters 12 and 13, both studies included in the present thesis involved 
secondary analysis of data collected from the NZHWR study (Towers & Noone, 2007; Towers 
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& Stevenson, 2014).  The study 1 sample (see section 12.4.a) included participants from the 
2006 HWR study (Towers & Noone, 2007), and the study 2 sample (see section 13.4.a) 
included participants from the 2010 HWR study (Towers & Stevenson, 2014).    Overall, the 
demographic characteristics of the two study samples were very similar, which is unsurprising 
given that 73% of the study 2 sample were recruited from the study 1 sample (see section 
13.4.a).  However, age distribution was an important point of difference between the two 
samples, as discussed below.   
Differences in age distribution between the two study samples were partly due to data 
collection occurring four years earlier for study 1 than study 2. Those who participated in both 
studies were therefore older at the time of data collection for study 2 (2010) than they were for 
study 1 (2006).   Additionally, participants newly recruited into the HWR study during the 
2010 data-wave were selected to increase the representation of both younger and older age 
groups (Towers & Stevenson, 2014), as discussed in section 13.4.a.  Consequently, there were 
two notable differences in age distribution across the two samples. Firstly, the 2010 sample 
(study 2) was older overall, with a higher portion of participants being aged ≥65-years (44% 
vs 29%).   Secondly, the 2010 sample captured a wider age bracket (48-83 years) than the 2006 
sample (54-70 years).  As mentioned in section 12.6.c, the results of study 2 therefore have 
more generalizability to the population of New Zealanders aged ≥65 years than the results of 
study 1.  
Observed rates of concomitant alcohol/AI-medication use 
Overall, the present research observed higher rates concomitant alcohol/AI-medication use in 
older study samples and subsamples. The prevalence concomitant of alcohol/AI-medication 
use were higher in the study 2 sample (36%) than the comparatively younger study 1 sample 
(24%). Similarly, sample rates of clinically significant AMI risk were also higher in study 2 
(25%) than study 1 (15%).   These differences likely reflect rates of AI-medication use across 
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the two samples, as rates of alcohol use were similar in both studies (approximately 70%), 
whereas the prevalence of AI-medication use was lower in study 1 (34%) than the 
comparatively older study 2 sample (54%). Additionally, rates of concomitant alcohol/AI-
medication use were higher in subsamples aged ≥65 years relative to the total samples in both 
studies (29% among those aged 65-70 in study 1, and 43% among those aged 65-83 in study 
2).  The variation in results observed between samples and subsamples in the present research 
therefore provides further evidence that concomitant alcohol/AI-medication use increases with 
age (Breslow et al., 2015; Moore et al., 2002).   
14.1.b: Comparing the results of Study 1 and Study 2 with those of other studies exploring 
the prevalence of alcohol/AI-medication use 
The results of survey studies exploring the prevalence of concomitant alcohol/AI-medication 
use in older adult populations were reviewed in chapter 4 (section 4.2).  As discussed in 
previous chapters (section 4.2.a; chapter 10), cross-study comparisons of reported rates of 
concomitant alcohol/AI-medication use are complicated due to methodological differences 
between studies. This subsection compares the present research findings to those of three 
studies reviewed in chapter 4 (Breslow et al., 2015; Cousins et al., 2014; Qato et al., 2015).  
These studies were selected for comparison because they had community older adult samples, 
included a wide variety of medications in their analyses, and utilized methods of AI-medication 
measurement and classification26 of comparable quality to those adopted in the present 
research.   There were however important differences between these studies and the present 
research with regards to alcohol use classification and the age distribution of study samples.  
 
26 Breslow et al. (2015), Cousins et al. (2015) and Qato et al. (2015) measured medication use by having 
participants provide medication containers and or prescription sheets. Each of these studies also utilized drug-
interaction identification resources to classify medications as AI   
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The potential impact of these methodological differences is therefore considered when 
comparing the study findings.    
Sample rates of AI-medication use 
All three studies reviewed (Breslow et al., 2015; Cousins et al., 2014; Qato et al., 2015) reported 
higher overall sample rates of AI-medication use than observed in the present research27, 
although the rate observed by Qato et al. (2015) was very similar to that of study 2.  
Specifically, sample rates of AI-medication use observed by Qato et al. (2015), Cousins et al. 
(2014), and Breslow et al. (2015) were 57%, 72%, and 78% respectively.   Much of this 
variation may be accounted for by age differences between samples, as rates of AI-medication 
use were higher in samples with a larger portion of participants aged ≥65 years28 (see figure 2).    
However, rates of AI-medication use among those aged 65-83 years in study 2 (67%) were still 
lower than observed in Cousins et al.’s (2014) sample of older adults living in Ireland and 
Breslow et al.’s (2015) US older adult sample.  These findings may therefore indicate that older 
adults living in New Zealand are less likely to use AI-medications than those living in Ireland 
or the US. 
 
27 Sample rates of AI-medication use were 34% in study 1 and 54% in study 2 
28 Sample rates or participants aged ≥65-years in the studies by Qato et al. (2015), Cousins et al. (2014), and 
Breslow et al. (2015) were 58%, 72%, and 100% respectively.  
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Figure 2: Sample Rates of AI-medication Use and Participants Aged ≥65 Years in the 
Present Research and Previous Research 
 
Concomitant alcohol use among AI-medication users 
Rates of alcohol use among AI-medication users in Cousins et al.’s (2014) sample of older 
adults living in Ireland (60%) were lower than observed in the present research (69% in study 
1, and 66% in study 2).  This difference is not fully explained by Cousins et al.’s (2014) study 
sample being comparatively older to those of the present research (see Figure 2), given that 
higher rates of alcohol use were also observed among subsamples of AI-medication users aged 
≥65 years in study 2 (67%).   It is noteworthy that the threshold Cousins et al. (2014) used to 
identify drinkers (past 6-month drinking) was considerably more inclusive than the threshold 
used in the present research (alcohol use at least twice monthly). As discussed in chapter 10, 
more inclusive thresholds have higher risk of false positive case identification, whereas more 
conservative thresholds have higher risk of false negative cases.  These results therefore 
indicate that alcohol use may be more common among older AI-medication users living in New 
















Qato et al. (2015) Cousens et al. (2014) Breslow et al. (2015)
Aged ≥ 65 years (%) AI-medication (%)
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Sample rates of concomitant alcohol/AI-medication use  
Two studies selected for comparison with the present research reported on overall sample rates 
of concomitant alcohol/AI-medication use (Breslow et al., 2015; Qato et al., 2015), both of 
which were conducted in the US.  The rate of concomitant alcohol/AI-medication use observed 
by Breslow et al. (2015) in their sample of adults aged ≥65 years (35%) was considerably lower 
than observed among the study 2 subsample of participants aged 65-83 years (43%).  
Additionally, Breslow et al. (2015) used a drinker classification threshold (past year drinking) 
that was considerably more inclusive (and therefore likely yielded more false positive cases), 
than the threshold used in the present research.  This would suggest the prevalence of 
concomitant alcohol/AI-medication use among adults aged ≥65 years is higher in New Zealand 
than in the US.  
The rate of concomitant alcohol/AI-medication use observed by Qato et al. (2015) in their 
sample of US adults aged 57-84 years (20%) was notably lower than the rate observed among 
New Zealanders aged 48-83 years in study 2 (36%). Both of these study samples were generally 
comparable in terms of age distribution and observed rates of AI-medication use (see Figure 
2).   The threshold Qato et al. (2015) used to identify drinkers (weekly drinking) was slightly 
more conservative, yet comparable to the threshold used in the present research (drinking at 
least twice monthly).    Overall, when taking sample differences and alcohol use classification 
methods into consideration, the results described above indicate rates of concomitant 
alcohol/AI-medication use are likely higher among older adults living in NZ than those living 
in the US.  
14.1.c: Strengths and limitations of studies 1 and 2 
The present research had several methodological strengths. As discussed in section 10.5, the 
operationalization of concomitant alcohol/AI-medication use adopted in the present research 
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was carefully considered and aimed to achieve an optimal balance between sensitivity and 
specificity.  Methods used to classify AI-medications and identify participant AI-medication 
use by accessing their pharmaceutical claims records were informed by an evidence-based 
protocol (section 11.1). The AI-medication measurement methods utilized in the present 
research were therefore a key strength of both studies. Additionally, the present research 
utilized a widely used measure of alcohol consumption (the AUDIT-C (Bush et al., 1998)), 
which may help the research design to be replicated more easily.   
There were some important limitations regarding the alcohol consumption measure used in 
study 1 and study 2.  The present research did not measure drinking quantity or episodic binge 
drinking among participants. As discussed in section 10.4, this decision was based on the 
assumption that drinking frequency is the most reliable indication of simultaneous alcohol/AI-
medication exposure (Breslow et al., 2015).  However, this approach did not allow for a 
standardized threshold score to be applied to the AUDIT-C (Bush et al., 1998), which also 
requires consideration of average drinking quantity and binge drinking frequency. 
Additionally, as mentioned in chapter 12, while drinking frequency may be the best indicator 
of simultaneous alcohol/medication use, the specific type of medication and the amount of 
alcohol consumed also contribute to the likelihood of AMI (see sections 12.6.b, and 12.6.c).  
Future studies may therefore enhance concomitant alcohol/AI-medication use measurement 
precision by establishing appropriate drinking quantity thresholds to be applied to specific AI-
medication classes.   
There was also a key limitation regarding the categorization of AI-medications in the present 
research. Specifically, the likelihood and clinical relevance of particular AMIs often depends 
on the health status of the patient medications are prescribed to. For example, interactions 
between alcohol and paracetamol (which was classified as a ‘major AI-medication in the 
present research) are only relevant to a small group of alcoholics who use high doses of 
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paracetamol on a long-term basis (NZF, 2017). In such cases permanent liver damage may 
occur, which may be fatal, however for most people no interaction will not occur (NZF, 2017). 
Therefore, the extent to which the present research was able to provide information about the 
clinical relevance of concomitant alcohol/AI-medication use was limited.  
14.2: CONTRIBUTIONS OF THE PRESENT THESIS 
There were two major contributions of this project overall. Firstly, rates of concomitant 
alcohol/AI-medication use by older adults living in New Zealand had not been explored 
previously. The present research therefore provides much needed information about the 
prevalence of a potentially serious public health issue in New Zealand’s rapidly growing older 
adult population.  Secondly, an important issue highlighted throughout the present thesis is that 
there are many methodological challenges apparent when assessing concomitant alcohol/AI-
medication use among survey participants.   The research protocol described in chapter 11 is 
therefore an important contribution of this project, as this provides an evidence-based 
framework for measuring AI-medication use in survey research by accessing pharmaceutical 
dispensing records. Moreover, by implementing this protocol using data from an ongoing 
nationally representative survey of older adults (Towers & Noone, 2007; Towers & Stevenson, 
2014), this project could help facilitate further research into concomitant alcohol/AI-
medication use in New Zealand’s older adult population.    
14.3: CONCLUSIONS  
There are many issues apparent when assessing the prevalence and correlates of concomitant 
alcohol/AI-medication use in community samples.  In addition to the challenges of measuring 
concomitant alcohol/AI-medication use, many health-related outcome measures may not 
capture the specific harms associated with AMIs, and the utility of cross-sectional research 
designs may be limited given that drinking patterns may change in response to AMI-related 
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harm.  Overall, the findings of the present research suggest many older adults living in New 
Zealand are at risk of AMI exposure, and the prevalence of this issue may be higher in New 
Zealand than many other countries.  Importantly, the present research findings indicate rates of 
AMI risk are particularly high among New Zealanders aged ≥65 years, a rapidly growing 
population of people (Statistics New Zealand, 2020) who are highly vulnerable to alcohol-
related harm (Moore et al., 2007).   There is therefore a need for further research into the 
predictors and outcomes of concomitant alcohol/AI-medication use in this population.   
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APPENDIX A: LIST OF AI-MEDICATIONS WITHIN THE PHARMS DATA  
Information pertaining to medications within the PHARMS data identified as AI-medications by NZF is provided in Tables 26 and 27.  Both 
Tables are organized according to unique chemical names of AI-medications listed in the PHARMS data, which are listed in the left column of 
each table. PHARMS chemical ids and AI-medication severity categorizations are provided for each unique chemical name. Any medications that 
were classified as benzodiazepines, NSAIDs, or antibiotics are identified, and where applicable, associated medication brand names and brand 
codes are provided.  Table 26 includes all unique chemical names with multiple associated brand names, and Table 27 includes those with one or 
less associated brand names.  
 
Table 26: Relevant Information About PHARMS Medications Identified as AI By NZF: Chemical Names with Multiple Associated Brand 
Names 
Chemical Names ID 
AI-
Classification 
Drug Class (where 









   
Glucobay 12470201 
Acebutolol 1001 Mild 
 
ACB 10010302 
   
Sectral 10010101 
Acitretin 2363 Moderate 
 
Neotigason 23630201 
   
Novatretin 23630225 
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Table 26: Continued       
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Alprazolam 2632 Moderate Benzodiazepines Arrow-Alprazolam 26320325 
 
    
Xanax 26320301 
Amitriptyline 1059 Moderate 
 
Amirol 10590125 
    
Amitrip 10590301 
    
Arrow-Amitriptyline 10590126 
 
    
Tryptanol 10590303 
Amlodipine 2793 Moderate 
 
Apo-Amlodipine 27930226 
    
Calvasc 27930225 
 
    
Norvasc 27930101 
Apomorphine hydrochloride 1024 Moderate 
 
APO-go 10242525 
    
Apomine 10242526 
    
Mayne 10240101 
 
    
Movapo 10242527 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Aspirin 1087 Mild 
 
Aspec 300 10870501 
    
Aspro Clear 10870102 
    
Cartia 10872526 
    
Disprin 10870103 
    
Ecotrin 10870601 
    
Ethics Aspirin 10870125 
    
Ethics Aspirin EC 10872525 
    
HMG 10870201 
    
Solprin 10870101 
 
    
SRA 10870701 
Atenolol 1094 Mild 
 
Anselol 10940101 
    
Apo-Atenolol 10940103 
    
Atenolol AFT 10942525 
    
Atenolol Tablet USP 10940226 
    
Global Atenolol 10940105 
    
Loten 10940202 
    
Mylan Atenolol 10940225 
    
Noten 10940126 
 
    
Tenormin 10940104 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Atenolol with chlorthalidone 1095 Mild 
 
Loten-C 10950102 
    
Tenoret 50 10950201 
 
    
Tenoretic 10950101 
Atropine sulphate 1097 Major 
 
AstraZeneca 10970401 
    
Atropt 10970601 
    
Baxter 10970302 
 
    
Fawns and McAllan 10970101 
Azathioprine 1100 Major 
 
Azamun 11000102 
    
Imuprine 11000125 
    
Imuran 11000201 
 
    
Thioprine 11000103 
Baclofen 2364 Moderate 
 
Alpha-Baclofen 23640104 
    
Lioresal 23640102 
    
Lioresal Intrathecal 23642525 
 
    
Pacifen 23640101 
Betaxolol 1149 Mild 
 
Apo-Betaxolol 11490225 
    
Betoptic 11490201 
 
    
Betoptic S 11490101 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Brimonidine tartrate 3713 Mild 
 
AFT 37132526 
    
Alphagan 37132525 
 
    
Arrow-Brimonidine 37132527 
Bromocriptine mesylate 1167 Moderate 
 
Alpha-Bromocriptine 11670103 
    
Apo-Bromcriptine 11670301 
    
Apo-Bromocriptine 11670102 
 
    
Parlodel 11670101 
Bupivacaine hydrochloride 2855 Moderate 
 
Marcain Heavy 28550101 
 
    
Marcain Isobaric 28550201 
Buspirone hydrochloride 6006 Moderate 
 
Biron 60060201 
    
Buspar 60060202 
    
Orion 60060226 
 
    
Pacific Buspirone 60060225 




    
Candestar 12542526 
Captopril 2841 Mild 
 
Apo-Captopril 28410326 
    
Capoten 28410601 
    
Captohexal 28410125 
    
m-Captopril 28410327 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Carbamazepine 1217 Moderate 
 
Tegretol 12170301 
    
Tegretol CR 12170701 
 
 
    
Teril 12170401 




    
Dilatrend 37722525 
Cefamandole nafate 1230 Moderate Antibiotics Baxter 12300203 
 
    
Mandol 12300202 




    
Selectol 25140101 
Cetirizine hydrochloride 2833 Mild 
 
Allerid C 28332525 
    
Cetirizine - AFT 28332526 
    
Histaclear 28332527 
    
Razene 28330125 
    
Zetop 28330126 
 
    
Zyrtec 28330101 




    
Largactil Forte 12830501 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 




    
Sandimmun 24210101 




    
Zapril 27700125 




    
Inhibace Plus 11270101 
Cimetidine 1297 Mild 
 
Apo-Cimetidine 12970204 
    
Cytine 12970103 
    
Duomet 12970201 
 
    
Tagamet 12970401 
Ciprofloxacin 2819 Moderate Antibiotics  Ciloxan 28190401 
    
Cipflox 28190325 
    
Ciprofloxacin Rex 28190326 
    
Ciproxin 28190301 
 
    
Rex Medical 28190226 
Citalopram hydrobromide 1193 Moderate 
 
Arrow-Citalopram 11930126 
    
Cipramil 11930101 
    
Citalopram - Rex 11930127 
 
    
PSM Citalopram 11930128 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Clomipramine hydrochloride 1315 Moderate 
 
Anafranil 13150101 
    
Apo-Clomipramine 13150225 
 
    
Clopress 13150202 
Clonazepam 1316 Moderate Benzodiazepines Paxam 13160225 
 
    
Rivotril 13160201 
Clonidine 1317 Moderate 
 
Catapres-TTS-1 13170201 
    
Catapres-TTS-2 13170301 
 
    
Catapres-TTS-3 13170401 
Clonidine hydrochloride 1318 Moderate 
 
Catapres 13180501 
    
Clonidine BNM 13180825 
    
Dixarit 13180801 




    
Clozaril 10780201 
Codeine phosphate 1332 Moderate 
 
Alpha-codeine phosphate 13320203 
    
Douglas 13320501 
 
    
PSM 13320302 
Cyclizine hydrochloride 6010 Moderate 
 
Marzine 60100101 
    
Nausicalm 60100125 
 
    
Nauzene 60100126 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Cyclizine lactate 6011 Moderate 
 
Nausicalm 60110126 
    
Valoid 60110101 
 
    
Valoid (AFT) 60110125 
Cyproterone acetate 2707 Moderate 
 
Androcur 27070101 
    
Androcur Depot 27070201 
    
Pacific Cyproterone 27070126 
    
Procur 27070127 
 
    
Siterone 27072525 
Cyproterone acetate with ethinyloestradiol 2706 Moderate 
 
Diane-35 27060101 
    
Diane-35 ED 27060201 
    
Estelle 35-ED 27060225 
    
Ginet 27060227 
 
    
Ginet 84 27060226 
Dextropropoxyphene with paracetamol 1392 Major 
 
Apo-Paradex 13920201 
    
Capadex 13920101 
    
Di-Gesic 13920202 
 
    
Paradex 13920203 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Diazepam 1397 Moderate Benzodiazepines Arrow-Diazepam 13970225 
    
D-Pam 13970203 
    
Diazemuls 13970602 
    
Hospira 13970601 
    
Pro-Pam 13970303 
    
Stesolid 13970501 
Diclofenac sodium 1401 Major NSAIDs Anfenax SR 14011301 
    
Apo-Diclo 14010103 
    
Apo-Diclo SR 14011203 
    
Diclax 14010202 
    
Diclax SR 14011201 
    
Diclofenac Sandoz 14010226 
    
Diclohexal 14010225 
    
Flameril 14010204 
    
Flameril Retard 14011204 
    
Voltaren 14010901 
    
Voltaren D 14011101 
    
Voltaren Ophtha 14011001 
 
    
Voltaren SR 14010302 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Diflunisal 1411 Major NSAIDs Ansal 14110202 
 
    
Dolobid 14110201 
Diltiazem hydrochloride 2528 Moderate 
 
Apo-Diltiazem 25280205 
    
Apo-Diltiazem CD 25280625 
    
Cardizem 25280201 
    
Cardizem CD 25280403 
    
Dilacor XR 25280902 
    
Dilcard 30 25280102 
    
Dilcard 60 25280202 
    
Dilzem 25280203 
    
Dilzem LA 25280701 
 
    
Dilzem SR 25280901 
Diphenoxylate hydrochloride with 




    
Lomotil 14240101 




    
Cosopt 37812525 
Doxazosin 2515 Mild 
 
Apo-Doxazosin 25150326 
    
Cardoxan 25150302 
 
    
Dosan 25150225 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 




    
Sinequan 14380402 
Doxycycline 2529 Mild Antibiotics Doryx 25290301 
    
Doxine 25290401 
    
Doxy 25290303 
    
Doxy-100 25290402 
    
Doxy-50 25290102 
 
    
Vibra-Tab 25290101 
Enalapril maleate 2711 Mild 
 
Acetec 27110228 
    
Arrow-Enalapril 27110327 
    
Enahexal 27110325 
    
Ethics Enalapril 27110329 
    
m-Enalapril 27110126 
 
    
Renitec 27110201 
Ergotamine tartrate with caffeine 1462 Mild 
   
    
Cafergot 14620301 
 
    
Cafergot S29 14620325 
Erythromycin 1465 Moderate Antibiotics Emu-V 14650401 
    
Eryc 14650501 
 
    
Stiemycin 14650301 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Erythromycin ethyl succinate 6026 Moderate Antibiotics E-Mycin 60260502 




    
ERA 60260601 
Erythromycin lactobionate 6028 Moderate Antibiotics Baxter 60280201 
    
ERA 60280202 
    
Erythrocin IV 60280225 
 
    
Mayne 60280101 
Escitalopram 3926 Moderate 
 
Air Flow Products 39262626 
    
Loxalate 39262625 
Famotidine 2373 Mild 
 
Apo-Famotidine 23730104 
    
Famox 23730103 




    
Pepzan 23730102 
Felodipine 2398 Moderate 
 
Agon SR 23980202 
    
Felo 10 ER 23980225 
    
Felo 2.5 ER 23980325 
    
Felo 5 ER 23980125 
 
    
Plendil ER 23980301 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Fentanyl 3801 Moderate 
 
Boucher and Muir 38011526 
    
Durogesic 38012925 
    
Fentanyl Sandoz 38013726 




    
Mylan Fentanyl Patch 38013725 
Fluoxetine hydrochloride 2636 Moderate 
 
Arrow-Fluoxetine 26360226 
    
Fluox 26360103 
    
Lovan 26360202 
    
Plinzene 26360104 
 
    
Prozac 20 26360201 
Fluphenazine decanoate 1533 Moderate 
 
Baxter 15330102 
    
Mayne 15330301 
 
    
Modecate 15330325 
Flurbiprofen 1536 Major NSAIDs Froben 15360101 
 
    
Froben SR 15360301 
Gabapentin 1062 Moderate 
 
Arrow-Gabapentin 10620226 
    
Neurontin 10622528 
 
    
Nupentin 10620225 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Glibenclamide 1567 Major 
 
Apo-Glibenclamide 15670204 
    
Daonil 15670202 




    
Semi-Daonil 15670101 
Gliclazide 1568 Major 
 
Apo-Gliclazide 15680125 
    
Diamicron 15680101 




    
Nidem 15680126 




    
Minidiab 15690102 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Glyceryl trinitrate 1577 Moderate 
 
Anginine 15770201 
    
Glytrin 15772525 
    
Lycinate 15770225 
    
Minitran 15770105 
    
Nitro-Dur 15770104 
    
Nitrobid 15770301 
    
Nitrocor 15770102 
    
Nitroderm TTS 15770103 
    
Nitrolingual 15770401 
    
Nitrolingual Pump Spray 15770601 
 
 
    
Rectogesic 15772625 




    
Grisovin 500 15790301 
Haloperidol 1583 Moderate 
 
Haloperidol - MercuryPharma 15830625 
 
 
    
Serenace 15830301 





    
Haldol Concentrate 25300301 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Hyoscine hydrobromide 1629 Moderate 
 
Hospira 16290301 
    
Isopto Hyoscine 16290201 




    
Scopoderm TTS 16290101 





    
Gastrosoothe 16310125 
Ibuprofen 2798 Major NSAIDs Anafen 27980301 
    
Arrowcare 27980127 
    
Brufen 27980202 
    
Brufen SR 27980401 
    
Ethics Ibuprofen 27980126 
    
Fenpaed 27980525 
    
I-Profen 27980125 




    
Panafen 27980103 
Imipramine hydrochloride 1642 Moderate 
 
Imipramin 16420101 
    
Tofranil 16420125 
 
    
Tofranil s29 16420126 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Insulin aspart 3783 Moderate 
 
NovoRapid 37832625 
    
NovoRapid FlexPen 37832725 
 
    
NovoRapid Penfill 37832525 




    
Lantus SoloStar 38572725 




    
Apidra SoloStar 39082625 
Insulin isophane 1649 Moderate 
 
Humulin N 16490201 
    
Humulin NPH 16490325 
    
Insulatard 16492501 
    
Protaphane 16490402 
 
    
Protaphane Penfill 16490301 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Insulin isophane with insulin neutral 6300 Moderate 
 
Humulin 30/70 63000225 
    
Humulin 50/50 63000301 
    
Humulin 60/40 63000302 
    
Humulin 70/30 63000102 
    
Humulin 80/20 63000103 
    
Humulin 90/10 63000305 
    
Mixtard 15 63000306 
    
Mixtard 30 63000307 
    
Mixtard 50 63000308 
    
Penmix 10 63000106 
    
PenMix 10 63000201 
    
PenMix 20 63000202 
    
PenMix 30 63000203 
    
PenMix 40 63000204 
 
    
PenMix 50 63000205 
Insulin lispro with insulin lispro 
protamine 3882 Moderate 
 
Humalog Mix 25 38822525 
 
    
Humalog Mix 50 38822625 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Insulin neutral 1648 Moderate 
 
Actrapid 16480101 
    
Actrapid Penfill 16480301 
    
Humulin R 16480202 
 
    
Velosulin 16482501 
Insulin zinc suspension 1655 Moderate 
 
Humulin L 16550101 
    
Humulin U 16550201 




    
Ultratard 16550202 
Interferon alpha-2a with ribavirin 3823 Moderate 
 
Roferon RBV Combination Pack 38232525 
    
Roferon RBV Combination Pack Starter 
Kit 38232625 





    
Avonex Pen 12482625 




    
Rifinah 16790301 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 




    
Coronex 23770201 
Isosorbide mononitrate 2836 Moderate 
 
Corangin 28360201 
    
Duride 28360304 
    
Imdur 28360302 
    
Imtrate 28360303 
    
Ismo 20 28360101 
 
    
Ismo 40 Retard 28360225 
Isotretinoin 1688 Moderate 
 
Isotane 10 16880126 
    
Isotane 20 16880225 
    
Oratane 16880125 
 
    
Roaccutane 16880101 




    
Dynacirc-SRO 27710201 
Ketoconazole 1696 Major 
 
Ketopine 16960325 
    
Link Healthcare 16960125 
    
Nizoral 16960201 
 
    
Sebizole 16960302 
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Table 26: Continued      
 
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Codes 
Ketoprofen 1697 Major NSAIDs Kefen SR 16970302 
    
Orudis 16970701 
    
Oruvail 16970505 
    
Oruvail EC 16970601 
 
    
Oruvail SR 16970303 




    
Zasten 16980101 
Labetalol 1699 Mild 
 
Albetol 16990302 
    
Hybloc 16990102 
 
    
Trandate 16992525 




    
Arava 37632525 
Lisinopril 2797 Mild 
 
Arrow-Lisinopril 27970325 
    
Ethics Lisinopril 27970326 
    
Prinivil 27970301 
 
    
Zestril 27970202 




    
Zestoretic 27950102 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Lithium carbonate 2466 Moderate 
 
Douglas 24660401 
    
Lithicarb FC 24660201 
 
    
Priadel 24660301 
Loratadine 2831 Mild 
 
Apo-Loratadine 28310126 
    
Claratyne 28310101 
    
Lora-tabs 28310125 
    
Loraclear Hayfever Relief 28310127 
    
Lorafix 28310128 
 
    
LoraPaed 28310225 
Lorazepam 1730 Moderate Benzodiazepines Ativan 17300403 
    
Lorapam 17300401 
 
    
Lorzem 17300402 
Losartan potassium 1061 Mild 
 
Cozaar 10610201 
    
Losartan Actavis 10612527 
 
    
Lostaar 10612526 
Losartan potassium with 
hydrochlorothiazide 1068 Mild 
 
Arrow-Losartan & Hydrochlorothiazide 10680526 
 
    
Hyzaar 10680525 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Mefenamic acid 1769 Major NSAIDs Mefic 17690102 
 
    
Ponstan 17690101 
Metformin hydrochloride 1794 Moderate 
 
3M 17940106 
    
Apo-Metformin 17940205 
    
Apotex 17940227 
    
Arrow-Metformin 17940226 
    
Diabex 17940225 
    
Glucomet 17940104 
    
Glucophage 17940201 
    
Metchek 17940127 
    
Metformin Mylan 17940228 
 
    
Metomin 17940103 
      
      
      
      
      
      
      
      
      
      
      
      
  
192 | P a g e  
 
Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Methadone hydrochloride 1795 Moderate 
 
AFT 17950425 
    
Biodone 17950501 
    
Biodone Extra Forte 17950701 
    
Biodone Forte 17950602 
    
Douglas 17950402 
    
GlaxoWellcome 17950601 
    
Martindale 17950225 
    
Methaforte 17950502 
    
Methatabs 17950101 
    
Pallidone 17950102 
    
PSM 17950301 
 
    
PSM Methaforte 17950525 
Methotrexate 1797 Major 
 
Baxter 17972525 
    
Biomed 17972626 
    
DBL Methotrexate 17972825 
    
Hospira 17971001 
    
Ledertrexate 17970101 
    
Mayne 17971201 
    
Methoblastin 17970201 
    
Methotrexate Ebewe 17971125 
    
Methotrexate Sandoz 17973425 
    
Pharmacia 17971202 
 
    
Trexate 17970225 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Methyldopa 1806 Mild 
 
Aldomet 18060202 
    
Douglas 18060301 
 
    
Prodopa 18060201 
Methylphenidate hydrochloride 1809 Major 
 
Ritalin 18090101 
    
Ritalin SR 18092525 
    
Rubifen 18090125 
 
    
Rubifen SR 18092526 
Methylphenidate hydrochloride extended-
release 3880 Major 
 
Concerta 38802725 
    
Ritalin LA 38803225 
Metoclopramide hydrochloride 1814 Moderate 
 
AstraZeneca 18140325 
    
Maxolon 18140101 
    
Metamide 18140102 
    
Pfizer 18140302 
Metoprolol succinate 1817 Mild 
 
Betaloc CR 18170301 
    
Metoprolol - AFT CR 18170325 
    
Myloc CR 18170326 
Metoprolol tartrate 1818 Mild 
 
Betaloc 18180401 
    
Lopresor 18180201 
    
Mycol 18180202 
    
Slow-Lopresor 18180301 
      
  
194 | P a g e  
 
Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Metronidazole 1820 Contraindicated 
 
Flagyl 18200203 
    
Flagyl-S 18200301 
    
Trichozole 18200202 
Midazolam 2539 Moderate Benzodiazepines Baxter 25390225 
    
Hypnovel 25390101 
    
Pfizer 25390226 
Mirtazapine 3901 Major 
 
Apo-Mirtazapine 39012626 
    
Avanza 39012625 
Morphine hydrochloride 1830 Major 
 
Douglas 18300502 
    
PSM 18300501 
    
RA-Morph 18300401 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Morphine sulphate 1831 Major 
 
Arrow-Morphine LA 18310125 
    
AstraZeneca 18311102 
    
Baxter 18310901 
    
DBL Morphine Sulphate 18310801 
    
Douglas 18311601 
    
Kapanol 18311801 
    
LA-Morph 18310402 
    
m-Eslon 18312225 
    
Martindale 18311425 
    
MST Continus 18310401 
    
RMS 18311401 
    
Sevredol 18312101 
Nadolol 1838 Mild 
 
Apo-Nadolol 18380202 
    
Corgard 18380101 
Naproxen 2782 Major NSAIDs Naprosyn 27820901 
    
Naprosyn Enteric 27821201 
    
Naprosyn SR 1000 27820601 
    
Naprosyn SR 750 27820501 
    
Naxen 27821102 
    
Noflam 250 27820904 
    
Noflam 500 27821103 
    
Noflam EC 27821202 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Naproxen sodium 2783 Major NSAIDs Naxen Sodium 27830103 
    
Noflam-N 27830201 
    
Sonaflam 27830125 
    
Synflex 27830202 
Nicotine 3722 Mild 
 
Habitrol 37223626 
    
Nicabate 37222525 
    
Nicotinell 37222925 
    
Nicotrol 37223225 
Nicotinic acid 1861 Major 
 
Apo-Nicotinic Acid 18610402 
    
Niacin-Odan 18610425 
    
PSM 18610401 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Nifedipine 1863 Moderate 
 
Adalat 18630501 
    
Adalat 10 18630125 
    
Adalat Oros 18630401 
    
Adalat Retard 18630201 
    
Adefin XL 18630326 
    
Alpha-Nifedipine 18630204 
    
Apo-Nifedipine Retard 18630202 
    
Arrow-Nifedipine XR 18630425 
    
Nical 18630602 
    
Nyefax 18630603 
    
Nyefax Retard 18630203 
Nitrazepam 1865 Moderate Benzodiazepines Insoma 18650102 
    
Nitrados 18650104 
Nortriptyline hydrochloride 1876 Moderate 
 
Allegron 18760101 
    
Norpress 18760125 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Olanzapine 1140 Moderate 
 
Dr Reddy's Olanzapine 11402825 
    
Olanzine 11400226 
    
Olanzine-D 11402826 
    
Zypine 11400227 
    
Zypine ODT 11402827 
    
Zyprexa 11400201 
    
Zyprexa Relprevv 11401725 
    
Zyprexa Zydis 11402728 
Ondansetron 2710 Moderate 
 
Dr Reddy's Ondansetron 27100125 
    
Ondansetron ODT-DRLA 27102826 
    
Onrex 27100326 
    
Zofran 27100302 
    
Zofran Zydis 27102725 
Ornidazole 1906 Moderate 
 
Arrow-Ornidazole 19060125 
    
Tiberal 19060101 
Oxazepam 1911 Moderate Benzodiazepines Benzotran 19110103 
    
Ox-Pam 19110202 
    
Serepax 19110203 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Oxprenolol 1912 Mild 
 
Captol 40 19120101 
    
Captol 80 19120201 
    
Captol SR 19120401 
    
Slow Trasicor 19120402 
    
Trasicor 19120102 
Oxybutynin 1914 Moderate 
 
Apo-Oxybutynin 19140102 
    
Ditropan 19140101 
Oxycodone hydrochloride 3822 Moderate 
 
Oxycodone Controlled Release 
Tablets(BNM) 38223127 
    
Oxycodone Orion 38223526 
    
OxyContin 38223125 
    
Oxydone BNM 38223126 
    
OxyNorm 38223625 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Paracetamol 1929 Major 
 
Apo-Paracetamol 19290803 
    
Disprol 19290805 
    
Douglas 19290205 
    
Ethics Paracetamol 19290226 
    
Gacet 19290525 
    
HMG 19290601 
    
Junior Parapaed 19290225 
    
Pacimol 19290825 
    
Pamol 19290301 
    
Panadol 19290501 
    
Panadol Colourfree 19290204 
    
Paracare 19290625 
    
Paracare Double Strength 19290305 
    
Parafast 19290827 
    
Pharmacare 19290826 
    
PSM 19290701 
    
PSM Paracetamol Double Strength 19290303 
    
PSM Paracetamol Elixir Paediatric 19290202 
    
PSM Paracetamol Junior Suspension 19290206 
    
Six Plus Parapaed 19290325 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Paracetamol with codeine 1931 Major 
 
Apo-Paracodeine 19310102 
    
Codalgin 19310125 
    
Codral Pain 19310105 
    
Pamol Plus 19310103 
    
Panadeine 19310101 
    
Paracetamol + Codeine (Relieve) 19310127 
    
ParaCode 19310126 
Paroxetine hydrochloride 6009 Moderate 
 
Aropax 60090101 
    
Loxamine 60090125 
Perindopril 2806 Mild 
 
Apo-Perindopril 28060125 
    
Coversyl 28060101 
Pethidine hydrochloride 1953 Moderate 
 
AstraZeneca 19530502 
    
DBL Pethidine Hydrochloride 19530301 
    
Douglas 19530202 
    
Mayne 19530401 
    
PSM 19530201 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Phenytoin sodium 1978 Moderate 
 
Dilantin 19780401 
    
Dilantin Forte 19780501 
    
Dilantin Infatab 19780101 
    
Hospira 19780625 
Pimozide 1990 Moderate 
 
Orap 19900101 
    
Orap Forte 19902525 
Pindolol 1991 Mild 
 
Apo-Pindolol 19910601 
    
Pindol 19910603 
    
Visken 19910504 
    
Vypen 19910404 
Pioglitazone 3800 Moderate 
 
Actos 38002725 
    
Pizaccord 38002726 
    
Vexazone 38002727 
Piroxicam 1996 Major NSAIDs Candyl D 19960401 
    
Douglas 19960701 
    
Feldene 19960702 
    
Piram-D 19960402 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Prazosin 2031 Mild 
 
Apo-Prazo 20310225 
    
Apo-Prazosin 20310426 
    
Hyprosin 20310101 
    
Minipress 20310402 
    
Pratsiol 20310301 
Primidone 2041 Moderate 
 
Apo-Primidone 20410125 
    
Mysoline 20410101 
Prochlorperazine 6012 Moderate 
 
Antinaus 60120201 
    
Buccastem 60120101 
    
Stemetil 60120501 
    
Stemetil EFF 60120701 
Promethazine hydrochloride 2478 Moderate 
 
Allersoothe 24780225 
    
Hospira 24780502 
    
Phenergan 24780301 
    
Promethazine Winthrop Elixir 24780325 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Propranolol 2060 Mild 
 
Angilol 20600102 
    
Angilol LA 20600601 
    
Apo-Propranolol 20600203 
    
Cardinol 20600103 
    
Cardinol 160 20600502 
    
Cardinol LA 20600602 
    
Inderal 20600101 
    
Inderal LA 20600603 
    
Roxane 20602525 
Quetiapine 1183 Moderate 
 
Dr Reddy's Quetiapine 11832527 
    
Quetapel 11832526 
    
Seroquel 11832525 
Quinapril 2772 Mild 
 
Accupril 27720301 
    
Accupro 27720102 
    
Arrow-Quinapril 10 27720225 
    
Arrow-Quinapril 20 27720325 
    
Arrow-Quinapril 5 27720125 
Quinapril with hydrochlorothiazide 3749 Mild 
 
Accuretic 10 37492525 
    
Accuretic 20 37492625 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Ranitidine 2080 Mild 
 
Apo-Ranitidine 20800602 
    
Arrow-Ranitidine 20800625 
    
Douglas 20802602 
    
Peptisoothe 20800325 
    
Ranitidine Relief 20800626 
    
Zanidin 20800503 
    
Zantac 20800601 
    
Zantac-C 20802601 
Risperidone 1011 Moderate 
 
Actavis 10110428 
    
Apo-Risperidone 10110526 
    
Dr Reddy's Risperidone 10112528 
    
Ridal 10110425 
    
Risperdal 10110401 
    
Risperdal Consta 10112825 
    
Risperdal Quicklet 10113125 
    
Risperon 10110525 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Salbutamol 2096 Major 
 
Airomir 20961601 
    
Asmol 20960602 
    
Asthalin 20961526 
    
Broncolin 20960326 
    
Pharmacia 20961425 
    
Respax 20961501 
    
Respigen 20961627 
    
Respolin 20960604 
    
Respolin Autohaler 20961101 
    
SalAir 20961628 
    
Salamol 20961626 
    
Salapin 20960325 
    
Salbutamol Turbuhaler 20961701 
    
Salbuvent 20960603 
    
Salbuvent Forte 20960902 
    
Ventodisk 20961302 
    
Ventolin 20960301 
    
Ventolin Forte 20960901 
    
Ventolin Nebules 20961402 
    
Volmax 20960201 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Salbutamol with ipratropium bromide 6311 Major 
 
Combivent 63110101 
    
Duolin 63110225 
    
Duolin HFA 63112525 
Selegiline hydrochloride 2642 Major 
 
Apo-Selegiline 26420102 
    
Apo-Selegiline S29 26420125 
    
Eldepryl 26420201 
    
Selgene 26420103 
Sertraline 3927 Moderate 
 
Arrow-Sertraline 39272525 
    
Sertraline Actavis 39272527 
    
Zoloft 39272526 
Sildenafil 3890 Moderate 
 
Silagra 38902626 
    
Vedafil 38902727 
    
Viagra 38902725 
Sotalol 2169 Mild 
 
Apo-Sotalol 21690225 
    
Mylan 21690102 
    
Sotacor 21690301 
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Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Sulindac 2193 Major NSAIDs Aclin 21930225 
    
Clinoril 21930202 
    
Daclin 21930201 
    
Saldac 21930203 
Tacrolimus 1088 Major 
 
Prograf 10880201 
    
Tacrolimus Sandoz 10880225 
Temazepam 2224 Moderate Benzodiazepines Euhypnos 22240102 
    
Normison 22242525 
    
Somapam 22240103 
Tenoxicam 2536 Major NSAIDs AFT 25362625 
    
Reutenox 25360125 
    
Tilcotil 25360101 
Terazosin 2543 Mild 
 
Apo-Terazosin 25432525 
    
Arrow 25430326 
    
Hytrin 25430701 
    
Hytrin BPH 25430302 
    
Hytrin BPH Starter Pack 25430501 
    
Hytrin Starter Pack 25430502 
      
      
      
  
209 | P a g e  
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Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Thalidomide 3845 Major 
 
Thalidomide Pharmion 38452525 
    
Thalomid 38452625 
Thioridazine hydrochloride 2255 Moderate 
 
Aldazine 22550302 
    
Melleril 22550201 
    
Melleril Retard 22550501 
Tiaprofenic acid 2537 Major NSAIDs Surgam 25370201 
    
Surgam SA 25370301 
Timolol 2266 Mild 
 
Apo-Timol 22660104 
    
Apo-Timop 22660425 
    
Arrow-Timolol 22660226 
    
Blocadren 22660105 
    
Gen-Timolol 22660204 
    
Hypermol 22660102 
    
Tilmat 22660101 
    
Timoptol 22660402 
    
Timoptol XE 22660501 
Timolol maleate with pilocarpine 2268 Mild 
 
Timpilo 2 22680101 
    
Timpilo 4 22680201 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Tinidazole 2269 Contraindicated 
 
Dyzole 22690102 
    
Fasigyn 22690101 
Topiramate 1133 Moderate 
 
Arrow-Topiramate 11330425 
    
Topamax 11332525 
    
Topiramate Actavis 11330426 
Tramadol hydrochloride 3906 Moderate 
 
Arrow-Tramadol 39062525 
    
Tramal SR 100 39062625 
    
Tramal SR 150 39062725 
    
Tramal SR 200 39062825 
Trandolapril 1031 Mild 
 
Gopten 10310301 
    
Odrik 10310102 
Triazolam 2295 Moderate Benzodiazepines Halcion 22950101 
    
Hypam 22950104 
    
Pharmacia 22950102 
    
Trycam 22950103 
Trifluoperazine hydrochloride 2298 Moderate 
 
Stelazine 22980101 
    
Stelazine Section 29 22980325 
    
Stelazine Spansules 22980401 
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Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Trimethoprim 2300 Moderate Antibiotics TMP 23000202 
    
Triprim 23000201 
Trimipramine maleate 2301 Moderate 
 
Surmontil 23010501 
    
Tripress 23010302 
Venlafaxine 3785 Moderate 
 
Arrow-Venlafaxine XR 37853025 
    
Efexor XR 37852725 
Verapamil hydrochloride 2317 Moderate 
 
Civicor 23170102 
    
Civicor Retard 23170801 
    
Isoptin 23170101 
    
Isoptin SR 23170901 
    
Verpamil 23170104 
    
Verpamil SR 23170902 
Warfarin sodium 2331 Mild 
 
Coumadin 23310401 
    
Marevan 23310602 
Ziprasidone 3873 Moderate 
 
Zeldox 38732825 
    
Zusdone 38732826 
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Table 26: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Zopiclone 2484 Moderate Benzodiazepines Apo-Zopiclone 24840125 
    
Imovane 24840101 
    
Zo-Tab 24840102 
    
Zopiclone Actavis 24840126 
 
 
      
Table 27: Relevant Information About PHARMS Medications Identified as AI By NZF: Chemical Names with One or Less Associated 
Brand Names 
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Acebutolol with hydrochlorothiazide 1005 Mild 
 
Secadrex 10050101 
Amantadine hydrochloride 1048 Moderate 
 
Symmetrel 10480101 
Amisulpride 3884 Moderate 
 
Solian 38842825 
Aripiprazole 3878 Moderate 
 
Abilify 38782925 
Aspirin with Chloroform 3216 Mild 
   
Aspirin with Codeine 1093 Moderate 
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Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Aspirin with paracetamol and codeine 1092 Major 
 
Codcomol 10920101 
Benazepril 2794 Mild 
 
Cibacen 27940301 





Bisoprolol fumarate 3949 Mild 
 
Bosvate 39492725 
Brimonidine tartrate with timolol maleate 3839 Mild 
 
Combigan 38392525 
Bromazepam 1166 Moderate Benzodiazepines Lexotan 11660201 
Bupivacaine Hydrochloride 2855 Moderate 
   
Buprenorphine hydrochloride 2521 Moderate 
 
Temgesic 25210101 
Buprenorphine Hydrochloride 2521 Moderate 
   
Buprenorphine with naloxone 3950 Moderate 
 
Suboxone 39502625 
Bupropion hydrochloride 3892 Major 
 
Zyban 38922525 
Caffeine 3740 Mild 
   
Caffeine citrate 3933 Mild 
 
Biomed 39332525 
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Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Captopril with hydrochlorothiazide 2840 Mild 
 
Capozide 28400201 
Celecoxib 1271 Major NSAIDs 
  
Chlordiazepoxide hydrochloride 6007 Moderate Benzodiazepines Nova-Pam 60070201 
Cisapride 2781 Moderate 
 
Prepulsid 27810201 
Citalopram hydrobromide (Celapram) 1190 Moderate 
 
Celapram 11902525 
Clobazam 1308 Moderate Benzodiazepines Frisium 13080101 
Clonidine Hydrochloride 1317 Moderate 
   
Codeine 3267 Moderate 
   
Cycloserine 3994 Contraindicated 
 
King 39942525 
Cyproheptadine hydrochloride 2470 Moderate 
 
Periactin 24700101 
Dantrolene 1373 Moderate 
 
Dantrium 13730201 
Desipramine hydrochloride 1379 Moderate 
 
Pertofran 13790101 
Dexamfetamine sulfate 1389 Major 
 
PSM 13890101 
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Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Dextromethorphan 1256 Moderate 
   
Dextropropoxyphene 1391 Major 
 
Doloxene 13910101 
Dihydrocodeine tartrate 2427 Moderate 
 
DHC Continus 24270101 
Dimenhydrinate 1418 Moderate 
 
Dramamine 14180101 
Dimethyl fumarate 4053 Moderate 
 
Tecfidera 40532625 
Dimethyl sulphoxide 3277 Moderate 
 
Douglas 32770101 
Diphenhydramine hydrochloride 2472 Moderate 
 
Benadryl 24720101 
Disulfiram 1432 Contraindicated 
 
Antabuse 14320101 
Droperidol 8792 Moderate 
 
Droleptan 87920101 





Ergotamine tartrate with cyclizine 1459 Moderate 
 
Migril 14590101 
Ergotamine tartrate with diphenhydramine 1460 Moderate 
 
Ergodryl 14600101 
Erythromycin estolate 1466 Moderate Antibiotics Eromycin 14660201 
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Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Erythromycin stearate 6027 Moderate Antibiotics ERA 60270401 
Ethionamide 2858 Mild 
   
Ethosuximide 1481 Moderate 
 
Zarontin 14810201 
Fenbufen 1489 Major NSAIDs 
  
Fenoprofen Calcium 1490 Major NSAIDs 
  
Fentanyl citrate 3896 Moderate 
   
Fentanyl Citrate 1274 Moderate 
   
Fexofenadine hydrochloride 1194 Mild 
 
Telfast 11940301 
Flunarizine 1049 Moderate 
   
Flunitrazepam 2436 Moderate Benzodiazepines Rohypnol 24360101 
Fluoxetine Hydrochloride 2636 Moderate 
   
Fluphenazine hydrochloride 1535 Moderate 
 
Anatensol 15350201 
Gabapentin (Neurontin) 1060 Moderate 
 
Neurontin 10602625 
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Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Glycopyrronium 4043 Major 
 
Seebri Breezhaler 40432525 
Glycopyrronium bromide 4047 Major 
 
Max Health 40472525 
Glycopyrronium Bromide 1578 Major 
   
Glycopyrronium with indacaterol 4058 Major 
 
Ultibro Breezhaler 40582525 
Haloperidol Decanoate 2530 Moderate 
   
Hydroxyzine Hydrochloride 1627 Moderate 
   
Idoxuridine with dimethyl sulphoxide 3307 Moderate 
 
Douglas 33070101 




NovoMix 30 FlexPen 39822725 
Insulin lispro 1192 Moderate 
 
Humalog 11920101 
Insulin Neutral 1648 Moderate 
   
Interferon alfa-2a 2845 Moderate 
 
Roferon-A 28451501 
Interferon alfa-2b 2445 Moderate 
 
Intron-A 24451601 
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Table 27: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Interferon Alpha-2B 2445 Moderate 
   
Interferon alpha-n 6023 Moderate 
 
Wellferon 60230101 
Interferon beta-1-beta 3707 Moderate 
 
Betaferon 37072525 
Isosorbide Dinitrate 2377 Moderate 
   
Ivermectin 3964 Mild 
 
Stromectol 39642525 
Levamisole 1186 Moderate 
   
Levomepromazine maleate 1799 Moderate 
 
Nozinan 17990101 
Loprazolam mesylate 1729 Moderate Benzodiazepines Dormonoct 17290101 
Lormetazepam 1731 Moderate Benzodiazepines Noctamid 17310101 
Losartan 1061 Mild 
   
Losartan with hydrochlorothiazide 3788 Mild 
   
Loxapine succinate 1732 Moderate 
 
Loxapac 17320101 
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Table 27: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Maprotiline hydrochloride 1760 Moderate 
 
Ludiomil 17600201 
Meloxicam 3912 Major NSAIDs Arrow-Meloxicam 39122525 
Meprobamate 1780 Major 
 
Equanil 17800101 
Methyldopa with hydrochlorothiazide 1805 Mild 
 
Hydromet 18050101 
Metoclopramide Hydrochloride 1814 Moderate 
   





Mianserin hydrochloride 1824 Moderate 
 
Tolvon 18240101 
Morphine tartrate 2383 Major 
 
Hospira 23830101 
Niclosamide 1859 Major 
 
Yomesan 18590101 
Nicorandil 3975 Moderate 
 
Ikorel 39752625 
Nimorazole 1864 Moderate 
 
Naxogin 18640101 
Nizatidine 2490 Mild 
 
Axid 24900101 
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Table 27: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Nortriptyline Hydrochloride 1876 Moderate 
   
Olanzapine pamoate monohydrate 3940 Moderate 
   





Papaveretum 1927 Moderate 
 
Baxter 19270101 
Paracetamol with Codeine 1931 Major 
   
Paraldehyde 2059 Major 
 
AFT 20590101 
Pentazocine 1944 Moderate 
 
Fortral 19440301 
Pericyazine 1950 Moderate 
 
Neulactil 19500201 
Phenelzine sulphate 1955 Contraindicated 
 
Nardil 19550101 
Phenylbutazone 2494 Major NSAIDs Butazolidin 24940101 
Pindolol with clopamide 1989 Mild 
 
Viskaldix 19890101 
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Table 27: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Procainamide hydrochloride 2044 Mild 
 
Procainamide Durules 20440101 
Procarbazine hydrochloride 2047 Moderate 
 
Natulan 20470101 
Promethazine theoclate 2054 Moderate 
 
Avomine 20540101 
Quetiapine Fumarate 1183 Moderate 
   
Rosiglitazone 3739 Moderate 
   
Sertraline Hydrochloride 1030 Moderate 
   
Sulpiride 1007 Moderate 
   
Tamsulosin hydrochloride 3910 Mild 
 
Tamsulosin-Rex 39102525 
Terazosin Hydrochloride 2543 Mild 
   
Teriflunomide 4054 Moderate 
 
Aubagio 40542525 
Timolol Maleate 2266 Mild 
   
Tolbutamide 2277 Major 
 
Diatol 22770101 
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Table 27: Continued      
Chemical Names ID 
AI-
Classification 
Drug Class (where 
relevant) Brand Names 
Brand 
Code 
Tramadol 1229 Moderate 
   
Tranylcypromine sulphate 2285 Contraindicated 
 
Parnate 22850101 
Varenicline tartrate 3920 Major 
 
Champix 39202525 
Verapamil Hydrochloride 2317 Moderate 
   
Zuclopenthixol decanoate 3803 Moderate 
 
Clopixol 38032525 
Zuclopenthixol dihydrochloride 1226 Moderate 
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APPENDIX B: LIST OF AI-MEDICATION MATCHES 
BETWEEN THE PHARMS AND NZF DATA-SETS 
Chapter 11 described the data-matching process that were applied to identify medications 
within the PHARMS data that were classified as AI-medications by NZF (see section 11.2.c). 
As discussed, SPSS syntax scripts were generated to prepare the two datasets for matching. 
The following preparation salts were removed from medication chemical names within the 
PHARMS data using automated processes: acetate; bromide; calcium; carbonate; citrate; 
decanoate; estolate; fumarate; hydrochloride; maleate; mesylate; pamoate; phosphate; 
potassium; sodium; succinate; sulfate; sulphate; and tartrate. Some medications within the 
PHARMS data contained multiple active ingredients. In such cases, a new variable was created 
for each chemical, and matching processes were applied to these individually.   Matches were 
considered finalized when strings within the cleaned datasets matched exactly. In some cases, 
strings within the NZF data matched with single substrings in PHARMS data entries containing 
multiple substrings. These matches were checked manually and corrected accordingly.  
Matches between the PHARMS data and NZF data are listed in Tables 28 and 29.  PHARMS 
medications containing a single active ingredient are listed in Table 28, and those containing 
multiple active ingredients are listed in Table 29.  In both tables, the alcohol-interactivity 
classification of matched medications are listed in the right hand column, and matches that 
required manual checking are listed in bold font. In Table 29, the alcohol interactivity of the 
individual active ingredients of matched medications are identified where applicable (*mild; 
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Table 28: NZF/PHARMS Matches: Medications Containing One Active Ingredient 
PHARMS Chemical Name NZF Match AI-Classification 
Acarbose Acarbose Moderate 
Acebutolol Acebutolol Mild 
Acitretin Acitretin Moderate 
Alprazolam alprazolam Moderate 
Amantadine hydrochloride amantadine Moderate 
Amisulpride amisulpride Moderate 
Amitriptyline amitriptyline Moderate 
Amlodipine amlodipine Moderate 
Apomorphine hydrochloride apomorphine Moderate 
Aripiprazole aripiprazole Moderate 
Aspirin aspirin Mild 
Atenolol atenolol Mild 
Atropine sulphate atropine Major 
Azathioprine azathioprine Major 
Baclofen baclofen Moderate 
Benazepril benazepril Mild 
Betaxolol betaxolol Mild 
Bisoprolol fumarate bisoprolol Mild 
Brimonidine tartrate brimonidine Mild 
Bromazepam bromazepam Moderate 
Bromocriptine mesylate bromocriptine Moderate 
Bupivacaine hydrochloride bupivacaine Moderate 
Bupivacaine Hydrochloride bupivacaine Moderate 
Buprenorphine hydrochloride buprenorphine Moderate 
Buprenorphine Hydrochloride buprenorphine Moderate 
Bupropion hydrochloride bupropion Major 
Buspirone hydrochloride buspirone Moderate 
Caffeine caffeine Mild 
Caffeine citrate caffeine Mild 
Candesartan cilexetil candesartan Mild 
Captopril captopril Mild 
Carbamazepine carbamazepine Moderate 
Carvedilol carvedilol Mild 
Cefamandole nafate cefamandole Moderate 
Celecoxib celecoxib Major 
Celiprolol celiprolol Mild 
Cetirizine hydrochloride cetirizine Mild 
Chlordiazepoxide hydrochloride chlordiazepoxide Moderate 
Chlorpromazine hydrochloride chlorpromazine Moderate 
Chlorpropamide chlorpropamide Major 
Ciclosporin ciclosporin Mild 
Cilazapril cilazapril Mild 
Note: Items in bold font required manual correction   
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Table 28: Continued    
PHARMS Chemical Name NZF Match AI-Classification 
Cimetidine cimetidine Mild 
Ciprofloxacin ciprofloxacin Moderate 
Cisapride cisapride Moderate 
Citalopram hydrobromide citalopram Moderate 
Citalopram hydrobromide (Celapram) citalopram Moderate 
Clobazam clobazam Moderate 
Clomipramine hydrochloride clomipramine Moderate 
Clonazepam clonazepam Moderate 
Clonidine clonidine Moderate 
Clonidine hydrochloride clonidine Moderate 
Clonidine Hydrochloride clonidine Moderate 
Clozapine clozapine Moderate 
Codeine codeine Moderate 
Codeine phosphate codeine Moderate 
Cyclizine hydrochloride cyclizine Moderate 
Cyclizine lactate cyclizine Moderate 
Cycloserine cycloserine Contraindicated 
Cyproheptadine hydrochloride cyproheptadine Moderate 
Cyproterone acetate cyproterone Moderate 
Dantrolene dantrolene Moderate 
Desipramine hydrochloride desipramine Moderate 
Dexamfetamine sulfate dexamfetamine Major 
Dextromethorphan dextromethorphan Moderate 
Dextropropoxyphene dextropropoxyphene Major 
Diazepam diazepam Moderate 
Diclofenac sodium diclofenac Major 
Diflunisal diflunisal Major 
Dihydrocodeine tartrate dihydrocodeine Moderate 
Diltiazem hydrochloride diltiazem Moderate 
Dimenhydrinate dimenhydrinate Moderate 
Dimethyl fumarate dimethyl fumarate Moderate 
Dimethyl sulphoxide dimethyl sulfoxide Moderate 
Diphenhydramine hydrochloride diphenhydramine Moderate 
Disulfiram disulfiram Contraindicated 
Doxazosin doxazosin Mild 
Doxepin hydrochloride doxepin Moderate 
Doxycycline doxycycline Mild 
Droperidol droperidol Moderate 
Enalapril maleate enalapril Mild 
Erythromycin erythromycin Moderate 
Erythromycin estolate erythromycin Moderate 
Note: items in bold font required manual correction   
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Table 28: Continued    
PHARMS Chemical Name NZF Match AI-Classification 
Erythromycin ethyl succinate erythromycin Moderate 
Erythromycin lactobionate erythromycin Moderate 
Erythromycin stearate erythromycin Moderate 
Escitalopram escitalopram Moderate 
Ethionamide ethionamide Mild 
Ethosuximide ethosuximide Moderate 
Famotidine famotidine Mild 
Felodipine felodipine Moderate 
Fenbufen fenbufen Major 
Fenoprofen Calcium fenoprofen Major 
Fentanyl fentanyl Moderate 
Fentanyl citrate fentanyl Moderate 
Fentanyl Citrate fentanyl Moderate 
Fexofenadine hydrochloride fexofenadine Mild 
Flunarizine flunarizine Moderate 
Flunitrazepam flunitrazepam Moderate 
Fluoxetine hydrochloride fluoxetine Moderate 
Fluoxetine Hydrochloride fluoxetine Moderate 
Fluphenazine decanoate fluphenazine Moderate 
Fluphenazine hydrochloride fluphenazine Moderate 
Flurbiprofen flurbiprofen Major 
Gabapentin gabapentin Moderate 
Gabapentin (Neurontin) gabapentin Moderate 
Glibenclamide glibenclamide Major 
Gliclazide gliclazide Major 
Glipizide glipizide Major 
Glyceryl trinitrate glyceryl Moderate 
Glycopyrronium glycopyrronium Major 
Glycopyrronium bromide glycopyrronium Major 
Glycopyrronium Bromide glycopyrronium Major 
Griseofulvin griseofulvin Moderate 
Haloperidol haloperidol Moderate 
Haloperidol decanoate haloperidol Moderate 
Haloperidol Decanoate haloperidol Moderate 
Hydroxyzine Hydrochloride hydroxyzine Moderate 
Hyoscine hydrobromide hyoscine Moderate 
Hyoscine N-butylbromide hyoscine Moderate 
Ibuprofen ibuprofen Major 
Imipramine hydrochloride imipramine Moderate 
Insulin aspart insulin Moderate 
Insulin glargine insulin Moderate 
Note: items in bold font required manual correction   
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Table 28: Continued    
PHARMS Chemical Name NZF Match AI-Classification 
Insulin glulisine insulin Moderate 
Insulin isophane insulin Moderate 
Insulin lispro insulin Moderate 
Insulin neutral insulin Moderate 
Insulin Neutral insulin Moderate 
Insulin zinc suspension insulin Moderate 
Interferon alfa-2a interferon Moderate 
Interferon alfa-2b interferon Moderate 
Interferon Alpha-2B interferon Moderate 
Interferon alpha-n interferon Moderate 
Interferon beta-1-alpha interferon Moderate 
Interferon beta-1-beta interferon Moderate 
Isoniazid isoniazid Moderate 
Isosorbide dinitrate isosorbide Moderate 
Isosorbide Dinitrate isosorbide Moderate 
Isosorbide mononitrate isosorbide Moderate 
Isotretinoin isotretinoin Moderate 
Isradipine isradipine Mild 
Ivermectin ivermectin Mild 
Ketoconazole ketoconazole Major 
Ketoprofen ketoprofen Major 
Ketotifen ketotifen Moderate 
Labetalol labetalol Mild 
Leflunomide leflunomide Major 
Levamisole levamisole Moderate 
Levomepromazine maleate levomepromazine Moderate 
Lisinopril lisinopril Mild 
Lithium carbonate lithium Moderate 
Loprazolam mesylate loprazolam Moderate 
Loratadine loratadine Mild 
Lorazepam lorazepam Moderate 
Lormetazepam lormetazepam Moderate 
Losartan losartan Mild 
Losartan potassium losartan Mild 
Loxapine succinate loxapine Moderate 
Maprotiline hydrochloride maprotiline Moderate 
Mefenamic acid mefenamic-acid Major 
Meloxicam meloxicam Major 
Meprobamate meprobamate Major 
Metformin hydrochloride metformin Moderate 
Methadone hydrochloride methadone Moderate 
   
Note: Items in bold font required manual correction   
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Table 28: Continued    
PHARMS Chemical Name NZF Match AI-Classification 
Methotrexate methotrexate Major 
Methyldopa methyldopa Mild 
Methylphenidate hydrochloride methylphenidate Major 
Methylphenidate hydrochloride extended-release methylphenidate Major 
Metoclopramide hydrochloride metoclopramide Moderate 
Metoclopramide Hydrochloride metoclopramide Moderate 
Metoprolol succinate metoprolol Mild 
PHARMS Chemical Name NZF Match AI-Classification 
Metoprolol tartrate metoprolol Mild 
Metronidazole metronidazole Contraindicated 
Mianserin hydrochloride mianserin Moderate 
Midazolam midazolam Moderate 
Mirtazapine mirtazapine Major 
Morphine hydrochloride morphine Major 
Morphine sulphate morphine Major 
Morphine tartrate morphine Major 
Nadolol nadolol Mild 
Naproxen naproxen Major 
Naproxen sodium naproxen Major 
Niclosamide niclosamide Major 
Nicorandil nicorandil Moderate 
Nicotine nicotine Mild 
Nicotinic acid nicotinic-acid Major 
Nifedipine nifedipine Moderate 
Nimorazole nimorazole Moderate 
Nitrazepam nitrazepam Moderate 
Nizatidine nizatidine Mild 
Nortriptyline hydrochloride nortriptyline Moderate 
Nortriptyline Hydrochloride nortriptyline Moderate 
Olanzapine olanzapine Moderate 
Olanzapine pamoate monohydrate olanzapine Moderate 
Ondansetron ondansetron Moderate 
Ornidazole ornidazole Moderate 
Oxazepam oxazepam Moderate 
Oxprenolol oxprenolol Mild 
Oxybutynin oxybutynin Moderate 
Oxycodone hydrochloride oxycodone Moderate 
Papaveretum papaveretum Moderate 
Paracetamol paracetamol Major 
Paraldehyde paraldehyde Major 
Paroxetine hydrochloride paroxetine Moderate 
Note: Items in bold font required manual correction   
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Table 28: Continued    
PHARMS Chemical Name NZF Match AI-Classification 
Pentazocine pentazocine Moderate 
Pericyazine periciazine Moderate 
Perindopril perindopril Mild 
Pethidine hydrochloride pethidine Moderate 
Phenelzine sulphate phenelzine Contraindicated 
Phenylbutazone phenylbutazone Major 
Phenytoin sodium phenytoin Moderate 
Pimozide pimozide Moderate 
Pindolol pindolol Mild 
Pioglitazone pioglitazone Moderate 
Piroxicam piroxicam Major 
Pizotifen pizotifen Moderate 
Prazosin prazosin Mild 
Primidone primidone Moderate 
Procainamide hydrochloride procainamide Mild 
Procarbazine hydrochloride procarbazine Moderate 
Prochlorperazine prochlorperazine Moderate 
Promethazine hydrochloride promethazine Moderate 
Promethazine theoclate promethazine Moderate 
Propranolol propranolol Mild 
Quetiapine quetiapine Moderate 
Quetiapine Fumarate quetiapine Moderate 
Quinapril quinapril Mild 
Ranitidine ranitidine Mild 
Risperidone risperidone Moderate 
Rosiglitazone rosiglitazone Moderate 
Salbutamol salbutamol Major 
Selegiline hydrochloride selegiline Major 
Sertraline sertraline Moderate 
Sertraline Hydrochloride sertraline Moderate 
Sildenafil sildenafil Moderate 
Sotalol sotalol Mild 
Sulindac sulindac Major 
Sulpiride sulpiride Moderate 
Tacrolimus tacrolimus Major 
Tamsulosin hydrochloride tamsulosin Mild 
Temazepam temazepam Moderate 
Tenoxicam tenoxicam Major 
Terazosin terazosin Mild 
Terazosin Hydrochloride terazosin Mild 
Teriflunomide teriflunomide Moderate 
Note: Items in bold font required manual correction   
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Table 28: Continued    
PHARMS Chemical Name NZF Match AI-Classification 
Thalidomide thalidomide Major 
Thioridazine hydrochloride thioridazine Moderate 
Tiaprofenic acid tiaprofenic-acid Major 
Timolol timolol Mild 
Timolol Maleate timolol Mild 
Tinidazole tinidazole Contraindicated 
Tolbutamide tolbutamide Major 
Topiramate topiramate Moderate 
Tramadol tramadol Moderate 
Tramadol hydrochloride tramadol Moderate 
Trandolapril trandolapril Mild 
Tranylcypromine sulphate tranylcypromine Contraindicated 
Triazolam triazolam Moderate 
Trifluoperazine hydrochloride trifluoperazine Moderate 
Trimethoprim trimethoprim Moderate 
Trimipramine maleate trimipramine Moderate 
Varenicline tartrate varenicline Major 
Venlafaxine venlafaxine Moderate 
Verapamil hydrochloride verapamil Moderate 
Verapamil Hydrochloride verapamil Moderate 
Warfarin sodium warfarin Mild 
Ziprasidone ziprasidone Moderate 
Zopiclone zopiclone Moderate 
Zuclopenthixol decanoate zuclopenthixol Moderate 
Zuclopenthixol dihydrochloride zuclopenthixol Moderate 
Zuclopenthixol hydrochloride zuclopenthixol Moderate 
Note: Items in bold font required manual correction   
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Table 29: NZF/PHARMS Matches: Medications Containing Multiple Active Ingredients 
PHARMS Chemical Name  
Active Ingredients NZF 
AI-Classification Chemical 1 Chemical 2 Chemical 3 
Diphenoxylate hydrochloride with atropine sulphate diphenoxylate atropine***  Major 
Ergotamine tartrate with caffeine ergotamine caffeine*  Mild 
Ergotamine Tartrate with Caffeine ergotamine caffeine*  Mild 
Aspirin with Chloroform aspirin* chloroform  Mild 
Atenolol with chlorthalidone atenolol* chlorthalidone  Mild 
Pindolol with clopamide pindolol* clopamide  Mild 
Aspirin with Codeine aspirin* codeine**  Moderate 
Paracetamol with codeine paracetamol*** codeine**  Major 
Paracetamol with Codeine paracetamol*** codeine**  Major 
Ergotamine tartrate with cyclizine ergotamine cyclizine  Moderate 
Idoxuridine with dimethyl sulphoxide idoxuridine dimethyl sulfoxide**  Moderate 
Ergotamine tartrate with diphenhydramine ergotamine diphenhydramine**  Moderate 
Cyproterone acetate with ethinyloestradiol cyproterone** ethinyloestradiol  Moderate 
Acebutolol with hydrochlorothiazide acebutolol* hydrochlorothiazide  Mild 
Captopril with hydrochlorothiazide captopril* hydrochlorothiazide  Mild 
Cilazapril with hydrochlorothiazide cilazapril* hydrochlorothiazide  Mild 
Enalapril maleate with hydrochlorothiazide enalapril* hydrochlorothiazide  Mild 
Lisinopril with hydrochlorothiazide lisinopril* hydrochlorothiazide  Mild 
Losartan potassium with hydrochlorothiazide losartan* hydrochlorothiazide  Mild 
Losartan with hydrochlorothiazide losartan* hydrochlorothiazide  Mild 
Losartan with Hydrochlorothiazide losartan* hydrochlorothiazide  Mild 
Methyldopa with hydrochlorothiazide methyldopa* hydrochlorothiazide  Mild 
Quinapril with hydrochlorothiazide quinapril* hydrochlorothiazide  Mild 
Glycopyrronium with indacaterol glycopyrronium*** indacaterol  Major 
Note: Items in bold font required manual correction 
Note: Single chemical alcohol interactivity level indicators = *mild; **moderate; ***major; ****contraindicated   
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Table 29: Continued     
PHARMS Chemical Name  
Active Ingredients NZF 
AI-Classification Chemical 1 Chemical 2 Chemical 3 
Insulin aspart with insulin aspart protamine insulin** insulin**  Moderate 
Insulin isophane with insulin neutral insulin** insulin**  Moderate 
Insulin lispro with insulin lispro protamine insulin** insulin**  Moderate 
Salbutamol with ipratropium bromide salbutamol*** ipratropium  Major 
Buprenorphine with naloxone buprenorphine** naloxone  Moderate 
Dextropropoxyphene with paracetamol dextropropoxyphene*** paracetamol***  Major 
Metoclopramide hydrochloride with paracetamol metoclopramide** paracetamol***  Major 
Timolol maleate with pilocarpine timolol* pilocarpine  Mild 
Interferon alpha-2a with ribavirin interferon** ribavirin  Moderate 
Brimonidine tartrate with timolol maleate brimonidine* timolol*  Mild 
Dorzolamide with timolol dorzolamide timolol*  Mild 
Aspirin with paracetamol and codeine aspirin* paracetamol*** codeine** Major 
Omeprazole, amoxycillin and metronidazole omeprazole amoxycillin metronidazole**** Contraindicated 
Bismuth subcitrate, metronidazole and tetracycline bismuth subcitrate metronidazole**** tetracycline Contraindicated 
Note: Items in bold font required manual correction 
Note: Single chemical alcohol interactivity level indicators = *mild; **moderate; ***major; ****contraindicated   
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APPENDIX C: STUDY 1 AND STUDY 2 UNWEIGHTED 
SAMPLE CHARACTERISTICS BY DRINKING FREQUENCY 
Table 30: Study 1 Unweighted Sample Characteristics by Drinking Frequency 
  
Total % of 
Sample 
Drinking Frequency (AUDIT-C) 














Gender     


















Age      






























Ethnicity      






























Education level     


















    Missing (n = 26) 2.0%    
Marital Status      
    Married, civil union,  



















    Missing (n = 13) 1.0%    
Living Standards     






























    Missing (n = 28) 2.1%    
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Gender     
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Ethnicity    ‘  
    NZ   





























Education level     
    Tertiary   










    No tertiary  










Marital Status      
    Married, civil 




















Living Standards     
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APPENDIX D: CASE STUDY 
Case Study 5: Research  
 
Alcohol and Alcohol-Interactive Medication Use 




This case study was completed during the period of an internship as part of a 
Doctor of Clinical Psychology, and represents the work of Eddie Barnard under 











Candidate:  Eddie Barnard, Intern Psychologist, Alcohol and Other Drug Services (MidCentral Health)  
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Abstract 
Background: Vulnerability to adverse alcohol-medication interactions (AMIs) increases 
during older adulthood. Existing research findings indicate differences in awareness of AMI 
risks and mental health factors such as depression influence alcohol use among older alcohol 
interactive (AI)-medication users. Objectives:  This study explored associations between AI-
medication use, alcohol use, and depression among older adults. Design and Methods: This 
study included a large community sample of New Zealand older adults, and involved secondary 
analysis of survey data and pharmaceutical claims records.  Associations between variables of 
interest were explored using Chi-squared tests and hierarchical binary logistic regression. 
Results: One-in-three participants were at risk of AMI. AI-medication use was associated with 
less alcohol use, with lower rates of alcohol use being seen among those using AI-medications 
associated with higher AMI-severity. Depression did not influence the association between AI-
medication use and alcohol use. Discussion: Many New Zealand older adults are at risk of 
AMI exposure.  These risks may be mitigated by alerting older adults to their risk of AMI 
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Introduction 
Interactions between alcohol and medications can increase risks of overdosing, cause a number 
of serious side effects such as gastrointestinal bleeding and psychomotor impairment, and 
interfere with the therapeutic effects of medication treatment regimens (Adams, 1995; Moore, 
Whiteman, & Ward, 2007; Weathermon & Crabb, 1999).  These risks are of particular concern 
for older adults, as this population is more likely to be using medications with the potential to 
interact negatively with alcohol, and are particularly sensitive to the effects of alcohol-
medication interactions (AMI’s) due to age-related changes in body mass and metabolism 
(Moore et al., 2007).  Survey research exploring rates of alcohol and alcohol-interactive (AI) 
medication use among older adults has shown that, while AI-medication use is negatively 
associated with alcohol use, concurrent alcohol and AI-medication use is common among 
community dwelling older adults (Cousins et al., 2014; Breslow et al., 2015; Pringle et al., 
2005; Qato et al., 2015). Given the potential for alcohol related harm in older people, there is 
a need to identify factors underlying drinking behaviour among older AI-medication users that 
may inform intervention strategies aimed at reducing alcohol AMI exposure.  
One factor which appears to differ between older AI-medication users who use alcohol 
and those who abstain from alcohol is knowledge about the risks of AMIs.  Survey findings 
have shown that, compared with non-drinkers, older drinkers are able to identify fewer AI-
medications from a medication list (containing both AI and non-AI medications) and are less 
knowledgeable about the potential alcohol-interactivity of medications they use (Zanjani et al., 
2013). Similarly, qualitative findings indicate reduced alcohol intake following chronic illness 
onset during older adulthood is often motivated by discussions with health providers about 
potential AMIs (Gavens et al., 2016). These findings suggest decisions to reduce alcohol 
consumption among older AI-medication users are often motivated by awareness about the 
risks of AMI.   
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Given the evidence that relevant health knowledge motivates changes in alcohol 
consumption among many AI-medication users, it would be reasonable to assume that 
providing information about AMI risks would lead to reduced alcohol consumption among 
older AI-medication users. However, a health education intervention developed by Zanjani et 
al. (2018a, 2018b, 2018c) successfully enhanced older adults’ AMI awareness, yet had little 
effect on drinking intentions in the short term, and actually appeared to significantly decrease 
intentions to reduce alcohol consumption in the long term (Zanjani et al., 2018a, 2018b, 2018c). 
While the likelihood of alcohol use is lower among AI-medication users who are aware of the 
potential for AMI related harm, Zanjani et al.’s results show that simply providing information 
about AMI risks does not necessarily facilitate healthy changes in drinking behaviour.  
A possible explanation is that AI-medication users who change their drinking behaviour 
in response to health information are more likely to have sought information about AMI risks 
than those less receptive to educational interventions.  Zanjani et al. (2013) found that older 
drinkers displayed less willingness to discuss the potential for AMI related harm with friends 
and family. Similarly, Gavens et al. (2016) found that older adults who did not reduce their 
alcohol intake following chronic illness onset reported avoiding discussions with health 
professionals about alcohol-related harm as a means of avoiding encouragement to alter 
drinking patterns. Gavens et al. also found that continued drinking was often rationalised 
through selective interpretations of health information that placed greater importance on 
evidence that health problems are unrelated to alcohol use. It is therefore likely that many AI-
medication users who continue to drink actively avoid exposure to information about AMI 
risks, and may selectively focus on evidence supporting their decision to continue drinking.  
According to a review by Sweeny, Melnyk, Miller, and Shepperd (2010) exploring 
motivators of information avoidance in multiple contexts, people typically avoid information 
that challenges cherished beliefs and identifies a need for unwanted action or change. In the 
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context of combined alcohol/AI-medication use, such information might be that which 
challenges beliefs about alcohol related harm and highlights a need for reduced alcohol 
consumption. Perceived barriers to changes in drinking behaviour may therefore serve to 
motivate avoidance of AMI related information for many older adults and may also prevent 
exposure to AMI information from leading to reduced alcohol consumption.  
One factor which may be perceived as a barrier to drinking behaviour change for many 
older AI-medication users is mental health.  A recent study of Canadian mental health service 
users found that nearly half of the sample reported having used alcohol and psychotropic 
medications concurrently despite having considered the risk of AMI prior to alcohol 
consumption (Cheng, Mithoowani, Ungar, & Lee, 2018). Findings from qualitative studies 
conducted in the UK suggest alcohol is often used to regulate emotion among chronically ill 
older adults (Gavens et al., 2016) and older AI-medication users often self-medicate with 
alcohol to manage mental health problems, most commonly depression (Haighton, O’Donnell, 
Wilson, McCabe, & Ling, 2018). These findings are in line with research into self-medication 
behaviour suggesting alcohol use is often used to regulate emotion among people with 
depression (Bolton, Robinson, & Sareen, 2009; Boschloo et al., 2012 Brown & Stewart, 2008). 
As such, mental health factors such as depression may therefore moderate changes in alcohol 
consumption among older AI-medication users. 
The theoretical framework adopted in the present study was based on health behaviour 
principles detailed in the Health Belief Model (HBM) (Janz & Becker, 1984; Rosenstock, 1974) 
and the principle of co-existing mental health and substance use difficulties known as the Self-
Medication Hypothesis (Khantzian 1987; 1997). These theories of factors influencing health 
related behaviours were selected because they provide a parsimonious account regarding 
factors underlying drinking behaviour among AI-medication users.   
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The HBM conceptualises health promoting information as a cue of action which leads 
to behaviour change by increasing one’s perceived susceptibility to harm and eliciting the belief 
that behaviour change will have positive health consequences (perceived benefits). The 
likelihood of behaviour change is thought to increase with the perceived severity of the related 
health consequence (Janz & Becker, 1984; Rosenstock, 1974). Research supports this 
relationship between information and healthy behaviour, showing a negative association 
between AI-medication use and alcohol use (Cousins et al., 2014; Breslow et al., 2015; Pringle 
et al., 2005; Qato et al., 2015), and differences in AMI related knowledge between AI-
medication users who are drinkers and those who are non-drinkers (Zanjani et al., 2013).  
The HBM also proposes health behaviour change is dependent on the individual’s 
beliefs about their ability to successfully change behaviour (self-efficacy) and potential 
negative consequences of behaviour change (perceived barriers). In other words, healthy 
behaviour change will not occur when perceived barriers outweigh the perceived benefits, 
and/or the individual does not believe they are capable of successfully changing their behaviour 
(Rosenstock, Strecher, & Becker 1988). Therefore, people who self-medicate with alcohol to 
alleviate emotional distress would be less likely to give up alcohol when prescribed AI-
medications due to a) the perceived barrier of increased emotional distress, and b) low feelings 
of self-efficacy due to reliance on alcohol to regulate emotion. This view is supported by the 
high rates of concurrent alcohol/AI-medication use observed among mental health service users 
(Cheng et al., 2018) as well as qualitative findings implicating self-medication as a motivator 
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Aims and Hypothesis 
The present study analysed data from a nationwide survey of community dwelling older adults 
living in New Zealand to explore the potential relationships between AI-medication use, 
alcohol use, and depression. The study had three hypotheses. Firstly,  based on previous 
epidemiological research showing a negative association between AI-medication use and 
alcohol use (Cousins et al., 2014; Breslow et al., 2015; Pringle et al., 2005; Qato et al., 2015)., 
it was hypothesised that alcohol use would be less prevalent among AI-medication users than 
non-users of AI-medications. Secondly, it was hypothesised that alcohol use would be less 
common among participants using medications with higher levels of alcohol-interactivity than 
those using forms of AI-medication associated with milder AMIs. This hypothesis was based 
on the HBM principles of perceived severity and perceived susceptibility (Janz & Becker, 
1984; Rosenstock, 1974), as well as research findings suggesting older AI-medication users 
who stop drinking often do so in response to knowledge of AMI risks (Gavens et al., 2016; 
Zanjani et al., 2013). The third hypothesis was that depression would weaken the negative 
association between AI-medication use and alcohol use. This hypothesis was based on the 
HBM principles of self-efficacy and perceived barriers (Rosenstock et al., 1988), the self-
medication hypothesis (Khantzian 1987; 1997), and research suggesting alcohol is often used 
to alleviate emotional distress among AI-medication users with symptoms of depression 




Health, Work and Retirement study (HWR) 2010  
The present study is a secondary analysis of data from the 2010 wave of the Health, Work and 
Retirement (HWR) study, which is a large ongoing nationally representative survey of older 
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adults living in New Zealand that started in 2005.  The cohort consists of participants recruited 
across two waves occurring in 2006 and 2010.  Participants were randomly selected from the 
New Zealand electoral roll, and over sampling of those indicated as having Māori descent was 
undertaken to ensure adequate representation of New Zealand’s Māori (indigenous) 
population. Participants recruited in 2006 participated in the initial HWR study, which 
originally consisted of 6,662 participants aged 55-70 years.  The 2010 HWR recruitment wave 
aimed to increase representation of younger (aged 50-84 years) and older (70-84) age groups 
within the sample.  The 2010 HWR sample consisted of 3,305 New Zealand adults aged ≥48 
years, 1,981 of whom were recruited in 2006 and 1,324 were recruited in 2010 (Towers & 
Stevenson, 2014).  The present study includes a subsample of the 2010 HWR cohort who 
consented to having their survey data linked with their national health records as part of the 
HWR data-linkage project.  
Data-linkage  
The HWR data linkage project links consenting participants’ survey data with their national 
health records. In 2014, written informed consent was sought among participants of the 2010 
HWR study. A second approach to data linkage consent occurred in 2015 and included those 
who did not respond in the 2014 approach, yet were active participants in the 2014 HWR 
survey.  Consent was sought from 2,475 participants across the two approaches, 1,727 of whom 
consented to data linkage. Minimum identifiers of consenting participants (name, gender, and 
date of birth) were provided to the Ministry of Health Analytic Services (formerly New Zealand 
Health Information Service) and a direct-match strategy was implemented to link to 
participants’ National Health Index (NHI) number (Allen, 2016). Data were then matched by 
the Ministry of Health Analytic Services to health records based on NHI number, before all 
identifying information were removed and records assigned a new identification number for 
the purposes of linkage to HWR study research data.  Of the 1,727 participants who consented 
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to data-linkage, 1,625 were matched successfully to their NHI number and included in the 
present study sample (49.2% of the original sample).  For the purposes of this study, 
participants’ pharmaceutical dispensing data from their national health records were used to 
facilitate identification of their prescription medication use.  Table 1 shows the number of 2010 
HWR participants who were approached for and consented to data linkage, and were 
successfully matched to their NHI number across both waves of recruitment. 
 
Table 1: Process of data-linkage recruitment among 2010 HWR participants 
 Wave of recruitment Total 
 2006 2010 
Total HWR 2010 sample 1,981 1,324 3,305 
Approached for data linkage  1,783 692 2,475 
Consented to data linkage 1,257 470 1,727 




Participants’ pharmaceutical claims data was provided by the New Zealand Pharmaceutical 
Collection (PHARMS). The New Zealand Formulary (NZF; 2017) was used to identify AI-
medications29 within the PHARMS data and categorize them into ordinal groups of varying 
alcohol interactivity levels (mild30, moderate31, major32, and contraindicated33).  
 
29 AI-medications: those referred to as having potential alcohol-interactivity, those including a cautionary warning 
against alcohol use, and/or those including some sort of recommendation regarding alcohol consumption 
30 Mild AI-medications: potential interactions are of little clinical significance 
31 Moderate AI-medications: interactions may result in significant distress or incapacitation, but the likelihood of 
interaction is not high enough to warrant close monitoring or dosage adjustment 
32 Major AI-medications: for interactions with detrimental effects that may be permanent or life-threatening OR 
interactions that may result in significant distress or incapacitation and the likelihood of interaction is high enough 
to warrant close monitoring or dosage adjustment 
33 Contraindicated AI-medications: medications contraindicated for use with alcohol 
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Participants were identified as AI-medication users if their pharmaceutical dispensing 
records indicated they (a) were currently using AI-medication at the time of survey completion, 
and (b) had used AI-medication on a regular basis prior to survey completion. The research 
protocol developed for this project informed the specific methods used to determine which 
participants could be defined as AI-medication users based on this definition (see Appendix 
A). Briefly, current use of antibiotics was determined using the legend-time method34; current 
use of nonsteroidal anti-inflammatory drugs (NSAIDs) and benzodiazepines was determined 
using a 30-day fixed-window35; and current use of all other medications (i.e. excluding 
antibiotics, NSAIDs, and benzodiazepines) was determined using a 90-day fixed-window36.  
Participants were defined as regular AI-medication users if they were (1) identified as currently 
using AI-medications based on the criteria just described, and 2) dispensed at least one other 
AI-medication supply during the past 244 days (prior to survey completion) that was not in 
current use at the time of survey completion.  AI-medication users were then assigned to one 
of three groups based on the highest alcohol-interactivity level of medications in current use 







34 Legend-time method: data-linkage method of identifying current medication use. Infers current use when the 
number of days for which the medication is supplied is greater than or equal to the number of days between 
medication dispensing date and survey response date 
35 30-day fixed window: data-linkage method of identifying current medication use. Infers current use when a 
medication is dispensed during the past 30 days prior to survey response date  
36 90-day fixed window: data-linkage method of identifying current medication use. Infers current use when a 
medication is dispensed during the past 90 days prior to survey response date 
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Table 2: Dispensing Records of AI-Medication User Groups 
AI-Medication User 
Groups 
Pharmaceutical Dispensing’s Received by Group Members   
Current use Past 244 days 




At least one contraindicated AI-
medication 
At least one AI-medication 




At least one major AI-medication, and no 
contraindicated AI-medications 




At least one moderate AI-medication, and 
no major or contraindicated AI-
medications 
At least one AI-medication 
Mild AI-medication 
users 
At least one mild AI-medication, and no 
moderate, major, or contraindicated AI-
medications 
At least one AI-medication 
Note: Current use = Legend time for antibiotics; 30-day fixed-window for benzodiazepines & NSAIDs; 90-
day fixed-window for all other drugs. 
 
Alcohol Use 
The HWR survey included the Alcohol Use Disorders Identification Test – C (AUDIT-C, Bush 
et al., 1998), which consists of three items assessing the quantity and frequency of alcohol use, 
and binge drinking frequency. The present study used the AUDIT-C frequency item to 
categorize participants into one of three drinking groups:  
• Minimal/non-drinkers (those who reported using alcohol ‘never’ or ‘monthly or less’) 
• Light/moderate-drinkers (those who reported using alcohol ‘2-4 times monthly’ or ‘2-
3 times weekly’ 
• Heavy-drinkers (those who reported using alcohol ‘4 or more times weekly’) 
 
Depression  
Depression was measured with a shortened version of the Centre for Epidemiologic 
Studies Depression Scale (CES-D; Radolff, 1977), which includes 10 items selected for the 
assessment of depression in older people (CES-D-10; Irwin, Artin, & Oxman, 1999). The CES-
D-10 had high sensitivity (97%), specificity (84%) and positive predictive value (85%) in the 
identification of major depression in a sample of the U.S. older population, and the Cronbach’s 
alpha was .92 for the CES-D-10 in a sample of middle-aged U.S. adults (Irwin et al., 1999). 
Raw scores on the CES-D-10 range from 0 – 30. The present study adopted this dichotomous 
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scoring, with participants scoring below 10 categorized as ‘not depressed’ and those scoring 
≥10 categorized as ‘depressed’. 
Demographic variables 
In light of the association of SES with alcohol use (Scott, Wiener, &  Paulson, 2018; 
Towers, Philipp, Dulin, & Allen, 2016), participant SES was measured using the Economic 
Living Standard Index short form (ELSI-sf), a 25-item self-report measure of consumption 
capacity, economic social restrictions, and material wealth (Jensen, Spittal, & Krishnan, 2005). 
Raw scores on the ELSI-sf range from 0-31, with higher scores indicating higher SES.  ELSI-
sf raw scores are then converted into seven levels of living standards ranging from ‘severe 
hardship’ to ‘very good’. Other demographic variables of interest included ethnicity, age, 
marital status, and education level. Ethnicity was defined as ‘New Zealand European’ (NZE), 
‘Māori’, or ‘Other’. Age groups included '48-54 years', '55-64 years', '65-74 years', and ' ≥75 
years'. Marital status groups included ‘Married, Civil Union, or De Facto’, and ‘Other’.  
Education level was defined as ‘Tertiary Education’ or ‘No Tertiary Education’.   
Analysis 
All analyses were conducted using SPSS software. Descriptive statistics were used to explore 
the demographic characteristics of the sample, and chi-square tests of independence were used 
to explore variation in drinking frequency across demographic variables.  
To test the hypothesis that alcohol use would be less common among those using AI-
medications, 2x2 chi-square test of independence was used to compare rates of minimal/non-
drinker status versus light-moderate/heavy drinker status among users and non-users of AI-
medications.  A 2x3 chi-square test of independence was used to further explore this hypothesis 
across drinking frequency categories, and standardized residuals were analysed to determine 
whether cells deviated from expected frequencies at <.05 or <.01 levels of significance. 
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To test the hypothesis that alcohol use would be less common among those using AI-
medications with higher alcohol interactivity, a 4x2 chi-squared test of independence was used 
to compare rates of minimal/non-drinker status versus light-moderate/heavy drinker status 
across AI-medication user severity categories. This was then further explored across drinking 
frequency categories using a 4x3 chi-squared test of independence. Standardized residuals were 
used to determine whether cells deviated from expected frequencies at <.05 or <.01 levels of 
significance.  
A binary hierarchical logistic regression model was used to test the hypothesis that the 
predicted negative relationship between AI-medication use and alcohol use would be 
moderated by depression.  In this model, alcohol use was entered as binary outcome variable 
(drinkers versus non-drinkers).  ELSI-sf scores were used control for the effects of living 
standards on alcohol use. AI-medication use was entered as a binary variable (non-users and 
mild AI-medication users versus moderate and major/contraindicated AI-medication users). A 
binary depression variable was entered using a CES-D-10 cut-off score of ≥10.  The interaction 
term variable was then entered as AI-medication*depression.   
Results 
Alcohol Consumption Rates Across the Sample 
A total of 1075 participants (66.3%) were identified as drinkers (light/moderate and heavy), 
and 546 (33.7%) were identified as minimal/non-drinkers. The sample rates of light/moderate 
and heavy drinking were 38.9% and 27.4%, respectively. Table 3 shows the demographic 
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Chi square  φc  
Total sample       
       
Gender       










X2 (2, N = 
1,621) = 51.45, 
p <.001 
.18 








Age        










X2 (6, N = 
1,621) = 8.21, p 
=.223 
.05 




























Ethnicity    ‘    
    NZ   









X2 (4, N = 
1,597) = 59.14, 
p <.001 
.14 




















Education level       
    Tertiary   










X2 (2, N = 
1,614) = 23.46, 
p <.001 
.12 
    No tertiary  










Marital Status        
    Married, civil 










X2 (2, N = 
1,615) = 45.05, 
p <.001 
.17 










Living Standards       








X2 (4, N = 
1,584) = 110.40, 
p <001 
.19 


















Note: φc = Cramér's V  
Chi-square tests of independence indicated significant differences in drinking frequency by 
gender, ethnicity, education level, marital status, and living standards (p < .001) but not age 
(see Table 3). Minimal/non-drinker status was most common among women, those of Māori 
ethnicity, those without tertiary education, those living in hardship, and those of ‘other’ marital 
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status.   In contrast, rates of minimal/non-drinker status were lowest among those who were 
male, NZ European, educated at tertiary level, those with good living standards, and those who 
were of married, civil union, or de facto marital status.  Light/moderate drinking was most 
common among participants who were male, NZ European, educated at tertiary level, with 
comfortable standards of living, and of married, civil union, or de facto marital status. 
Conversely, light/moderate drinking was less common among those who were female, Māori, 
those without tertiary education, those living in hardship and those of other marital status. Rates 
of heavy drinking were highest among those who were male, NZ European, educated at tertiary 
level, with good living standards, and of married, civil union, or de facto marital status. Heavy 
drinking rates were lowest among those who were female, Māori, those without tertiary 
education, those living in hardship, and of other marital status.   
Rates of AI-Medication Use 
Across the sample, 879 participants (55.3%) used at least one AI-medication regularly, with 
the remaining 724 participants (44.7%) identified as non-users. The sample rates of mild, 
moderate, and major/contraindicated AI-medication use were 14.6%, 17.5%, and 23.2%, 
respectively.  
Alcohol Use Among AI-medication Users 
Users vs. Non-users (Binary AI-Medication Use) 
The sample rate of participants identified as both drinkers and AI-medication users was 
34.0% (551 participants). A chi-square test of independence showed the rate of alcohol use was 
significantly lower among AI-medication users (61.4%) than non-users of AI-medications 
(72.4%), X2 (1, N = 1,621) = 21.50, p <.001, phi = 0.11. When this relationship was explored 
across drinking frequency categories (see Table 4), standardized residuals showed rates of 
minimal/non-drinker status were significantly lower than expected among non-users of AI-
medications (p <.01) and significantly higher than expected among AI-medication users (p 
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<.05), X2 (2, N = 1,621) = 21.82, p <.001, Cramer’s V = .12. However, no significant deviations 
from expected frequencies were observed across light/moderate and heavy drinking categories. 




Drinking Frequency (AUDIT-C) 

















Note: Values in parentheses represent standardized residuals; * p <.05; ** p <.01 
Mild, Moderate, and Major/Contraindicated AI-Medication Users 
The sample rates of participants identified as both drinkers (light/moderate or heavy) 
and users of mild, moderate, and major/contraindicated AI-medications were 10.5%, 11.3%, 
and 12.2% respectively. The respective sample rates of participants identified as both 
light/moderate drinkers and users of mild, moderate, or major/contraindicated AI-medications 
were 5.6%, 6.9%, and 7.8%. The sample rates of participants identified as both heavy-drinkers 
and users of mild, moderate, major/contraindicated AI-medications were 4.9%, 4.4%, and 4.4% 
respectively.  
A chi-square test of independence showed significant differences in alcohol use across 
AI-medication user categories (see Table 5), X2 (3, N = 1,621) = 47.48, p <.001, Cramer’s V = 
0.17. Standardized residuals showed rates of non-drinker status were significantly lower than 
expected among those not using AI-medications and significantly higher than expected among 
major/contraindicated AI-medication users (p < .01), while rates of drinker status were 
significantly higher than expected among those not using AI-medications (p <.05) and 
significantly lower than expected among those using major/contraindicated AI-medications. 
When this relationship was further explored across drinking frequency categories (X2 (6, N = 
1,621) = 52.21, p <.001, Cramer’s V = 0.13), the rate of heavy drinking was significantly lower 
than expected among major/contraindicated AI-medication users only (p <.01), and rates of 
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light/moderate drinking did not deviate significantly from expected frequencies across AI-
medication use categories (see Table 6).   
Table 5:  AI-Medication Severety across Binary Drinking: Chi-Squared Test 























Note: values in parenthesis represent standardized residuals; * <.05; **<.01 
Note: X2 (3, N = 1,621) = 47.48, p <.001, phi = .17. 
 
Table 6: AI-Medication Severity Across Drinking Frequency: Chi-Squared Test 
AI-Medication User 
Severity Categories 
Drinking Frequency (AUDIT-C) 

























Notes: values in parenthesis represent standardized residuals; * <.05; **<.01 
Note: X2 (6, N = 1,621) = 52.21, p <.001, phi = .179. 
 
AI-Medication use, Depression, and Alcohol Use 
A hierarchical binary logistic regression model was used to explore the interaction 
effects of AI-medication use (moderate or major/contraindicated AI-medication use vs no use 
or mild-AI-medication use) and depression (CES-D-10 score of ≤10) on the likelihood of 
alcohol use (drinkers vs. non-drinkers) after controlling for living standards (ELSI-sf scores) 
and the main effects of depression and AI-medication use. The ELSI-sf scale was entered at 
step 1, AI-medication use and depression were entered at step 2, and the interaction term (AI-
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medication*depression) entered at step 3. As shown in Table 7, step 1 of the model was 
statistically significant (X2 (1, N = 1,488) = 82.12, p = <.001), indicating ELSI-sf scores 
accurately distinguished drinkers from non-drinkers. ELSI-sf scores explained between 5.4% 
(Cox and Snell R square) and 7.5% (Nagelkerke R square) of the variance in alcohol use. The 
model was significantly improved with the addition of step 2 (block: X2 (2, N = 1,488) = 15.83, 
p <.001; full model: X2 (3, N = 1,488) = 97.95, p <.001), with the overall model at step 2 
explaining between 6.4% (Cox and Snell R square) and 8.8% (Nagelkerke R square) of the 
variance in alcohol use (the additional variables therefore explained between 1% and 1.3% of 
the variance in alcohol use). The model was not significantly improved with the addition of 
step 3 (block X2 (1, N = 1,488) = 0.22, p =.638; full model X2 (4, N = 1,488) = 98.12, p <.001). 
The final model explained between 6.4% (Cox and Snell R Square) and 8.9% (Nagelkerke R 
Square) of the variance in alcohol use, and had adequate fit as indicated by non-significant 
HLT (X2 (7, N = 1,488) = 4.18, p = .758). The only significant predictors of alcohol use in the 
final model were living standards and AI-medication use. 
Table 7: Hierarchical Binary Logistic Regression Model  
Predictor and 
Step 
B S.E Wald Df P OR 
95 % CI for OR X2 Block 
(N = 1,488) Lower Upper 
Step 1              
  Living    
  Standards .333 .038 78.347 1 .000 1.395 1.296 1.502 
X2 (1) = 82.12, p 
<.001 
Step 2               
  Living  
  Standards .301 .041 52.826 1 .000 1.351 1.246 1.466 




-.463 .118 15.301 1 .000 .629 .499 .794 
 
  Depression -.028 .154 .032 1 .858 .973 .719 1.316  
Step 3              
  Living  
  Standards .301 .041 52.921 1 .000 1.352 1.246 1.466 




-.434 .133 10.671 1 .001 .648 .499 .840 
 
  Depression .054 .233 .054 1 .817 1.056 .668 1.668  
  AI-
Medication *  
  Depression 
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Discussion 
The aims of the present study were to explore the potential relationships between AI-
medication use, alcohol use, and depression in a sample of New Zealand older adults.  Most 
participants (approximately 60%) reported using alcohol at least two days monthly, and just 
over half of the sample regularly used at least one AI-medication.  Approximately one-in-three 
participants in this study sample were at risk of AMI exposure, and one-in-four were at risk of 
suffering an adverse AMI of clinical significance.    
The hypothesis that alcohol use would be less common among those using AI-
medications was supported, as participants identified as AI-medication users were significantly 
less likely than non-users of AI-medications to report using alcohol two or more times monthly. 
This finding is consistent with previous studies exploring rates of concurrent alcohol/AI-
medication use among older adults in the United States and Ireland (Cousins et al., 2014; 
Breslow et al., 2015; Pringle et al., 2005; Qato et al., 2015).  
The hypothesis that AI-medications with higher levels of alcohol-interactivity would 
be associated with less alcohol use was generally supported by the results.  Rates of self-
reported alcohol use (at least twice monthly) were significantly lower among those using AI-
medications identified as having the highest level of alcohol-interactivity (i.e. 
major/contraindicated AI-medications).  When this association was explored across drinking 
frequency groups, the data showed that those using medications identified as highly alcohol 
were significantly less likely to report heavy drinking (four days weekly), but rates of light-
moderate drinking (two days monthly to three days weekly) did not differ significantly across 
AI-medication severity groups. 
Given that the AI-medication severity categories utilized in this study were identified 
using the same drug-interaction identification system used by New Zealand prescribers and 
pharmacists, participants most likely to have been advised about AMI risks are those identified 
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as major/contraindicated AI-medication users.  As such, the observed negative association 
between alcohol use and major/contraindicated AI-medication use is consistent with previous 
studies indicating AMI related knowledge leads to reduced alcohol use (Gavens et al., 2016; 
Zanjani et al., 2013)).  This finding also supported the principles of perceived severity and 
perceived susceptibility, described in the HBM (Janz & Becker, 1984; Rosenstock, 1974).  
 The hypothesis that depression would moderate the negative association between AI-
medication use and alcohol use was not supported by the results. Among variables entered into 
the hierarchical regression model, only living standards and AI-medication use significantly 
accounted for variance in alcohol use within the sample.  While these results do not support 
findings of previous studies implicating self-medication as a motivator for alcohol use among 
AI-medication users (Gavens et al., 2016 Haighton, et al., 2018), it should be noted that 
drinking motives were not directly measured in the present study.  Although drinking to 
alleviate distress is common among people with depression (Bolton et al., 2009; Boschloo et 
al., 2012 Brown & Stewart, 2008), it cannot be assumed that all people with depression self-
medicate with alcohol, or that self-medication motivated alcohol use occurs exclusively in the 
context of depression. As such, the negative findings should not be interpreted as evidence 
against the potential role of self-medication in concurrent alcohol/AI-medication use. 
The present study had several methodological limitations. Due to the oversampling of 
Māori participants in the HWR recruitment process, there was an overrepresentation of Māori 
participants and an underrepresentation of NZE participants within the sample relative to the 
New Zealand older adult population. Given that Māori participants in this study reported using 
significantly less alcohol than NZE participants, the results likely underestimate actual 
population rates of alcohol use and risk of AMI exposure among older adults living in New 
Zealand.   In addition, as stated previously, drinking motives were not directly measured in the 
present study.  Future survey research exploring factors motivating alcohol use among AI-
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medication users could address this issue by utilizing measures that directly assess participants 
reasons for drinking, such as the older adult version of The Drinking Motives Questionnaire 
(Gilson et al., 2013).  
Overall, the results of this study indicate that many New Zealand older adults are at risk 
of AMI related harm.  Providing older adults with information about the risks of combined 
alcohol/AI-medication use may help mitigate their risk of AMI exposure. Such interventions 
should emphasize information about heightened susceptibility to AMIs during older adulthood, 
and the severity of AMI related harm.   
Research Contribution to Clinical Training 
Given that my internship was based in an Alcohol and Other Drug (AOD) service, the research 
questions explored in this study were highly relevant to my clinical practice.  Reviewing 
relevant literature regarding the consequences of alcohol-medication interactions provided me 
with knowledge about alcohol and drug metabolism processes, drug interaction processes, and 
age-related changes in alcohol sensitivity. I was therefore acutely aware of the physical health 
risks posed to many clients within the AOD service setting.  For example, when discussing 
older clients during MDT meetings I would ensure their risk of alcohol related harm was 
considered in light of other factors such as age, medication use, mobility, and health conditions. 
This knowledge base therefore furthered my ability to advocate for client’s safety, and to think 
more broadly about risk by considering longer-term physical health factors.  
The theoretical framework of this study was also highly relevant to my practice.  
Motivational factors underlying health related behaviour are always an important consideration 
when working with people with substance use problems.  Having reflected on the theoretical 
constructs explored in this study, I began my internship with awareness that many people may 
underestimate the potential harm their use of substance poses. I also understood that providing 
information about these risks, enhancing self-efficacy, and addressing perceived barriers could 
  
256 | P a g e  
 
facilitate positive changes.  Additionally, this project required me consider the impact mental 
health problems might have on clients’ motivation to use substances. This knowledge base was 
highly beneficial during my internship, and my understanding of these concepts deepened 
throughout the year as I applied them in a clinical setting.   For example, highlighting problem 
severity and increasing self-efficacy in order to enhance motivation is an important first step 
toward positive change when treating substance use problems.  
 
